{"version": "v2.0", "data": [{"id": "3708949_1_0", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3708949_1_1", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3708949_1_2", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3708949_1_3", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3708949_1_4", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3708949_1_5", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3708949_1_6", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3708949_1_7", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3708949_1_8", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3708949_1_9", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3708949_1_10", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3708949_1_11", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3708949_1_12", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8467620_3_13", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8467620_3_14", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8467620_3_15", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8467620_3_16", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8467620_3_17", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8467620_3_18", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8467620_3_19", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8467620_3_20", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8467620_3_21", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8467620_3_22", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8467620_3_23", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8467620_3_24", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8467620_3_25", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1422497_6_26", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "1422497_6_27", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "1422497_6_28", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "1422497_6_29", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "1422497_6_30", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "1422497_6_31", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "1422497_6_32", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "1422497_6_33", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "1422497_6_34", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "1422497_6_35", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1422497_6_36", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "1422497_6_37", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "1422497_6_38", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10082597_3_39", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10082597_3_40", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10082597_3_41", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10082597_3_42", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10082597_3_43", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10082597_3_44", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10082597_3_45", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10082597_3_46", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10082597_3_47", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10082597_3_48", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10082597_3_49", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10082597_3_50", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10082597_3_51", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16018164_1_52", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16018164_1_53", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16018164_1_54", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16018164_1_55", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16018164_1_56", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16018164_1_57", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16018164_1_58", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16018164_1_59", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16018164_1_60", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16018164_1_61", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16018164_1_62", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16018164_1_63", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16018164_1_64", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8467620_1_65", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8467620_1_66", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8467620_1_67", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8467620_1_68", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8467620_1_69", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8467620_1_70", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8467620_1_71", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8467620_1_72", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8467620_1_73", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8467620_1_74", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8467620_1_75", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8467620_1_76", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8467620_1_77", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14742791_4_78", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14742791_4_79", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14742791_4_80", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14742791_4_81", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14742791_4_82", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14742791_4_83", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14742791_4_84", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14742791_4_85", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14742791_4_86", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14742791_4_87", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14742791_4_88", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14742791_4_89", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14742791_4_90", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8442800_11_91", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8442800_11_92", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8442800_11_93", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8442800_11_94", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8442800_11_95", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8442800_11_96", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8442800_11_97", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8442800_11_98", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8442800_11_99", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8442800_11_100", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8442800_11_101", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8442800_11_102", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8442800_11_103", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15368548_4_104", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15368548_4_105", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15368548_4_106", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15368548_4_107", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15368548_4_108", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15368548_4_109", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15368548_4_110", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15368548_4_111", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15368548_4_112", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15368548_4_113", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15368548_4_114", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15368548_4_115", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15368548_4_116", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21630612_2_117", "context": "Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21630612_2_118", "context": "Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21630612_2_119", "context": "Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21630612_2_120", "context": "Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21630612_2_121", "context": "Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21630612_2_122", "context": "Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21630612_2_123", "context": "Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21630612_2_124", "context": "Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18855892_1_125", "context": "Management and successful desensitization in methotrexate-induced anaphylaxis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18855892_1_126", "context": "Management and successful desensitization in methotrexate-induced anaphylaxis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18855892_1_127", "context": "Management and successful desensitization in methotrexate-induced anaphylaxis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18855892_1_128", "context": "Management and successful desensitization in methotrexate-induced anaphylaxis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18855892_1_129", "context": "Management and successful desensitization in methotrexate-induced anaphylaxis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18855892_1_130", "context": "Management and successful desensitization in methotrexate-induced anaphylaxis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18855892_1_131", "context": "Management and successful desensitization in methotrexate-induced anaphylaxis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18855892_1_132", "context": "Management and successful desensitization in methotrexate-induced anaphylaxis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12166705_1_133", "context": "Mitomycin-C induced hemolytic uremic syndrome: a case report.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12166705_1_134", "context": "Mitomycin-C induced hemolytic uremic syndrome: a case report.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12166705_1_135", "context": "Mitomycin-C induced hemolytic uremic syndrome: a case report.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12166705_1_136", "context": "Mitomycin-C induced hemolytic uremic syndrome: a case report.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12166705_1_137", "context": "Mitomycin-C induced hemolytic uremic syndrome: a case report.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12166705_1_138", "context": "Mitomycin-C induced hemolytic uremic syndrome: a case report.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12166705_1_139", "context": "Mitomycin-C induced hemolytic uremic syndrome: a case report.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12166705_1_140", "context": "Mitomycin-C induced hemolytic uremic syndrome: a case report.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15588385_1_141", "context": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15588385_1_142", "context": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15588385_1_143", "context": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15588385_1_144", "context": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15588385_1_145", "context": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15588385_1_146", "context": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15588385_1_147", "context": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15588385_1_148", "context": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "748238_1_149", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "748238_1_150", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "748238_1_151", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "748238_1_152", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "748238_1_153", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "748238_1_154", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "748238_1_155", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "748238_1_156", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "748238_1_157", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "748238_1_158", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "748238_1_159", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "748238_1_160", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "748238_1_161", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3359700_3_162", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3359700_3_163", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3359700_3_164", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3359700_3_165", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3359700_3_166", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3359700_3_167", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3359700_3_168", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3359700_3_169", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3359700_3_170", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3359700_3_171", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3359700_3_172", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3359700_3_173", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3359700_3_174", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9352164_2_175", "context": "As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9352164_2_176", "context": "As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9352164_2_177", "context": "As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9352164_2_178", "context": "As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9352164_2_179", "context": "As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9352164_2_180", "context": "As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9352164_2_181", "context": "As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9352164_2_182", "context": "As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3693034_1_183", "context": "Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3693034_1_184", "context": "Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3693034_1_185", "context": "Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3693034_1_186", "context": "Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3693034_1_187", "context": "Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3693034_1_188", "context": "Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3693034_1_189", "context": "Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3693034_1_190", "context": "Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16018164_4_191", "context": "Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16018164_4_192", "context": "Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16018164_4_193", "context": "Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16018164_4_194", "context": "Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16018164_4_195", "context": "Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16018164_4_196", "context": "Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16018164_4_197", "context": "Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16018164_4_198", "context": "Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18523232_1_199", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18523232_1_200", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18523232_1_201", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18523232_1_202", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18523232_1_203", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18523232_1_204", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18523232_1_205", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18523232_1_206", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18523232_1_207", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18523232_1_208", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18523232_1_209", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18523232_1_210", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18523232_1_211", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9352164_4_212", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9352164_4_213", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9352164_4_214", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9352164_4_215", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9352164_4_216", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9352164_4_217", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9352164_4_218", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9352164_4_219", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9352164_4_220", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9352164_4_221", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9352164_4_222", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9352164_4_223", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9352164_4_224", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16192734_1_225", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16192734_1_226", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16192734_1_227", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16192734_1_228", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16192734_1_229", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16192734_1_230", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16192734_1_231", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16192734_1_232", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16192734_1_233", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16192734_1_234", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16192734_1_235", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16192734_1_236", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16192734_1_237", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "536470_2_238", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "536470_2_239", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "536470_2_240", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "536470_2_241", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "536470_2_242", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "536470_2_243", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "536470_2_244", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "536470_2_245", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "536470_2_246", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "536470_2_247", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "536470_2_248", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "536470_2_249", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "536470_2_250", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "536470_2_251", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "536470_2_252", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "536470_2_253", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "536470_2_254", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "536470_2_255", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "536470_2_256", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "536470_2_257", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "536470_2_258", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "536470_2_259", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "536470_2_260", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "536470_2_261", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "536470_2_262", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "536470_2_263", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8912599_7_264", "context": "Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8912599_7_265", "context": "Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8912599_7_266", "context": "Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8912599_7_267", "context": "Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8912599_7_268", "context": "Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8912599_7_269", "context": "Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8912599_7_270", "context": "Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8912599_7_271", "context": "Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16728538_2_272", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16728538_2_273", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16728538_2_274", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16728538_2_275", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16728538_2_276", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16728538_2_277", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16728538_2_278", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16728538_2_279", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16728538_2_280", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16728538_2_281", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16728538_2_282", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16728538_2_283", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16728538_2_284", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7978578_2_285", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7978578_2_286", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7978578_2_287", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7978578_2_288", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7978578_2_289", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7978578_2_290", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7978578_2_291", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7978578_2_292", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7978578_2_293", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7978578_2_294", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7978578_2_295", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7978578_2_296", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7978578_2_297", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18425523_3_298", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18425523_3_299", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18425523_3_300", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18425523_3_301", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18425523_3_302", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18425523_3_303", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18425523_3_304", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18425523_3_305", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18425523_3_306", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18425523_3_307", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18425523_3_308", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18425523_3_309", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18425523_3_310", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12022905_5_311", "context": "Priapism associated with zuclopenthixol.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12022905_5_312", "context": "Priapism associated with zuclopenthixol.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12022905_5_313", "context": "Priapism associated with zuclopenthixol.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12022905_5_314", "context": "Priapism associated with zuclopenthixol.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12022905_5_315", "context": "Priapism associated with zuclopenthixol.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12022905_5_316", "context": "Priapism associated with zuclopenthixol.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12022905_5_317", "context": "Priapism associated with zuclopenthixol.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12022905_5_318", "context": "Priapism associated with zuclopenthixol.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12488741_3_319", "context": "Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12488741_3_320", "context": "Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12488741_3_321", "context": "Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12488741_3_322", "context": "Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12488741_3_323", "context": "Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12488741_3_324", "context": "Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12488741_3_325", "context": "Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12488741_3_326", "context": "Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15857283_3_327", "context": "PURPOSE: The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15857283_3_328", "context": "PURPOSE: The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15857283_3_329", "context": "PURPOSE: The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15857283_3_330", "context": "PURPOSE: The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15857283_3_331", "context": "PURPOSE: The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15857283_3_332", "context": "PURPOSE: The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15857283_3_333", "context": "PURPOSE: The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15857283_3_334", "context": "PURPOSE: The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19318596_3_335", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19318596_3_336", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19318596_3_337", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19318596_3_338", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19318596_3_339", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19318596_3_340", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19318596_3_341", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19318596_3_342", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19318596_3_343", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19318596_3_344", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19318596_3_345", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19318596_3_346", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19318596_3_347", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14684937_4_348", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14684937_4_349", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14684937_4_350", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14684937_4_351", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14684937_4_352", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14684937_4_353", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14684937_4_354", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14684937_4_355", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14684937_4_356", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14684937_4_357", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14684937_4_358", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14684937_4_359", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14684937_4_360", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16341621_3_361", "context": "To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16341621_3_362", "context": "To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16341621_3_363", "context": "To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16341621_3_364", "context": "To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16341621_3_365", "context": "To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16341621_3_366", "context": "To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16341621_3_367", "context": "To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16341621_3_368", "context": "To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15595320_3_369", "context": "Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15595320_3_370", "context": "Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15595320_3_371", "context": "Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15595320_3_372", "context": "Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15595320_3_373", "context": "Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15595320_3_374", "context": "Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15595320_3_375", "context": "Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15595320_3_376", "context": "Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3868420_1_377", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3868420_1_378", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3868420_1_379", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3868420_1_380", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3868420_1_381", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3868420_1_382", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3868420_1_383", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3868420_1_384", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3868420_1_385", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3868420_1_386", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3868420_1_387", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3868420_1_388", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3868420_1_389", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3174043_1_390", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3174043_1_391", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3174043_1_392", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3174043_1_393", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3174043_1_394", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3174043_1_395", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3174043_1_396", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3174043_1_397", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3174043_1_398", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3174043_1_399", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3174043_1_400", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3174043_1_401", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3174043_1_402", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6854698_1_403", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6854698_1_404", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6854698_1_405", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6854698_1_406", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6854698_1_407", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6854698_1_408", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6854698_1_409", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6854698_1_410", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6854698_1_411", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6854698_1_412", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6854698_1_413", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6854698_1_414", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6854698_1_415", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12022905_2_416", "context": "CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12022905_2_417", "context": "CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12022905_2_418", "context": "CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12022905_2_419", "context": "CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12022905_2_420", "context": "CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12022905_2_421", "context": "CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12022905_2_422", "context": "CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12022905_2_423", "context": "CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14766993_2_424", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14766993_2_425", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14766993_2_426", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14766993_2_427", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14766993_2_428", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14766993_2_429", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14766993_2_430", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14766993_2_431", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14766993_2_432", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14766993_2_433", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14766993_2_434", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14766993_2_435", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14766993_2_436", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17167851_1_437", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17167851_1_438", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17167851_1_439", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17167851_1_440", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17167851_1_441", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17167851_1_442", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17167851_1_443", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17167851_1_444", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17167851_1_445", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17167851_1_446", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17167851_1_447", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17167851_1_448", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17167851_1_449", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14561622_1_450", "context": "Neurotoxicity of intrathecal methotrexate: MR imaging findings.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14561622_1_451", "context": "Neurotoxicity of intrathecal methotrexate: MR imaging findings.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14561622_1_452", "context": "Neurotoxicity of intrathecal methotrexate: MR imaging findings.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14561622_1_453", "context": "Neurotoxicity of intrathecal methotrexate: MR imaging findings.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14561622_1_454", "context": "Neurotoxicity of intrathecal methotrexate: MR imaging findings.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14561622_1_455", "context": "Neurotoxicity of intrathecal methotrexate: MR imaging findings.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14561622_1_456", "context": "Neurotoxicity of intrathecal methotrexate: MR imaging findings.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14561622_1_457", "context": "Neurotoxicity of intrathecal methotrexate: MR imaging findings.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11804071_2_458", "context": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11804071_2_459", "context": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11804071_2_460", "context": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11804071_2_461", "context": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11804071_2_462", "context": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11804071_2_463", "context": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11804071_2_464", "context": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11804071_2_465", "context": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18523232_5_466", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18523232_5_467", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18523232_5_468", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18523232_5_469", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18523232_5_470", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18523232_5_471", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18523232_5_472", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18523232_5_473", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18523232_5_474", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18523232_5_475", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18523232_5_476", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18523232_5_477", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18523232_5_478", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4066620_3_479", "context": "The elicitation of a movement disorder by trazodone: case report.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "4066620_3_480", "context": "The elicitation of a movement disorder by trazodone: case report.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4066620_3_481", "context": "The elicitation of a movement disorder by trazodone: case report.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4066620_3_482", "context": "The elicitation of a movement disorder by trazodone: case report.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4066620_3_483", "context": "The elicitation of a movement disorder by trazodone: case report.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4066620_3_484", "context": "The elicitation of a movement disorder by trazodone: case report.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4066620_3_485", "context": "The elicitation of a movement disorder by trazodone: case report.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4066620_3_486", "context": "The elicitation of a movement disorder by trazodone: case report.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6572542_2_487", "context": "Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6572542_2_488", "context": "Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6572542_2_489", "context": "Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6572542_2_490", "context": "Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6572542_2_491", "context": "Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6572542_2_492", "context": "Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6572542_2_493", "context": "Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6572542_2_494", "context": "Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9007910_2_495", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9007910_2_496", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9007910_2_497", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9007910_2_498", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9007910_2_499", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9007910_2_500", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9007910_2_501", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9007910_2_502", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9007910_2_503", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9007910_2_504", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9007910_2_505", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9007910_2_506", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9007910_2_507", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6697887_3_508", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6697887_3_509", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6697887_3_510", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6697887_3_511", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6697887_3_512", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6697887_3_513", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6697887_3_514", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6697887_3_515", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6697887_3_516", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6697887_3_517", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6697887_3_518", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6697887_3_519", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6697887_3_520", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10212021_4_521", "context": "Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "10212021_4_522", "context": "Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10212021_4_523", "context": "Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10212021_4_524", "context": "Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10212021_4_525", "context": "Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10212021_4_526", "context": "Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10212021_4_527", "context": "Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "10212021_4_528", "context": "Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "21515865_9_529", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "21515865_9_530", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "21515865_9_531", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "21515865_9_532", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "21515865_9_533", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "21515865_9_534", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21515865_9_535", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21515865_9_536", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21515865_9_537", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21515865_9_538", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21515865_9_539", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21515865_9_540", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21515865_9_541", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21515865_9_542", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "21515865_9_543", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "21515865_9_544", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "21515865_9_545", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "21515865_9_546", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21515865_9_547", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "21515865_9_548", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "21515865_9_549", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "22677303_3_550", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "22677303_3_551", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "22677303_3_552", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "22677303_3_553", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "22677303_3_554", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "22677303_3_555", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "22677303_3_556", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "22677303_3_557", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "22677303_3_558", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "22677303_3_559", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22677303_3_560", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "22677303_3_561", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "22677303_3_562", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "1703754_1_563", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1703754_1_564", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1703754_1_565", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1703754_1_566", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1703754_1_567", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1703754_1_568", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1703754_1_569", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1703754_1_570", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1703754_1_571", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1703754_1_572", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1703754_1_573", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1703754_1_574", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1703754_1_575", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9352164_1_576", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9352164_1_577", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9352164_1_578", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9352164_1_579", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9352164_1_580", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9352164_1_581", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9352164_1_582", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9352164_1_583", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9352164_1_584", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9352164_1_585", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9352164_1_586", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9352164_1_587", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9352164_1_588", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4066620_2_589", "context": "Although the movement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "4066620_2_590", "context": "Although the movement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4066620_2_591", "context": "Although the movement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4066620_2_592", "context": "Although the movement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4066620_2_593", "context": "Although the movement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4066620_2_594", "context": "Although the movement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4066620_2_595", "context": "Although the movement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4066620_2_596", "context": "Although the movement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18523232_2_597", "context": "CONCLUSIONS: Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18523232_2_598", "context": "CONCLUSIONS: Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18523232_2_599", "context": "CONCLUSIONS: Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18523232_2_600", "context": "CONCLUSIONS: Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18523232_2_601", "context": "CONCLUSIONS: Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18523232_2_602", "context": "CONCLUSIONS: Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18523232_2_603", "context": "CONCLUSIONS: Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18523232_2_604", "context": "CONCLUSIONS: Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "507889_1_605", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "507889_1_606", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "507889_1_607", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "507889_1_608", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "507889_1_609", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "507889_1_610", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "507889_1_611", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "507889_1_612", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "507889_1_613", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "507889_1_614", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "507889_1_615", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "507889_1_616", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "507889_1_617", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15663666_1_618", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15663666_1_619", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15663666_1_620", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15663666_1_621", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15663666_1_622", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15663666_1_623", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15663666_1_624", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15663666_1_625", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15663666_1_626", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15663666_1_627", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15663666_1_628", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15663666_1_629", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15663666_1_630", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6693840_1_631", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6693840_1_632", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6693840_1_633", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6693840_1_634", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6693840_1_635", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6693840_1_636", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6693840_1_637", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6693840_1_638", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6693840_1_639", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6693840_1_640", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6693840_1_641", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6693840_1_642", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6693840_1_643", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2483959_3_644", "context": "Several possible explanations of the mechanism of renal failure associated with the use of dextran-40 are discussed.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2483959_3_645", "context": "Several possible explanations of the mechanism of renal failure associated with the use of dextran-40 are discussed.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2483959_3_646", "context": "Several possible explanations of the mechanism of renal failure associated with the use of dextran-40 are discussed.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2483959_3_647", "context": "Several possible explanations of the mechanism of renal failure associated with the use of dextran-40 are discussed.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2483959_3_648", "context": "Several possible explanations of the mechanism of renal failure associated with the use of dextran-40 are discussed.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2483959_3_649", "context": "Several possible explanations of the mechanism of renal failure associated with the use of dextran-40 are discussed.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2483959_3_650", "context": "Several possible explanations of the mechanism of renal failure associated with the use of dextran-40 are discussed.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2483959_3_651", "context": "Several possible explanations of the mechanism of renal failure associated with the use of dextran-40 are discussed.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20349794_2_652", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20349794_2_653", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20349794_2_654", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20349794_2_655", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20349794_2_656", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20349794_2_657", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20349794_2_658", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20349794_2_659", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20349794_2_660", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20349794_2_661", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20349794_2_662", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20349794_2_663", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20349794_2_664", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18675768_5_665", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "18675768_5_666", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "18675768_5_667", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "18675768_5_668", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "18675768_5_669", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "18675768_5_670", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "18675768_5_671", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18675768_5_672", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18675768_5_673", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18675768_5_674", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18675768_5_675", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18675768_5_676", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "18675768_5_677", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "20925534_12_678", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20925534_12_679", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20925534_12_680", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20925534_12_681", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20925534_12_682", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20925534_12_683", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20925534_12_684", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20925534_12_685", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20925534_12_686", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20925534_12_687", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20925534_12_688", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20925534_12_689", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20925534_12_690", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6731466_10_691", "context": "The mechanism of anaphylactoid reaction to zomepirac in this case, therefore, remains unclear.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6731466_10_692", "context": "The mechanism of anaphylactoid reaction to zomepirac in this case, therefore, remains unclear.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6731466_10_693", "context": "The mechanism of anaphylactoid reaction to zomepirac in this case, therefore, remains unclear.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6731466_10_694", "context": "The mechanism of anaphylactoid reaction to zomepirac in this case, therefore, remains unclear.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6731466_10_695", "context": "The mechanism of anaphylactoid reaction to zomepirac in this case, therefore, remains unclear.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6731466_10_696", "context": "The mechanism of anaphylactoid reaction to zomepirac in this case, therefore, remains unclear.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6731466_10_697", "context": "The mechanism of anaphylactoid reaction to zomepirac in this case, therefore, remains unclear.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6731466_10_698", "context": "The mechanism of anaphylactoid reaction to zomepirac in this case, therefore, remains unclear.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18203308_1_699", "context": "New onset of CD may be considered as an immune-mediated injury induced by etanercept.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18203308_1_700", "context": "New onset of CD may be considered as an immune-mediated injury induced by etanercept.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18203308_1_701", "context": "New onset of CD may be considered as an immune-mediated injury induced by etanercept.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18203308_1_702", "context": "New onset of CD may be considered as an immune-mediated injury induced by etanercept.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18203308_1_703", "context": "New onset of CD may be considered as an immune-mediated injury induced by etanercept.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18203308_1_704", "context": "New onset of CD may be considered as an immune-mediated injury induced by etanercept.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18203308_1_705", "context": "New onset of CD may be considered as an immune-mediated injury induced by etanercept.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18203308_1_706", "context": "New onset of CD may be considered as an immune-mediated injury induced by etanercept.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11109149_2_707", "context": "This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11109149_2_708", "context": "This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11109149_2_709", "context": "This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11109149_2_710", "context": "This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11109149_2_711", "context": "This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11109149_2_712", "context": "This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11109149_2_713", "context": "This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11109149_2_714", "context": "This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "24918555_1_715", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "24918555_1_716", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "24918555_1_717", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "24918555_1_718", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "24918555_1_719", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "24918555_1_720", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "24918555_1_721", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "24918555_1_722", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "24918555_1_723", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "24918555_1_724", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "24918555_1_725", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "24918555_1_726", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "24918555_1_727", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16490518_4_728", "context": "This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16490518_4_729", "context": "This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16490518_4_730", "context": "This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16490518_4_731", "context": "This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16490518_4_732", "context": "This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16490518_4_733", "context": "This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16490518_4_734", "context": "This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16490518_4_735", "context": "This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3708949_4_736", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3708949_4_737", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3708949_4_738", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3708949_4_739", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3708949_4_740", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3708949_4_741", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3708949_4_742", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3708949_4_743", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3708949_4_744", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3708949_4_745", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3708949_4_746", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3708949_4_747", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3708949_4_748", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11485141_5_749", "context": "Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11485141_5_750", "context": "Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11485141_5_751", "context": "Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11485141_5_752", "context": "Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11485141_5_753", "context": "Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11485141_5_754", "context": "Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11485141_5_755", "context": "Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11485141_5_756", "context": "Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20925534_11_757", "context": "The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P = 0.001).", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20925534_11_758", "context": "The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P = 0.001).", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20925534_11_759", "context": "The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P = 0.001).", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20925534_11_760", "context": "The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P = 0.001).", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20925534_11_761", "context": "The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P = 0.001).", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20925534_11_762", "context": "The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P = 0.001).", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20925534_11_763", "context": "The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P = 0.001).", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20925534_11_764", "context": "The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P = 0.001).", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8145359_2_765", "context": "The association of phenothiazine overdose and respiratory distress syndrome merits consideration.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8145359_2_766", "context": "The association of phenothiazine overdose and respiratory distress syndrome merits consideration.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8145359_2_767", "context": "The association of phenothiazine overdose and respiratory distress syndrome merits consideration.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8145359_2_768", "context": "The association of phenothiazine overdose and respiratory distress syndrome merits consideration.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8145359_2_769", "context": "The association of phenothiazine overdose and respiratory distress syndrome merits consideration.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8145359_2_770", "context": "The association of phenothiazine overdose and respiratory distress syndrome merits consideration.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8145359_2_771", "context": "The association of phenothiazine overdose and respiratory distress syndrome merits consideration.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8145359_2_772", "context": "The association of phenothiazine overdose and respiratory distress syndrome merits consideration.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6340463_4_773", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6340463_4_774", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6340463_4_775", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6340463_4_776", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6340463_4_777", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6340463_4_778", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6340463_4_779", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6340463_4_780", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6340463_4_781", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6340463_4_782", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6340463_4_783", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6340463_4_784", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6340463_4_785", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12477460_1_786", "context": "Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12477460_1_787", "context": "Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12477460_1_788", "context": "Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12477460_1_789", "context": "Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12477460_1_790", "context": "Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12477460_1_791", "context": "Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12477460_1_792", "context": "Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12477460_1_793", "context": "Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9562211_1_794", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9562211_1_795", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9562211_1_796", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9562211_1_797", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9562211_1_798", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9562211_1_799", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9562211_1_800", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9562211_1_801", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9562211_1_802", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9562211_1_803", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9562211_1_804", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9562211_1_805", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9562211_1_806", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22047557_8_807", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "22047557_8_808", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "22047557_8_809", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "22047557_8_810", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "22047557_8_811", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "22047557_8_812", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "22047557_8_813", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22047557_8_814", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22047557_8_815", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22047557_8_816", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22047557_8_817", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22047557_8_818", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22047557_8_819", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10759907_2_820", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10759907_2_821", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10759907_2_822", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10759907_2_823", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10759907_2_824", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10759907_2_825", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10759907_2_826", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10759907_2_827", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10759907_2_828", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10759907_2_829", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10759907_2_830", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10759907_2_831", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10759907_2_832", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12854039_3_833", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12854039_3_834", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12854039_3_835", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12854039_3_836", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12854039_3_837", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12854039_3_838", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12854039_3_839", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12854039_3_840", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12854039_3_841", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12854039_3_842", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12854039_3_843", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12854039_3_844", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12854039_3_845", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6794018_3_846", "context": "These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6794018_3_847", "context": "These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6794018_3_848", "context": "These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6794018_3_849", "context": "These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6794018_3_850", "context": "These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6794018_3_851", "context": "These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6794018_3_852", "context": "These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6794018_3_853", "context": "These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9562211_2_854", "context": "Risperidone-induced tardive dyskinesia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9562211_2_855", "context": "Risperidone-induced tardive dyskinesia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9562211_2_856", "context": "Risperidone-induced tardive dyskinesia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9562211_2_857", "context": "Risperidone-induced tardive dyskinesia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9562211_2_858", "context": "Risperidone-induced tardive dyskinesia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9562211_2_859", "context": "Risperidone-induced tardive dyskinesia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9562211_2_860", "context": "Risperidone-induced tardive dyskinesia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9562211_2_861", "context": "Risperidone-induced tardive dyskinesia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9737132_2_862", "context": "Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9737132_2_863", "context": "Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9737132_2_864", "context": "Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9737132_2_865", "context": "Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9737132_2_866", "context": "Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9737132_2_867", "context": "Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9737132_2_868", "context": "Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9737132_2_869", "context": "Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3359700_2_870", "context": "Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3359700_2_871", "context": "Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3359700_2_872", "context": "Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3359700_2_873", "context": "Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3359700_2_874", "context": "Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3359700_2_875", "context": "Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3359700_2_876", "context": "Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3359700_2_877", "context": "Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3174043_2_878", "context": "Niacin maculopathy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3174043_2_879", "context": "Niacin maculopathy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3174043_2_880", "context": "Niacin maculopathy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3174043_2_881", "context": "Niacin maculopathy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3174043_2_882", "context": "Niacin maculopathy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3174043_2_883", "context": "Niacin maculopathy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3174043_2_884", "context": "Niacin maculopathy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3174043_2_885", "context": "Niacin maculopathy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22293514_5_886", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "22293514_5_887", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "22293514_5_888", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "22293514_5_889", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "22293514_5_890", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "22293514_5_891", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "22293514_5_892", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22293514_5_893", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22293514_5_894", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22293514_5_895", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22293514_5_896", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22293514_5_897", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22293514_5_898", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22293514_5_899", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "22293514_5_900", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "22293514_5_901", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "22293514_5_902", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "22293514_5_903", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22293514_5_904", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "22293514_5_905", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "22293514_5_906", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11202801_1_907", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11202801_1_908", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11202801_1_909", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11202801_1_910", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11202801_1_911", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11202801_1_912", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11202801_1_913", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11202801_1_914", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11202801_1_915", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11202801_1_916", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11202801_1_917", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11202801_1_918", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11202801_1_919", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18076602_3_920", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18076602_3_921", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18076602_3_922", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18076602_3_923", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18076602_3_924", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18076602_3_925", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18076602_3_926", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18076602_3_927", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18076602_3_928", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18076602_3_929", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18076602_3_930", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18076602_3_931", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18076602_3_932", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18364401_5_933", "context": "There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18364401_5_934", "context": "There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18364401_5_935", "context": "There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18364401_5_936", "context": "There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18364401_5_937", "context": "There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18364401_5_938", "context": "There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18364401_5_939", "context": "There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18364401_5_940", "context": "There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23970584_2_941", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "23970584_2_942", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "23970584_2_943", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "23970584_2_944", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "23970584_2_945", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "23970584_2_946", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "23970584_2_947", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "23970584_2_948", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "23970584_2_949", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "23970584_2_950", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23970584_2_951", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "23970584_2_952", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "23970584_2_953", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16101941_2_954", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16101941_2_955", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16101941_2_956", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16101941_2_957", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16101941_2_958", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16101941_2_959", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16101941_2_960", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16101941_2_961", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16101941_2_962", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16101941_2_963", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16101941_2_964", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16101941_2_965", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16101941_2_966", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2483959_2_967", "context": "Renal failure associated with the use of dextran-40.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2483959_2_968", "context": "Renal failure associated with the use of dextran-40.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2483959_2_969", "context": "Renal failure associated with the use of dextran-40.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2483959_2_970", "context": "Renal failure associated with the use of dextran-40.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2483959_2_971", "context": "Renal failure associated with the use of dextran-40.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2483959_2_972", "context": "Renal failure associated with the use of dextran-40.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2483959_2_973", "context": "Renal failure associated with the use of dextran-40.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2483959_2_974", "context": "Renal failure associated with the use of dextran-40.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11510798_1_975", "context": "Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11510798_1_976", "context": "Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11510798_1_977", "context": "Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11510798_1_978", "context": "Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11510798_1_979", "context": "Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11510798_1_980", "context": "Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11510798_1_981", "context": "Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11510798_1_982", "context": "Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11155197_3_983", "context": "Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11155197_3_984", "context": "Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11155197_3_985", "context": "Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11155197_3_986", "context": "Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11155197_3_987", "context": "Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11155197_3_988", "context": "Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11155197_3_989", "context": "Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11155197_3_990", "context": "Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7485371_3_991", "context": "RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7485371_3_992", "context": "RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7485371_3_993", "context": "RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7485371_3_994", "context": "RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7485371_3_995", "context": "RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7485371_3_996", "context": "RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7485371_3_997", "context": "RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7485371_3_998", "context": "RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11109149_1_999", "context": "Gangrene of the fingertips after bleomycin and methotrexate.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11109149_1_1000", "context": "Gangrene of the fingertips after bleomycin and methotrexate.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11109149_1_1001", "context": "Gangrene of the fingertips after bleomycin and methotrexate.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11109149_1_1002", "context": "Gangrene of the fingertips after bleomycin and methotrexate.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11109149_1_1003", "context": "Gangrene of the fingertips after bleomycin and methotrexate.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11109149_1_1004", "context": "Gangrene of the fingertips after bleomycin and methotrexate.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11109149_1_1005", "context": "Gangrene of the fingertips after bleomycin and methotrexate.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11109149_1_1006", "context": "Gangrene of the fingertips after bleomycin and methotrexate.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8404753_9_1007", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8404753_9_1008", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8404753_9_1009", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8404753_9_1010", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8404753_9_1011", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8404753_9_1012", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8404753_9_1013", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8404753_9_1014", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8404753_9_1015", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8404753_9_1016", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8404753_9_1017", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8404753_9_1018", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8404753_9_1019", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3964363_2_1020", "context": "Esophageal spasm following propranolol overdose relieved by glucagon.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "3964363_2_1021", "context": "Esophageal spasm following propranolol overdose relieved by glucagon.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "3964363_2_1022", "context": "Esophageal spasm following propranolol overdose relieved by glucagon.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "3964363_2_1023", "context": "Esophageal spasm following propranolol overdose relieved by glucagon.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "3964363_2_1024", "context": "Esophageal spasm following propranolol overdose relieved by glucagon.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3964363_2_1025", "context": "Esophageal spasm following propranolol overdose relieved by glucagon.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "3964363_2_1026", "context": "Esophageal spasm following propranolol overdose relieved by glucagon.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "3964363_2_1027", "context": "Esophageal spasm following propranolol overdose relieved by glucagon.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9352164_3_1028", "context": "She was thus diagnosed as having AZ intoxication.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9352164_3_1029", "context": "She was thus diagnosed as having AZ intoxication.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9352164_3_1030", "context": "She was thus diagnosed as having AZ intoxication.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9352164_3_1031", "context": "She was thus diagnosed as having AZ intoxication.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9352164_3_1032", "context": "She was thus diagnosed as having AZ intoxication.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9352164_3_1033", "context": "She was thus diagnosed as having AZ intoxication.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9352164_3_1034", "context": "She was thus diagnosed as having AZ intoxication.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9352164_3_1035", "context": "She was thus diagnosed as having AZ intoxication.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9352164_3_1036", "context": "She was thus diagnosed as having AZ intoxication.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9352164_3_1037", "context": "She was thus diagnosed as having AZ intoxication.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9352164_3_1038", "context": "She was thus diagnosed as having AZ intoxication.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9352164_3_1039", "context": "She was thus diagnosed as having AZ intoxication.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9352164_3_1040", "context": "She was thus diagnosed as having AZ intoxication.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10592946_3_1041", "context": "Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10592946_3_1042", "context": "Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10592946_3_1043", "context": "Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10592946_3_1044", "context": "Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10592946_3_1045", "context": "Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10592946_3_1046", "context": "Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10592946_3_1047", "context": "Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10592946_3_1048", "context": "Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15663666_2_1049", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "15663666_2_1050", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15663666_2_1051", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15663666_2_1052", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15663666_2_1053", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15663666_2_1054", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15663666_2_1055", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "15663666_2_1056", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9726762_1_1057", "context": "Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9726762_1_1058", "context": "Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9726762_1_1059", "context": "Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9726762_1_1060", "context": "Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9726762_1_1061", "context": "Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9726762_1_1062", "context": "Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9726762_1_1063", "context": "Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9726762_1_1064", "context": "Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17665812_2_1065", "context": "Drug-induced eosinophilia is a non-dose-dependent side effect of clozapine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17665812_2_1066", "context": "Drug-induced eosinophilia is a non-dose-dependent side effect of clozapine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17665812_2_1067", "context": "Drug-induced eosinophilia is a non-dose-dependent side effect of clozapine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17665812_2_1068", "context": "Drug-induced eosinophilia is a non-dose-dependent side effect of clozapine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17665812_2_1069", "context": "Drug-induced eosinophilia is a non-dose-dependent side effect of clozapine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17665812_2_1070", "context": "Drug-induced eosinophilia is a non-dose-dependent side effect of clozapine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17665812_2_1071", "context": "Drug-induced eosinophilia is a non-dose-dependent side effect of clozapine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17665812_2_1072", "context": "Drug-induced eosinophilia is a non-dose-dependent side effect of clozapine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7485371_4_1073", "context": "Vortex keratopathy associated with atovaquone.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7485371_4_1074", "context": "Vortex keratopathy associated with atovaquone.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7485371_4_1075", "context": "Vortex keratopathy associated with atovaquone.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7485371_4_1076", "context": "Vortex keratopathy associated with atovaquone.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7485371_4_1077", "context": "Vortex keratopathy associated with atovaquone.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7485371_4_1078", "context": "Vortex keratopathy associated with atovaquone.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7485371_4_1079", "context": "Vortex keratopathy associated with atovaquone.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7485371_4_1080", "context": "Vortex keratopathy associated with atovaquone.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18037876_1_1081", "context": "DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18037876_1_1082", "context": "DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18037876_1_1083", "context": "DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18037876_1_1084", "context": "DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18037876_1_1085", "context": "DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18037876_1_1086", "context": "DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18037876_1_1087", "context": "DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18037876_1_1088", "context": "DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "910864_1_1089", "context": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "910864_1_1090", "context": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "910864_1_1091", "context": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "910864_1_1092", "context": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "910864_1_1093", "context": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "910864_1_1094", "context": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "910864_1_1095", "context": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "910864_1_1096", "context": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17182354_1_1097", "context": "However, an association of Ritalin with glaucoma has been reported.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17182354_1_1098", "context": "However, an association of Ritalin with glaucoma has been reported.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17182354_1_1099", "context": "However, an association of Ritalin with glaucoma has been reported.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17182354_1_1100", "context": "However, an association of Ritalin with glaucoma has been reported.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17182354_1_1101", "context": "However, an association of Ritalin with glaucoma has been reported.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17182354_1_1102", "context": "However, an association of Ritalin with glaucoma has been reported.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17182354_1_1103", "context": "However, an association of Ritalin with glaucoma has been reported.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17182354_1_1104", "context": "However, an association of Ritalin with glaucoma has been reported.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12854039_1_1105", "context": "After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12854039_1_1106", "context": "After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12854039_1_1107", "context": "After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12854039_1_1108", "context": "After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12854039_1_1109", "context": "After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12854039_1_1110", "context": "After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12854039_1_1111", "context": "After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12854039_1_1112", "context": "After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "25842648_7_1113", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "25842648_7_1114", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "25842648_7_1115", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "25842648_7_1116", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "25842648_7_1117", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "25842648_7_1118", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "25842648_7_1119", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "25842648_7_1120", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2483959_4_1121", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2483959_4_1122", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2483959_4_1123", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2483959_4_1124", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2483959_4_1125", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2483959_4_1126", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2483959_4_1127", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2483959_4_1128", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9865241_4_1129", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "9865241_4_1130", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9865241_4_1131", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9865241_4_1132", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9865241_4_1133", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9865241_4_1134", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9865241_4_1135", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "9865241_4_1136", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "14614357_1_1137", "context": "Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14614357_1_1138", "context": "Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14614357_1_1139", "context": "Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14614357_1_1140", "context": "Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14614357_1_1141", "context": "Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14614357_1_1142", "context": "Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14614357_1_1143", "context": "Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14614357_1_1144", "context": "Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8589490_3_1145", "context": "We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8589490_3_1146", "context": "We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8589490_3_1147", "context": "We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8589490_3_1148", "context": "We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8589490_3_1149", "context": "We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8589490_3_1150", "context": "We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8589490_3_1151", "context": "We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8589490_3_1152", "context": "We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12488741_2_1153", "context": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12488741_2_1154", "context": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12488741_2_1155", "context": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12488741_2_1156", "context": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12488741_2_1157", "context": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12488741_2_1158", "context": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12488741_2_1159", "context": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12488741_2_1160", "context": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1422497_1_1161", "context": "Encephalopathy and seizures induced by intravesical alum irrigations.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1422497_1_1162", "context": "Encephalopathy and seizures induced by intravesical alum irrigations.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1422497_1_1163", "context": "Encephalopathy and seizures induced by intravesical alum irrigations.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1422497_1_1164", "context": "Encephalopathy and seizures induced by intravesical alum irrigations.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1422497_1_1165", "context": "Encephalopathy and seizures induced by intravesical alum irrigations.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1422497_1_1166", "context": "Encephalopathy and seizures induced by intravesical alum irrigations.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1422497_1_1167", "context": "Encephalopathy and seizures induced by intravesical alum irrigations.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1422497_1_1168", "context": "Encephalopathy and seizures induced by intravesical alum irrigations.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15522120_17_1169", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15522120_17_1170", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15522120_17_1171", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15522120_17_1172", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15522120_17_1173", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15522120_17_1174", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15522120_17_1175", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15522120_17_1176", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15522120_17_1177", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15522120_17_1178", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15522120_17_1179", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15522120_17_1180", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15522120_17_1181", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12659609_3_1182", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "12659609_3_1183", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "12659609_3_1184", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "12659609_3_1185", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "12659609_3_1186", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "12659609_3_1187", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "12659609_3_1188", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12659609_3_1189", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12659609_3_1190", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12659609_3_1191", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12659609_3_1192", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12659609_3_1193", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "12659609_3_1194", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "19266307_2_1195", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19266307_2_1196", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19266307_2_1197", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19266307_2_1198", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19266307_2_1199", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19266307_2_1200", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19266307_2_1201", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19266307_2_1202", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19266307_2_1203", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19266307_2_1204", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19266307_2_1205", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19266307_2_1206", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19266307_2_1207", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18628507_2_1208", "context": "Angio-oedema as an unusual tolerable side effect of voriconazole therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18628507_2_1209", "context": "Angio-oedema as an unusual tolerable side effect of voriconazole therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18628507_2_1210", "context": "Angio-oedema as an unusual tolerable side effect of voriconazole therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18628507_2_1211", "context": "Angio-oedema as an unusual tolerable side effect of voriconazole therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18628507_2_1212", "context": "Angio-oedema as an unusual tolerable side effect of voriconazole therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18628507_2_1213", "context": "Angio-oedema as an unusual tolerable side effect of voriconazole therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18628507_2_1214", "context": "Angio-oedema as an unusual tolerable side effect of voriconazole therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18628507_2_1215", "context": "Angio-oedema as an unusual tolerable side effect of voriconazole therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18262450_8_1216", "context": "Oxycodone-gabapentin reduced pain score by 33% from baseline to end of treatment.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "18262450_8_1217", "context": "Oxycodone-gabapentin reduced pain score by 33% from baseline to end of treatment.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18262450_8_1218", "context": "Oxycodone-gabapentin reduced pain score by 33% from baseline to end of treatment.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18262450_8_1219", "context": "Oxycodone-gabapentin reduced pain score by 33% from baseline to end of treatment.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18262450_8_1220", "context": "Oxycodone-gabapentin reduced pain score by 33% from baseline to end of treatment.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18262450_8_1221", "context": "Oxycodone-gabapentin reduced pain score by 33% from baseline to end of treatment.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18262450_8_1222", "context": "Oxycodone-gabapentin reduced pain score by 33% from baseline to end of treatment.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "18262450_8_1223", "context": "Oxycodone-gabapentin reduced pain score by 33% from baseline to end of treatment.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10435399_2_1224", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10435399_2_1225", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10435399_2_1226", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10435399_2_1227", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10435399_2_1228", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10435399_2_1229", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10435399_2_1230", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10435399_2_1231", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10435399_2_1232", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10435399_2_1233", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10435399_2_1234", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10435399_2_1235", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10435399_2_1236", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11352235_5_1237", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11352235_5_1238", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11352235_5_1239", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11352235_5_1240", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11352235_5_1241", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11352235_5_1242", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11352235_5_1243", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11352235_5_1244", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11352235_5_1245", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11352235_5_1246", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11352235_5_1247", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11352235_5_1248", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11352235_5_1249", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16018164_2_1250", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16018164_2_1251", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16018164_2_1252", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16018164_2_1253", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16018164_2_1254", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16018164_2_1255", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16018164_2_1256", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16018164_2_1257", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16018164_2_1258", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16018164_2_1259", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16018164_2_1260", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16018164_2_1261", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16018164_2_1262", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16101941_1_1263", "context": "Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16101941_1_1264", "context": "Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16101941_1_1265", "context": "Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16101941_1_1266", "context": "Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16101941_1_1267", "context": "Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16101941_1_1268", "context": "Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16101941_1_1269", "context": "Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16101941_1_1270", "context": "Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8430717_4_1271", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8430717_4_1272", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8430717_4_1273", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8430717_4_1274", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8430717_4_1275", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8430717_4_1276", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8430717_4_1277", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8430717_4_1278", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8430717_4_1279", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8430717_4_1280", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8430717_4_1281", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8430717_4_1282", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8430717_4_1283", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16317298_3_1284", "context": "Radiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16317298_3_1285", "context": "Radiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16317298_3_1286", "context": "Radiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16317298_3_1287", "context": "Radiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16317298_3_1288", "context": "Radiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16317298_3_1289", "context": "Radiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16317298_3_1290", "context": "Radiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16317298_3_1291", "context": "Radiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15368548_3_1292", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15368548_3_1293", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15368548_3_1294", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15368548_3_1295", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15368548_3_1296", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15368548_3_1297", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15368548_3_1298", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15368548_3_1299", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23970584_6_1300", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "23970584_6_1301", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "23970584_6_1302", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "23970584_6_1303", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "23970584_6_1304", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "23970584_6_1305", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "23970584_6_1306", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "23970584_6_1307", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "23970584_6_1308", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "23970584_6_1309", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23970584_6_1310", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "23970584_6_1311", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "23970584_6_1312", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9562211_3_1313", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9562211_3_1314", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9562211_3_1315", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9562211_3_1316", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9562211_3_1317", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9562211_3_1318", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9562211_3_1319", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9562211_3_1320", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16288069_4_1321", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16288069_4_1322", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16288069_4_1323", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16288069_4_1324", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16288069_4_1325", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16288069_4_1326", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16288069_4_1327", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16288069_4_1328", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16288069_4_1329", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16288069_4_1330", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16288069_4_1331", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16288069_4_1332", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16288069_4_1333", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15927910_4_1334", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15927910_4_1335", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15927910_4_1336", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15927910_4_1337", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15927910_4_1338", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15927910_4_1339", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15927910_4_1340", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15927910_4_1341", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15286697_1_1342", "context": "Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15286697_1_1343", "context": "Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15286697_1_1344", "context": "Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15286697_1_1345", "context": "Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15286697_1_1346", "context": "Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15286697_1_1347", "context": "Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15286697_1_1348", "context": "Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15286697_1_1349", "context": "Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10492493_1_1350", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10492493_1_1351", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10492493_1_1352", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10492493_1_1353", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10492493_1_1354", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10492493_1_1355", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10492493_1_1356", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10492493_1_1357", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10492493_1_1358", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10492493_1_1359", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10492493_1_1360", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10492493_1_1361", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10492493_1_1362", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3211830_1_1363", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3211830_1_1364", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3211830_1_1365", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3211830_1_1366", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3211830_1_1367", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3211830_1_1368", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3211830_1_1369", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3211830_1_1370", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3211830_1_1371", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3211830_1_1372", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3211830_1_1373", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3211830_1_1374", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3211830_1_1375", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10492493_4_1376", "context": "The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10492493_4_1377", "context": "The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10492493_4_1378", "context": "The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10492493_4_1379", "context": "The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10492493_4_1380", "context": "The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10492493_4_1381", "context": "The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10492493_4_1382", "context": "The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10492493_4_1383", "context": "The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18347524_2_1384", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18347524_2_1385", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18347524_2_1386", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18347524_2_1387", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18347524_2_1388", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18347524_2_1389", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18347524_2_1390", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18347524_2_1391", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18347524_2_1392", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18347524_2_1393", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18347524_2_1394", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18347524_2_1395", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18347524_2_1396", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12659609_1_1397", "context": "Toxicity related to chloroquine treatment of resistant vivax malaria.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12659609_1_1398", "context": "Toxicity related to chloroquine treatment of resistant vivax malaria.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12659609_1_1399", "context": "Toxicity related to chloroquine treatment of resistant vivax malaria.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12659609_1_1400", "context": "Toxicity related to chloroquine treatment of resistant vivax malaria.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12659609_1_1401", "context": "Toxicity related to chloroquine treatment of resistant vivax malaria.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12659609_1_1402", "context": "Toxicity related to chloroquine treatment of resistant vivax malaria.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12659609_1_1403", "context": "Toxicity related to chloroquine treatment of resistant vivax malaria.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12659609_1_1404", "context": "Toxicity related to chloroquine treatment of resistant vivax malaria.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8250714_3_1405", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8250714_3_1406", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8250714_3_1407", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8250714_3_1408", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8250714_3_1409", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8250714_3_1410", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8250714_3_1411", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8250714_3_1412", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8250714_3_1413", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8250714_3_1414", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8250714_3_1415", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8250714_3_1416", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8250714_3_1417", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15072497_2_1418", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15072497_2_1419", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15072497_2_1420", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15072497_2_1421", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15072497_2_1422", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15072497_2_1423", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15072497_2_1424", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15072497_2_1425", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15072497_2_1426", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15072497_2_1427", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15072497_2_1428", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15072497_2_1429", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15072497_2_1430", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12786839_3_1431", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12786839_3_1432", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12786839_3_1433", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12786839_3_1434", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12786839_3_1435", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12786839_3_1436", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12786839_3_1437", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12786839_3_1438", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12786839_3_1439", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12786839_3_1440", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12786839_3_1441", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12786839_3_1442", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12786839_3_1443", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1655228_2_1444", "context": "Myocardial ischemia associated with high-dose carmustine infusion.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1655228_2_1445", "context": "Myocardial ischemia associated with high-dose carmustine infusion.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1655228_2_1446", "context": "Myocardial ischemia associated with high-dose carmustine infusion.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1655228_2_1447", "context": "Myocardial ischemia associated with high-dose carmustine infusion.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1655228_2_1448", "context": "Myocardial ischemia associated with high-dose carmustine infusion.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1655228_2_1449", "context": "Myocardial ischemia associated with high-dose carmustine infusion.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1655228_2_1450", "context": "Myocardial ischemia associated with high-dose carmustine infusion.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1655228_2_1451", "context": "Myocardial ischemia associated with high-dose carmustine infusion.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21802143_1_1452", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "21802143_1_1453", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "21802143_1_1454", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "21802143_1_1455", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "21802143_1_1456", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "21802143_1_1457", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21802143_1_1458", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21802143_1_1459", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21802143_1_1460", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21802143_1_1461", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21802143_1_1462", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21802143_1_1463", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21802143_1_1464", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12507063_2_1465", "context": "Gabapentin withdrawal presenting as status epilepticus.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12507063_2_1466", "context": "Gabapentin withdrawal presenting as status epilepticus.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12507063_2_1467", "context": "Gabapentin withdrawal presenting as status epilepticus.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12507063_2_1468", "context": "Gabapentin withdrawal presenting as status epilepticus.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12507063_2_1469", "context": "Gabapentin withdrawal presenting as status epilepticus.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12507063_2_1470", "context": "Gabapentin withdrawal presenting as status epilepticus.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12507063_2_1471", "context": "Gabapentin withdrawal presenting as status epilepticus.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12507063_2_1472", "context": "Gabapentin withdrawal presenting as status epilepticus.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7056119_1_1473", "context": "Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7056119_1_1474", "context": "Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7056119_1_1475", "context": "Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7056119_1_1476", "context": "Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7056119_1_1477", "context": "Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7056119_1_1478", "context": "Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7056119_1_1479", "context": "Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7056119_1_1480", "context": "Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17619811_3_1481", "context": "Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17619811_3_1482", "context": "Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17619811_3_1483", "context": "Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17619811_3_1484", "context": "Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17619811_3_1485", "context": "Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17619811_3_1486", "context": "Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17619811_3_1487", "context": "Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17619811_3_1488", "context": "Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4075534_2_1489", "context": "Spindle coma in benzodiazepine toxicity: case report.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "4075534_2_1490", "context": "Spindle coma in benzodiazepine toxicity: case report.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4075534_2_1491", "context": "Spindle coma in benzodiazepine toxicity: case report.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4075534_2_1492", "context": "Spindle coma in benzodiazepine toxicity: case report.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4075534_2_1493", "context": "Spindle coma in benzodiazepine toxicity: case report.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4075534_2_1494", "context": "Spindle coma in benzodiazepine toxicity: case report.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4075534_2_1495", "context": "Spindle coma in benzodiazepine toxicity: case report.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4075534_2_1496", "context": "Spindle coma in benzodiazepine toxicity: case report.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2483959_1_1497", "context": "A typical case of dextran-40 associated acute renal failure is presented.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2483959_1_1498", "context": "A typical case of dextran-40 associated acute renal failure is presented.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2483959_1_1499", "context": "A typical case of dextran-40 associated acute renal failure is presented.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2483959_1_1500", "context": "A typical case of dextran-40 associated acute renal failure is presented.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2483959_1_1501", "context": "A typical case of dextran-40 associated acute renal failure is presented.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2483959_1_1502", "context": "A typical case of dextran-40 associated acute renal failure is presented.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2483959_1_1503", "context": "A typical case of dextran-40 associated acute renal failure is presented.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2483959_1_1504", "context": "A typical case of dextran-40 associated acute renal failure is presented.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15895899_1_1505", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15895899_1_1506", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15895899_1_1507", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15895899_1_1508", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15895899_1_1509", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15895899_1_1510", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15895899_1_1511", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15895899_1_1512", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15895899_1_1513", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15895899_1_1514", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15895899_1_1515", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15895899_1_1516", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15895899_1_1517", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7712052_1_1518", "context": "Lithium for irritability in post-traumatic stress disorder.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "7712052_1_1519", "context": "Lithium for irritability in post-traumatic stress disorder.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "7712052_1_1520", "context": "Lithium for irritability in post-traumatic stress disorder.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "7712052_1_1521", "context": "Lithium for irritability in post-traumatic stress disorder.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "7712052_1_1522", "context": "Lithium for irritability in post-traumatic stress disorder.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7712052_1_1523", "context": "Lithium for irritability in post-traumatic stress disorder.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "7712052_1_1524", "context": "Lithium for irritability in post-traumatic stress disorder.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "7712052_1_1525", "context": "Lithium for irritability in post-traumatic stress disorder.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "14684937_2_1526", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14684937_2_1527", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14684937_2_1528", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14684937_2_1529", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14684937_2_1530", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14684937_2_1531", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14684937_2_1532", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14684937_2_1533", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14684937_2_1534", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14684937_2_1535", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14684937_2_1536", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14684937_2_1537", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14684937_2_1538", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6362443_1_1539", "context": "A case of mania associated with fluoxetine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6362443_1_1540", "context": "A case of mania associated with fluoxetine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6362443_1_1541", "context": "A case of mania associated with fluoxetine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6362443_1_1542", "context": "A case of mania associated with fluoxetine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6362443_1_1543", "context": "A case of mania associated with fluoxetine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6362443_1_1544", "context": "A case of mania associated with fluoxetine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6362443_1_1545", "context": "A case of mania associated with fluoxetine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6362443_1_1546", "context": "A case of mania associated with fluoxetine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7748076_3_1547", "context": "RESULTS: Extensive squamous metaplasia was found in endometrial glands following progestin therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7748076_3_1548", "context": "RESULTS: Extensive squamous metaplasia was found in endometrial glands following progestin therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7748076_3_1549", "context": "RESULTS: Extensive squamous metaplasia was found in endometrial glands following progestin therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7748076_3_1550", "context": "RESULTS: Extensive squamous metaplasia was found in endometrial glands following progestin therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7748076_3_1551", "context": "RESULTS: Extensive squamous metaplasia was found in endometrial glands following progestin therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7748076_3_1552", "context": "RESULTS: Extensive squamous metaplasia was found in endometrial glands following progestin therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7748076_3_1553", "context": "RESULTS: Extensive squamous metaplasia was found in endometrial glands following progestin therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7748076_3_1554", "context": "RESULTS: Extensive squamous metaplasia was found in endometrial glands following progestin therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16843118_1_1555", "context": "Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16843118_1_1556", "context": "Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16843118_1_1557", "context": "Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16843118_1_1558", "context": "Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16843118_1_1559", "context": "Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16843118_1_1560", "context": "Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16843118_1_1561", "context": "Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16843118_1_1562", "context": "Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9149614_1_1563", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9149614_1_1564", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9149614_1_1565", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9149614_1_1566", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9149614_1_1567", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9149614_1_1568", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9149614_1_1569", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9149614_1_1570", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9149614_1_1571", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9149614_1_1572", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9149614_1_1573", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9149614_1_1574", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9149614_1_1575", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8579054_3_1576", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8579054_3_1577", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8579054_3_1578", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8579054_3_1579", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8579054_3_1580", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8579054_3_1581", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8579054_3_1582", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8579054_3_1583", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8579054_3_1584", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8579054_3_1585", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8579054_3_1586", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8579054_3_1587", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8579054_3_1588", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "354311_2_1589", "context": "Metastatic osteomyelitis following BCG vaccination.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "354311_2_1590", "context": "Metastatic osteomyelitis following BCG vaccination.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "354311_2_1591", "context": "Metastatic osteomyelitis following BCG vaccination.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "354311_2_1592", "context": "Metastatic osteomyelitis following BCG vaccination.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "354311_2_1593", "context": "Metastatic osteomyelitis following BCG vaccination.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "354311_2_1594", "context": "Metastatic osteomyelitis following BCG vaccination.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "354311_2_1595", "context": "Metastatic osteomyelitis following BCG vaccination.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "354311_2_1596", "context": "Metastatic osteomyelitis following BCG vaccination.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1414247_1_1597", "context": "Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1414247_1_1598", "context": "Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1414247_1_1599", "context": "Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1414247_1_1600", "context": "Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1414247_1_1601", "context": "Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1414247_1_1602", "context": "Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1414247_1_1603", "context": "Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1414247_1_1604", "context": "Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8912599_5_1605", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8912599_5_1606", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8912599_5_1607", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8912599_5_1608", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8912599_5_1609", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8912599_5_1610", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8912599_5_1611", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8912599_5_1612", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8912599_5_1613", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8912599_5_1614", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8912599_5_1615", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8912599_5_1616", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8912599_5_1617", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9413296_2_1618", "context": "Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9413296_2_1619", "context": "Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9413296_2_1620", "context": "Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9413296_2_1621", "context": "Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9413296_2_1622", "context": "Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9413296_2_1623", "context": "Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9413296_2_1624", "context": "Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9413296_2_1625", "context": "Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11099623_1_1626", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11099623_1_1627", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11099623_1_1628", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11099623_1_1629", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11099623_1_1630", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11099623_1_1631", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11099623_1_1632", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11099623_1_1633", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11099623_1_1634", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11099623_1_1635", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11099623_1_1636", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11099623_1_1637", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11099623_1_1638", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "53128_2_1639", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "53128_2_1640", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "53128_2_1641", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "53128_2_1642", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "53128_2_1643", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "53128_2_1644", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "53128_2_1645", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "53128_2_1646", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "53128_2_1647", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "53128_2_1648", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "53128_2_1649", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "53128_2_1650", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "53128_2_1651", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9671138_1_1652", "context": "CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9671138_1_1653", "context": "CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9671138_1_1654", "context": "CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9671138_1_1655", "context": "CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9671138_1_1656", "context": "CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9671138_1_1657", "context": "CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9671138_1_1658", "context": "CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9671138_1_1659", "context": "CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16288069_3_1660", "context": "Penicillin-induced Jarisch-Herxheimer reaction.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16288069_3_1661", "context": "Penicillin-induced Jarisch-Herxheimer reaction.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16288069_3_1662", "context": "Penicillin-induced Jarisch-Herxheimer reaction.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16288069_3_1663", "context": "Penicillin-induced Jarisch-Herxheimer reaction.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16288069_3_1664", "context": "Penicillin-induced Jarisch-Herxheimer reaction.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16288069_3_1665", "context": "Penicillin-induced Jarisch-Herxheimer reaction.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16288069_3_1666", "context": "Penicillin-induced Jarisch-Herxheimer reaction.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16288069_3_1667", "context": "Penicillin-induced Jarisch-Herxheimer reaction.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9550246_4_1668", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9550246_4_1669", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9550246_4_1670", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9550246_4_1671", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9550246_4_1672", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9550246_4_1673", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9550246_4_1674", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9550246_4_1675", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9550246_4_1676", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9550246_4_1677", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9550246_4_1678", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9550246_4_1679", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9550246_4_1680", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11315123_1_1681", "context": "We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11315123_1_1682", "context": "We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11315123_1_1683", "context": "We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11315123_1_1684", "context": "We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11315123_1_1685", "context": "We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1557089_1_1686", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1557089_1_1687", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1557089_1_1688", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1557089_1_1689", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1557089_1_1690", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1557089_1_1691", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1557089_1_1692", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1557089_1_1693", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1557089_1_1694", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1557089_1_1695", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1557089_1_1696", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1557089_1_1697", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1557089_1_1698", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16288069_1_1699", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16288069_1_1700", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16288069_1_1701", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16288069_1_1702", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16288069_1_1703", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16288069_1_1704", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16288069_1_1705", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16288069_1_1706", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16288069_1_1707", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16288069_1_1708", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16288069_1_1709", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16288069_1_1710", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16288069_1_1711", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16490518_2_1712", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16490518_2_1713", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16490518_2_1714", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16490518_2_1715", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16490518_2_1716", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16490518_2_1717", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16490518_2_1718", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16490518_2_1719", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16490518_2_1720", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16490518_2_1721", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16490518_2_1722", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16490518_2_1723", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16490518_2_1724", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16537817_1_1725", "context": "Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16537817_1_1726", "context": "Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16537817_1_1727", "context": "Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16537817_1_1728", "context": "Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16537817_1_1729", "context": "Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16537817_1_1730", "context": "Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16537817_1_1731", "context": "Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16537817_1_1732", "context": "Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21330680_13_1733", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "21330680_13_1734", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "21330680_13_1735", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "21330680_13_1736", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "21330680_13_1737", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "21330680_13_1738", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21330680_13_1739", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21330680_13_1740", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21330680_13_1741", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21330680_13_1742", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21330680_13_1743", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21330680_13_1744", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21330680_13_1745", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16515630_2_1746", "context": "Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16515630_2_1747", "context": "Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16515630_2_1748", "context": "Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16515630_2_1749", "context": "Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16515630_2_1750", "context": "Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16515630_2_1751", "context": "Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16515630_2_1752", "context": "Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16515630_2_1753", "context": "Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23970584_1_1754", "context": "Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "23970584_1_1755", "context": "Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "23970584_1_1756", "context": "Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "23970584_1_1757", "context": "Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "23970584_1_1758", "context": "Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23970584_1_1759", "context": "Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "23970584_1_1760", "context": "Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "23970584_1_1761", "context": "Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19131789_1_1762", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19131789_1_1763", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19131789_1_1764", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19131789_1_1765", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19131789_1_1766", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19131789_1_1767", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19131789_1_1768", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19131789_1_1769", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19131789_1_1770", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19131789_1_1771", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19131789_1_1772", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19131789_1_1773", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19131789_1_1774", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2012922_1_1775", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2012922_1_1776", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2012922_1_1777", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2012922_1_1778", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2012922_1_1779", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2012922_1_1780", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2012922_1_1781", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2012922_1_1782", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2012922_1_1783", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2012922_1_1784", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2012922_1_1785", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2012922_1_1786", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2012922_1_1787", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9886213_4_1788", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9886213_4_1789", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9886213_4_1790", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9886213_4_1791", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9886213_4_1792", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9886213_4_1793", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9886213_4_1794", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9886213_4_1795", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1888256_2_1796", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1888256_2_1797", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1888256_2_1798", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1888256_2_1799", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1888256_2_1800", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1888256_2_1801", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1888256_2_1802", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1888256_2_1803", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1888256_2_1804", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1888256_2_1805", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1888256_2_1806", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1888256_2_1807", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1888256_2_1808", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9443627_1_1809", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9443627_1_1810", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9443627_1_1811", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9443627_1_1812", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9443627_1_1813", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9443627_1_1814", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9443627_1_1815", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9443627_1_1816", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18076602_2_1817", "context": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18076602_2_1818", "context": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18076602_2_1819", "context": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18076602_2_1820", "context": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18076602_2_1821", "context": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18076602_2_1822", "context": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18076602_2_1823", "context": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18076602_2_1824", "context": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6199475_2_1825", "context": "Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6199475_2_1826", "context": "Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6199475_2_1827", "context": "Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6199475_2_1828", "context": "Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6199475_2_1829", "context": "Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6199475_2_1830", "context": "Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6199475_2_1831", "context": "Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6199475_2_1832", "context": "Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3410226_2_1833", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3410226_2_1834", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3410226_2_1835", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3410226_2_1836", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3410226_2_1837", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3410226_2_1838", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3410226_2_1839", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3410226_2_1840", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3410226_2_1841", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3410226_2_1842", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3410226_2_1843", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3410226_2_1844", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3410226_2_1845", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "440873_2_1846", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "440873_2_1847", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "440873_2_1848", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "440873_2_1849", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "440873_2_1850", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "440873_2_1851", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "440873_2_1852", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "440873_2_1853", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "440873_2_1854", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "440873_2_1855", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "440873_2_1856", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "440873_2_1857", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "440873_2_1858", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8726608_1_1859", "context": "Does acyclovir increase serum lithium levels?", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8726608_1_1860", "context": "Does acyclovir increase serum lithium levels?", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8726608_1_1861", "context": "Does acyclovir increase serum lithium levels?", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8726608_1_1862", "context": "Does acyclovir increase serum lithium levels?", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8726608_1_1863", "context": "Does acyclovir increase serum lithium levels?", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8726608_1_1864", "context": "Does acyclovir increase serum lithium levels?", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8726608_1_1865", "context": "Does acyclovir increase serum lithium levels?", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8726608_1_1866", "context": "Does acyclovir increase serum lithium levels?", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2241449_2_1867", "context": "Sulfadiazine crystalluria revisited.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2241449_2_1868", "context": "Sulfadiazine crystalluria revisited.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2241449_2_1869", "context": "Sulfadiazine crystalluria revisited.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2241449_2_1870", "context": "Sulfadiazine crystalluria revisited.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2241449_2_1871", "context": "Sulfadiazine crystalluria revisited.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2241449_2_1872", "context": "Sulfadiazine crystalluria revisited.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2241449_2_1873", "context": "Sulfadiazine crystalluria revisited.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2241449_2_1874", "context": "Sulfadiazine crystalluria revisited.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16472339_1_1875", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16472339_1_1876", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16472339_1_1877", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16472339_1_1878", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16472339_1_1879", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16472339_1_1880", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16472339_1_1881", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16472339_1_1882", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16472339_1_1883", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16472339_1_1884", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16472339_1_1885", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16472339_1_1886", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16472339_1_1887", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9550246_2_1888", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9550246_2_1889", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9550246_2_1890", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9550246_2_1891", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9550246_2_1892", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9550246_2_1893", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9550246_2_1894", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9550246_2_1895", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9550246_2_1896", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9550246_2_1897", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9550246_2_1898", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9550246_2_1899", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9550246_2_1900", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10332990_1_1901", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10332990_1_1902", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10332990_1_1903", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10332990_1_1904", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10332990_1_1905", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10332990_1_1906", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10332990_1_1907", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10332990_1_1908", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10332990_1_1909", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10332990_1_1910", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10332990_1_1911", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10332990_1_1912", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10332990_1_1913", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3003260_3_1914", "context": "Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on cisplatin-induced vomiting.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "3003260_3_1915", "context": "Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on cisplatin-induced vomiting.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "3003260_3_1916", "context": "Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on cisplatin-induced vomiting.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "3003260_3_1917", "context": "Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on cisplatin-induced vomiting.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "3003260_3_1918", "context": "Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on cisplatin-induced vomiting.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3003260_3_1919", "context": "Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on cisplatin-induced vomiting.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "3003260_3_1920", "context": "Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on cisplatin-induced vomiting.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "3003260_3_1921", "context": "Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on cisplatin-induced vomiting.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16087771_1_1922", "context": "Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16087771_1_1923", "context": "Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16087771_1_1924", "context": "Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16087771_1_1925", "context": "Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16087771_1_1926", "context": "Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16087771_1_1927", "context": "Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16087771_1_1928", "context": "Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16087771_1_1929", "context": "Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "556126_1_1930", "context": "An infertile patient with amenorrhea-galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "556126_1_1931", "context": "An infertile patient with amenorrhea-galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "556126_1_1932", "context": "An infertile patient with amenorrhea-galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "556126_1_1933", "context": "An infertile patient with amenorrhea-galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "556126_1_1934", "context": "An infertile patient with amenorrhea-galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8430717_2_1935", "context": "CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8430717_2_1936", "context": "CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8430717_2_1937", "context": "CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8430717_2_1938", "context": "CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8430717_2_1939", "context": "CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8430717_2_1940", "context": "CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8430717_2_1941", "context": "CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8430717_2_1942", "context": "CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8850251_5_1943", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8850251_5_1944", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8850251_5_1945", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8850251_5_1946", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8850251_5_1947", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8850251_5_1948", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8850251_5_1949", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8850251_5_1950", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8850251_5_1951", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8850251_5_1952", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8850251_5_1953", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8850251_5_1954", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8850251_5_1955", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9704170_3_1956", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9704170_3_1957", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9704170_3_1958", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9704170_3_1959", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9704170_3_1960", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9704170_3_1961", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9704170_3_1962", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9704170_3_1963", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9704170_3_1964", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9704170_3_1965", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9704170_3_1966", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9704170_3_1967", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9704170_3_1968", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9737132_1_1969", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9737132_1_1970", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9737132_1_1971", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9737132_1_1972", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9737132_1_1973", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9737132_1_1974", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9737132_1_1975", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9737132_1_1976", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9737132_1_1977", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9737132_1_1978", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9737132_1_1979", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9737132_1_1980", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9737132_1_1981", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10592946_5_1982", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10592946_5_1983", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10592946_5_1984", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10592946_5_1985", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10592946_5_1986", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10592946_5_1987", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10592946_5_1988", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10592946_5_1989", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10592946_5_1990", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10592946_5_1991", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10592946_5_1992", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10592946_5_1993", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10592946_5_1994", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9533061_3_1995", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9533061_3_1996", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9533061_3_1997", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9533061_3_1998", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9533061_3_1999", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9533061_3_2000", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9533061_3_2001", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9533061_3_2002", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9533061_3_2003", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9533061_3_2004", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9533061_3_2005", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9533061_3_2006", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9533061_3_2007", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11236070_1_2008", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11236070_1_2009", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11236070_1_2010", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11236070_1_2011", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11236070_1_2012", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11236070_1_2013", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11236070_1_2014", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11236070_1_2015", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11236070_1_2016", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11236070_1_2017", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11236070_1_2018", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11236070_1_2019", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11236070_1_2020", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10682234_8_2021", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10682234_8_2022", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10682234_8_2023", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10682234_8_2024", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10682234_8_2025", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10682234_8_2026", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10682234_8_2027", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10682234_8_2028", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10682234_8_2029", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10682234_8_2030", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10682234_8_2031", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10682234_8_2032", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10682234_8_2033", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19112808_2_2034", "context": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19112808_2_2035", "context": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19112808_2_2036", "context": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19112808_2_2037", "context": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19112808_2_2038", "context": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19112808_2_2039", "context": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19112808_2_2040", "context": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19112808_2_2041", "context": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7056119_6_2042", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7056119_6_2043", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7056119_6_2044", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7056119_6_2045", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7056119_6_2046", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7056119_6_2047", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7056119_6_2048", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7056119_6_2049", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7056119_6_2050", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7056119_6_2051", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7056119_6_2052", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7056119_6_2053", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7056119_6_2054", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3003260_1_2055", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3003260_1_2056", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3003260_1_2057", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3003260_1_2058", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3003260_1_2059", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3003260_1_2060", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3003260_1_2061", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3003260_1_2062", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3003260_1_2063", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3003260_1_2064", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3003260_1_2065", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3003260_1_2066", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3003260_1_2067", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10492493_3_2068", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10492493_3_2069", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10492493_3_2070", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10492493_3_2071", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10492493_3_2072", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10492493_3_2073", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10492493_3_2074", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10492493_3_2075", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16341621_2_2076", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16341621_2_2077", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16341621_2_2078", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16341621_2_2079", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16341621_2_2080", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16341621_2_2081", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16341621_2_2082", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16341621_2_2083", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15595320_1_2084", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15595320_1_2085", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15595320_1_2086", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15595320_1_2087", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15595320_1_2088", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15595320_1_2089", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15595320_1_2090", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15595320_1_2091", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15595320_1_2092", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15595320_1_2093", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15595320_1_2094", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15595320_1_2095", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15595320_1_2096", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18755414_4_2097", "context": "On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18755414_4_2098", "context": "On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18755414_4_2099", "context": "On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18755414_4_2100", "context": "On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18755414_4_2101", "context": "On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18755414_4_2102", "context": "On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18755414_4_2103", "context": "On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18755414_4_2104", "context": "On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20925534_13_2105", "context": "The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20925534_13_2106", "context": "The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20925534_13_2107", "context": "The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20925534_13_2108", "context": "The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20925534_13_2109", "context": "The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20925534_13_2110", "context": "The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20925534_13_2111", "context": "The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20925534_13_2112", "context": "The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1469187_1_2113", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1469187_1_2114", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1469187_1_2115", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1469187_1_2116", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1469187_1_2117", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1469187_1_2118", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1469187_1_2119", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1469187_1_2120", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1469187_1_2121", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1469187_1_2122", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1469187_1_2123", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1469187_1_2124", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1469187_1_2125", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3410226_1_2126", "context": "Development of porphyria cutanea tarda after treatment with cyclophosphamide.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3410226_1_2127", "context": "Development of porphyria cutanea tarda after treatment with cyclophosphamide.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3410226_1_2128", "context": "Development of porphyria cutanea tarda after treatment with cyclophosphamide.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3410226_1_2129", "context": "Development of porphyria cutanea tarda after treatment with cyclophosphamide.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3410226_1_2130", "context": "Development of porphyria cutanea tarda after treatment with cyclophosphamide.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3410226_1_2131", "context": "Development of porphyria cutanea tarda after treatment with cyclophosphamide.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3410226_1_2132", "context": "Development of porphyria cutanea tarda after treatment with cyclophosphamide.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3410226_1_2133", "context": "Development of porphyria cutanea tarda after treatment with cyclophosphamide.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3242521_2_2134", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3242521_2_2135", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3242521_2_2136", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3242521_2_2137", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3242521_2_2138", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3242521_2_2139", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3242521_2_2140", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3242521_2_2141", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3242521_2_2142", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3242521_2_2143", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3242521_2_2144", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3242521_2_2145", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3242521_2_2146", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12022905_4_2147", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12022905_4_2148", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12022905_4_2149", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12022905_4_2150", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12022905_4_2151", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12022905_4_2152", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12022905_4_2153", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12022905_4_2154", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12022905_4_2155", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12022905_4_2156", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12022905_4_2157", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12022905_4_2158", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12022905_4_2159", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16685112_1_2160", "context": "CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16685112_1_2161", "context": "CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16685112_1_2162", "context": "CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16685112_1_2163", "context": "CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16685112_1_2164", "context": "CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16685112_1_2165", "context": "CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16685112_1_2166", "context": "CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16685112_1_2167", "context": "CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6427463_1_2168", "context": "Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6427463_1_2169", "context": "Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6427463_1_2170", "context": "Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6427463_1_2171", "context": "Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6427463_1_2172", "context": "Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6427463_1_2173", "context": "Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6427463_1_2174", "context": "Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6427463_1_2175", "context": "Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9870779_3_2176", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9870779_3_2177", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9870779_3_2178", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9870779_3_2179", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9870779_3_2180", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9870779_3_2181", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9870779_3_2182", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9870779_3_2183", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15522120_9_2184", "context": "An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15522120_9_2185", "context": "An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15522120_9_2186", "context": "An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15522120_9_2187", "context": "An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15522120_9_2188", "context": "An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15522120_9_2189", "context": "An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15522120_9_2190", "context": "An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15522120_9_2191", "context": "An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18203308_2_2192", "context": "New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18203308_2_2193", "context": "New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18203308_2_2194", "context": "New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18203308_2_2195", "context": "New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18203308_2_2196", "context": "New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18203308_2_2197", "context": "New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18203308_2_2198", "context": "New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18203308_2_2199", "context": "New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18523232_3_2200", "context": "Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18523232_3_2201", "context": "Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18523232_3_2202", "context": "Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18523232_3_2203", "context": "Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18523232_3_2204", "context": "Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18523232_3_2205", "context": "Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18523232_3_2206", "context": "Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18523232_3_2207", "context": "Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3824704_1_2208", "context": "Fatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3824704_1_2209", "context": "Fatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3824704_1_2210", "context": "Fatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3824704_1_2211", "context": "Fatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3824704_1_2212", "context": "Fatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3824704_1_2213", "context": "Fatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3824704_1_2214", "context": "Fatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3824704_1_2215", "context": "Fatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16101941_3_2216", "context": "Both reactions were caused due to this anti-emetic drug, but an additive effect of clemastine fumarate, prescribed to treat the anaphylactic reaction, is suggested by the sequence of events.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16101941_3_2217", "context": "Both reactions were caused due to this anti-emetic drug, but an additive effect of clemastine fumarate, prescribed to treat the anaphylactic reaction, is suggested by the sequence of events.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16101941_3_2218", "context": "Both reactions were caused due to this anti-emetic drug, but an additive effect of clemastine fumarate, prescribed to treat the anaphylactic reaction, is suggested by the sequence of events.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16101941_3_2219", "context": "Both reactions were caused due to this anti-emetic drug, but an additive effect of clemastine fumarate, prescribed to treat the anaphylactic reaction, is suggested by the sequence of events.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16101941_3_2220", "context": "Both reactions were caused due to this anti-emetic drug, but an additive effect of clemastine fumarate, prescribed to treat the anaphylactic reaction, is suggested by the sequence of events.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16101941_3_2221", "context": "Both reactions were caused due to this anti-emetic drug, but an additive effect of clemastine fumarate, prescribed to treat the anaphylactic reaction, is suggested by the sequence of events.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16101941_3_2222", "context": "Both reactions were caused due to this anti-emetic drug, but an additive effect of clemastine fumarate, prescribed to treat the anaphylactic reaction, is suggested by the sequence of events.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16101941_3_2223", "context": "Both reactions were caused due to this anti-emetic drug, but an additive effect of clemastine fumarate, prescribed to treat the anaphylactic reaction, is suggested by the sequence of events.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16357738_2_2224", "context": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16357738_2_2225", "context": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16357738_2_2226", "context": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16357738_2_2227", "context": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16357738_2_2228", "context": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16357738_2_2229", "context": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16357738_2_2230", "context": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16357738_2_2231", "context": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20925534_14_2232", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "20925534_14_2233", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "20925534_14_2234", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "20925534_14_2235", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "20925534_14_2236", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "20925534_14_2237", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "20925534_14_2238", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "20925534_14_2239", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "20925534_14_2240", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "20925534_14_2241", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20925534_14_2242", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "20925534_14_2243", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "20925534_14_2244", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11295724_3_2245", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11295724_3_2246", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11295724_3_2247", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11295724_3_2248", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11295724_3_2249", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11295724_3_2250", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11295724_3_2251", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11295724_3_2252", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11295724_3_2253", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11295724_3_2254", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11295724_3_2255", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11295724_3_2256", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11295724_3_2257", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11696132_2_2258", "context": "Anisocoria from transdermal scopolamine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11696132_2_2259", "context": "Anisocoria from transdermal scopolamine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11696132_2_2260", "context": "Anisocoria from transdermal scopolamine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11696132_2_2261", "context": "Anisocoria from transdermal scopolamine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11696132_2_2262", "context": "Anisocoria from transdermal scopolamine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11696132_2_2263", "context": "Anisocoria from transdermal scopolamine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11696132_2_2264", "context": "Anisocoria from transdermal scopolamine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11696132_2_2265", "context": "Anisocoria from transdermal scopolamine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12659609_4_2266", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12659609_4_2267", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12659609_4_2268", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12659609_4_2269", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12659609_4_2270", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12659609_4_2271", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12659609_4_2272", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12659609_4_2273", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12659609_4_2274", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12659609_4_2275", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12659609_4_2276", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12659609_4_2277", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12659609_4_2278", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6199475_1_2279", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6199475_1_2280", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6199475_1_2281", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6199475_1_2282", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6199475_1_2283", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6199475_1_2284", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6199475_1_2285", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6199475_1_2286", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6199475_1_2287", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6199475_1_2288", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6199475_1_2289", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6199475_1_2290", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6199475_1_2291", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12410494_2_2292", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12410494_2_2293", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12410494_2_2294", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12410494_2_2295", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12410494_2_2296", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12410494_2_2297", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12410494_2_2298", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12410494_2_2299", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12410494_2_2300", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12410494_2_2301", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12410494_2_2302", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12410494_2_2303", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12410494_2_2304", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15595320_2_2305", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15595320_2_2306", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15595320_2_2307", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15595320_2_2308", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15595320_2_2309", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15595320_2_2310", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15595320_2_2311", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15595320_2_2312", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15595320_2_2313", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15595320_2_2314", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15595320_2_2315", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15595320_2_2316", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15595320_2_2317", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18505911_2_2318", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18505911_2_2319", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18505911_2_2320", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18505911_2_2321", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18505911_2_2322", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18505911_2_2323", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18505911_2_2324", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18505911_2_2325", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18505911_2_2326", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18505911_2_2327", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18505911_2_2328", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18505911_2_2329", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18505911_2_2330", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16515630_4_2331", "context": "Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16515630_4_2332", "context": "Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16515630_4_2333", "context": "Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16515630_4_2334", "context": "Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16515630_4_2335", "context": "Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16515630_4_2336", "context": "Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16515630_4_2337", "context": "Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16515630_4_2338", "context": "Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2830062_2_2339", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "2830062_2_2340", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "2830062_2_2341", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "2830062_2_2342", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "2830062_2_2343", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "2830062_2_2344", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "2830062_2_2345", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "2830062_2_2346", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "2830062_2_2347", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "2830062_2_2348", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2830062_2_2349", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "2830062_2_2350", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "2830062_2_2351", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8430717_3_2352", "context": "METHODS: Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8430717_3_2353", "context": "METHODS: Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8430717_3_2354", "context": "METHODS: Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8430717_3_2355", "context": "METHODS: Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8430717_3_2356", "context": "METHODS: Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "354311_1_2357", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "354311_1_2358", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "354311_1_2359", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "354311_1_2360", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "354311_1_2361", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "354311_1_2362", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "354311_1_2363", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "354311_1_2364", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "354311_1_2365", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "354311_1_2366", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "354311_1_2367", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "354311_1_2368", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "354311_1_2369", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1469187_3_2370", "context": "Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1469187_3_2371", "context": "Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1469187_3_2372", "context": "Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1469187_3_2373", "context": "Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1469187_3_2374", "context": "Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1469187_3_2375", "context": "Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1469187_3_2376", "context": "Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1469187_3_2377", "context": "Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7369302_1_2378", "context": "Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7369302_1_2379", "context": "Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7369302_1_2380", "context": "Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7369302_1_2381", "context": "Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7369302_1_2382", "context": "Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7369302_1_2383", "context": "Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7369302_1_2384", "context": "Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7369302_1_2385", "context": "Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1275625_4_2386", "context": "A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1275625_4_2387", "context": "A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1275625_4_2388", "context": "A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1275625_4_2389", "context": "A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1275625_4_2390", "context": "A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1275625_4_2391", "context": "A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1275625_4_2392", "context": "A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1275625_4_2393", "context": "A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8124920_1_2394", "context": "Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8124920_1_2395", "context": "Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8124920_1_2396", "context": "Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8124920_1_2397", "context": "Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8124920_1_2398", "context": "Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8124920_1_2399", "context": "Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8124920_1_2400", "context": "Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8124920_1_2401", "context": "Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15061230_3_2402", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15061230_3_2403", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15061230_3_2404", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15061230_3_2405", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15061230_3_2406", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15061230_3_2407", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15061230_3_2408", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15061230_3_2409", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15061230_3_2410", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15061230_3_2411", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15061230_3_2412", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15061230_3_2413", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15061230_3_2414", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16317298_5_2415", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16317298_5_2416", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16317298_5_2417", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16317298_5_2418", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16317298_5_2419", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16317298_5_2420", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16317298_5_2421", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16317298_5_2422", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16317298_5_2423", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16317298_5_2424", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16317298_5_2425", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16317298_5_2426", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16317298_5_2427", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12836099_2_2428", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12836099_2_2429", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12836099_2_2430", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12836099_2_2431", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12836099_2_2432", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12836099_2_2433", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12836099_2_2434", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12836099_2_2435", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12836099_2_2436", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12836099_2_2437", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12836099_2_2438", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12836099_2_2439", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12836099_2_2440", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6865827_1_2441", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6865827_1_2442", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6865827_1_2443", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6865827_1_2444", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6865827_1_2445", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6865827_1_2446", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6865827_1_2447", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6865827_1_2448", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6865827_1_2449", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6865827_1_2450", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6865827_1_2451", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6865827_1_2452", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6865827_1_2453", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3136101_3_2454", "context": "We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3136101_3_2455", "context": "We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3136101_3_2456", "context": "We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3136101_3_2457", "context": "We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3136101_3_2458", "context": "We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3136101_3_2459", "context": "We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3136101_3_2460", "context": "We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3136101_3_2461", "context": "We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6401771_1_2462", "context": "Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6401771_1_2463", "context": "Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6401771_1_2464", "context": "Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6401771_1_2465", "context": "Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6401771_1_2466", "context": "Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6401771_1_2467", "context": "Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6401771_1_2468", "context": "Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6401771_1_2469", "context": "Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "25842648_6_2470", "context": "Although this article focuses on serotonin syndrome as a result of an adverse interaction of selective serotonin reuptake inhibitors (SSRI) and fentanyl, it is important for not only anesthesia professionals, but all clinicians--such as those in emergency medicine and critical care--to be aware of this syndrome and its management.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "25842648_6_2471", "context": "Although this article focuses on serotonin syndrome as a result of an adverse interaction of selective serotonin reuptake inhibitors (SSRI) and fentanyl, it is important for not only anesthesia professionals, but all clinicians--such as those in emergency medicine and critical care--to be aware of this syndrome and its management.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "25842648_6_2472", "context": "Although this article focuses on serotonin syndrome as a result of an adverse interaction of selective serotonin reuptake inhibitors (SSRI) and fentanyl, it is important for not only anesthesia professionals, but all clinicians--such as those in emergency medicine and critical care--to be aware of this syndrome and its management.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "25842648_6_2473", "context": "Although this article focuses on serotonin syndrome as a result of an adverse interaction of selective serotonin reuptake inhibitors (SSRI) and fentanyl, it is important for not only anesthesia professionals, but all clinicians--such as those in emergency medicine and critical care--to be aware of this syndrome and its management.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "25842648_6_2474", "context": "Although this article focuses on serotonin syndrome as a result of an adverse interaction of selective serotonin reuptake inhibitors (SSRI) and fentanyl, it is important for not only anesthesia professionals, but all clinicians--such as those in emergency medicine and critical care--to be aware of this syndrome and its management.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "25842648_6_2475", "context": "Although this article focuses on serotonin syndrome as a result of an adverse interaction of selective serotonin reuptake inhibitors (SSRI) and fentanyl, it is important for not only anesthesia professionals, but all clinicians--such as those in emergency medicine and critical care--to be aware of this syndrome and its management.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "25842648_6_2476", "context": "Although this article focuses on serotonin syndrome as a result of an adverse interaction of selective serotonin reuptake inhibitors (SSRI) and fentanyl, it is important for not only anesthesia professionals, but all clinicians--such as those in emergency medicine and critical care--to be aware of this syndrome and its management.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "25842648_6_2477", "context": "Although this article focuses on serotonin syndrome as a result of an adverse interaction of selective serotonin reuptake inhibitors (SSRI) and fentanyl, it is important for not only anesthesia professionals, but all clinicians--such as those in emergency medicine and critical care--to be aware of this syndrome and its management.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6794018_1_2478", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6794018_1_2479", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6794018_1_2480", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6794018_1_2481", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6794018_1_2482", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6794018_1_2483", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6794018_1_2484", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6794018_1_2485", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6794018_1_2486", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6794018_1_2487", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6794018_1_2488", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6794018_1_2489", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6794018_1_2490", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22677303_10_2491", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "22677303_10_2492", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "22677303_10_2493", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "22677303_10_2494", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "22677303_10_2495", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "22677303_10_2496", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "22677303_10_2497", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22677303_10_2498", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22677303_10_2499", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22677303_10_2500", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22677303_10_2501", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22677303_10_2502", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22677303_10_2503", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7783891_2_2504", "context": "Cardiac arrest following use of sumatriptan.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7783891_2_2505", "context": "Cardiac arrest following use of sumatriptan.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7783891_2_2506", "context": "Cardiac arrest following use of sumatriptan.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7783891_2_2507", "context": "Cardiac arrest following use of sumatriptan.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7783891_2_2508", "context": "Cardiac arrest following use of sumatriptan.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7783891_2_2509", "context": "Cardiac arrest following use of sumatriptan.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7783891_2_2510", "context": "Cardiac arrest following use of sumatriptan.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7783891_2_2511", "context": "Cardiac arrest following use of sumatriptan.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1422497_4_2512", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1422497_4_2513", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1422497_4_2514", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1422497_4_2515", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1422497_4_2516", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1422497_4_2517", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1422497_4_2518", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1422497_4_2519", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1422497_4_2520", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1422497_4_2521", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1422497_4_2522", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1422497_4_2523", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1422497_4_2524", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6671350_5_2525", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6671350_5_2526", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6671350_5_2527", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6671350_5_2528", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6671350_5_2529", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6671350_5_2530", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6671350_5_2531", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6671350_5_2532", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6671350_5_2533", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6671350_5_2534", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6671350_5_2535", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6671350_5_2536", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6671350_5_2537", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8442800_10_2538", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "8442800_10_2539", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "8442800_10_2540", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "8442800_10_2541", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "8442800_10_2542", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "8442800_10_2543", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "8442800_10_2544", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8442800_10_2545", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8442800_10_2546", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8442800_10_2547", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8442800_10_2548", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8442800_10_2549", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "8442800_10_2550", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10592946_6_2551", "context": "We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10592946_6_2552", "context": "We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10592946_6_2553", "context": "We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10592946_6_2554", "context": "We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10592946_6_2555", "context": "We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10592946_6_2556", "context": "We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10592946_6_2557", "context": "We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10592946_6_2558", "context": "We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18837734_2_2559", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18837734_2_2560", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18837734_2_2561", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18837734_2_2562", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18837734_2_2563", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18837734_2_2564", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18837734_2_2565", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18837734_2_2566", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18837734_2_2567", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18837734_2_2568", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18837734_2_2569", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18837734_2_2570", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18837734_2_2571", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11295724_1_2572", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11295724_1_2573", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11295724_1_2574", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11295724_1_2575", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11295724_1_2576", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11295724_1_2577", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11295724_1_2578", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11295724_1_2579", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11295724_1_2580", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11295724_1_2581", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11295724_1_2582", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11295724_1_2583", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11295724_1_2584", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3174043_3_2585", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3174043_3_2586", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3174043_3_2587", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3174043_3_2588", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3174043_3_2589", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3174043_3_2590", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3174043_3_2591", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3174043_3_2592", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3174043_3_2593", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3174043_3_2594", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3174043_3_2595", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3174043_3_2596", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3174043_3_2597", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14697943_2_2598", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14697943_2_2599", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14697943_2_2600", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14697943_2_2601", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14697943_2_2602", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14697943_2_2603", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14697943_2_2604", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14697943_2_2605", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14697943_2_2606", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14697943_2_2607", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14697943_2_2608", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14697943_2_2609", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14697943_2_2610", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17387702_2_2611", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17387702_2_2612", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17387702_2_2613", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17387702_2_2614", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17387702_2_2615", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17387702_2_2616", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17387702_2_2617", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17387702_2_2618", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17387702_2_2619", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17387702_2_2620", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17387702_2_2621", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17387702_2_2622", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17387702_2_2623", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11236070_3_2624", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11236070_3_2625", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11236070_3_2626", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11236070_3_2627", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11236070_3_2628", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11236070_3_2629", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11236070_3_2630", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11236070_3_2631", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11236070_3_2632", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11236070_3_2633", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11236070_3_2634", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11236070_3_2635", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11236070_3_2636", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17921794_2_2637", "context": "Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17921794_2_2638", "context": "Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17921794_2_2639", "context": "Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17921794_2_2640", "context": "Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17921794_2_2641", "context": "Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17921794_2_2642", "context": "Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17921794_2_2643", "context": "Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17921794_2_2644", "context": "Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4063627_1_2645", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "4063627_1_2646", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "4063627_1_2647", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "4063627_1_2648", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "4063627_1_2649", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "4063627_1_2650", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "4063627_1_2651", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4063627_1_2652", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4063627_1_2653", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4063627_1_2654", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4063627_1_2655", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4063627_1_2656", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4063627_1_2657", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15461766_1_2658", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15461766_1_2659", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15461766_1_2660", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15461766_1_2661", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15461766_1_2662", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15461766_1_2663", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15461766_1_2664", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15461766_1_2665", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15461766_1_2666", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15461766_1_2667", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15461766_1_2668", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15461766_1_2669", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15461766_1_2670", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8442800_4_2671", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8442800_4_2672", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8442800_4_2673", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8442800_4_2674", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8442800_4_2675", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8442800_4_2676", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8442800_4_2677", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8442800_4_2678", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8442800_4_2679", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8442800_4_2680", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8442800_4_2681", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8442800_4_2682", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8442800_4_2683", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15895899_3_2684", "context": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15895899_3_2685", "context": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15895899_3_2686", "context": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15895899_3_2687", "context": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15895899_3_2688", "context": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15895899_3_2689", "context": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15895899_3_2690", "context": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15895899_3_2691", "context": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12477460_4_2692", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12477460_4_2693", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12477460_4_2694", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12477460_4_2695", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12477460_4_2696", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12477460_4_2697", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12477460_4_2698", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12477460_4_2699", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12477460_4_2700", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12477460_4_2701", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12477460_4_2702", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12477460_4_2703", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12477460_4_2704", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17123120_1_2705", "context": "Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17123120_1_2706", "context": "Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17123120_1_2707", "context": "Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17123120_1_2708", "context": "Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17123120_1_2709", "context": "Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17123120_1_2710", "context": "Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17123120_1_2711", "context": "Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17123120_1_2712", "context": "Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17090724_2_2713", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17090724_2_2714", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17090724_2_2715", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17090724_2_2716", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17090724_2_2717", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17090724_2_2718", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17090724_2_2719", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17090724_2_2720", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17090724_2_2721", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17090724_2_2722", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17090724_2_2723", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17090724_2_2724", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17090724_2_2725", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3542612_2_2726", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3542612_2_2727", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3542612_2_2728", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3542612_2_2729", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3542612_2_2730", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3542612_2_2731", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3542612_2_2732", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3542612_2_2733", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3542612_2_2734", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3542612_2_2735", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3542612_2_2736", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3542612_2_2737", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3542612_2_2738", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2830062_4_2739", "context": "The hypoadrenalism was overcome by increasing steroid replacement therapy.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "2830062_4_2740", "context": "The hypoadrenalism was overcome by increasing steroid replacement therapy.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "2830062_4_2741", "context": "The hypoadrenalism was overcome by increasing steroid replacement therapy.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "2830062_4_2742", "context": "The hypoadrenalism was overcome by increasing steroid replacement therapy.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "2830062_4_2743", "context": "The hypoadrenalism was overcome by increasing steroid replacement therapy.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2830062_4_2744", "context": "The hypoadrenalism was overcome by increasing steroid replacement therapy.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "2830062_4_2745", "context": "The hypoadrenalism was overcome by increasing steroid replacement therapy.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "2830062_4_2746", "context": "The hypoadrenalism was overcome by increasing steroid replacement therapy.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16265343_1_2747", "context": "DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16265343_1_2748", "context": "DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16265343_1_2749", "context": "DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16265343_1_2750", "context": "DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16265343_1_2751", "context": "DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16265343_1_2752", "context": "DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16265343_1_2753", "context": "DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16265343_1_2754", "context": "DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8610807_1_2755", "context": "Choroidal hemorrhage associated with systemic tissue plasminogen activator.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8610807_1_2756", "context": "Choroidal hemorrhage associated with systemic tissue plasminogen activator.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8610807_1_2757", "context": "Choroidal hemorrhage associated with systemic tissue plasminogen activator.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8610807_1_2758", "context": "Choroidal hemorrhage associated with systemic tissue plasminogen activator.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8610807_1_2759", "context": "Choroidal hemorrhage associated with systemic tissue plasminogen activator.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8610807_1_2760", "context": "Choroidal hemorrhage associated with systemic tissue plasminogen activator.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8610807_1_2761", "context": "Choroidal hemorrhage associated with systemic tissue plasminogen activator.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8610807_1_2762", "context": "Choroidal hemorrhage associated with systemic tissue plasminogen activator.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17665812_1_2763", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17665812_1_2764", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17665812_1_2765", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17665812_1_2766", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17665812_1_2767", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17665812_1_2768", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17665812_1_2769", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17665812_1_2770", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17665812_1_2771", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17665812_1_2772", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17665812_1_2773", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17665812_1_2774", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17665812_1_2775", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18675768_1_2776", "context": "Adverse effects of propafenone after long-term therapy with the addition of citalopram.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18675768_1_2777", "context": "Adverse effects of propafenone after long-term therapy with the addition of citalopram.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18675768_1_2778", "context": "Adverse effects of propafenone after long-term therapy with the addition of citalopram.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18675768_1_2779", "context": "Adverse effects of propafenone after long-term therapy with the addition of citalopram.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18675768_1_2780", "context": "Adverse effects of propafenone after long-term therapy with the addition of citalopram.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18675768_1_2781", "context": "Adverse effects of propafenone after long-term therapy with the addition of citalopram.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18675768_1_2782", "context": "Adverse effects of propafenone after long-term therapy with the addition of citalopram.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18675768_1_2783", "context": "Adverse effects of propafenone after long-term therapy with the addition of citalopram.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7081289_2_2784", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7081289_2_2785", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7081289_2_2786", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7081289_2_2787", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7081289_2_2788", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7081289_2_2789", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7081289_2_2790", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7081289_2_2791", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7081289_2_2792", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7081289_2_2793", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7081289_2_2794", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7081289_2_2795", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7081289_2_2796", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16609346_3_2797", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16609346_3_2798", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16609346_3_2799", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16609346_3_2800", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16609346_3_2801", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16609346_3_2802", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16609346_3_2803", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16609346_3_2804", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16609346_3_2805", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16609346_3_2806", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16609346_3_2807", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16609346_3_2808", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16609346_3_2809", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15927910_1_2810", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15927910_1_2811", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15927910_1_2812", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15927910_1_2813", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15927910_1_2814", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15927910_1_2815", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15927910_1_2816", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15927910_1_2817", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15927910_1_2818", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15927910_1_2819", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15927910_1_2820", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15927910_1_2821", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15927910_1_2822", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7056119_2_2823", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7056119_2_2824", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7056119_2_2825", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7056119_2_2826", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7056119_2_2827", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7056119_2_2828", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7056119_2_2829", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7056119_2_2830", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7056119_2_2831", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7056119_2_2832", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7056119_2_2833", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7056119_2_2834", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7056119_2_2835", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18505911_9_2836", "context": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale, and a possible causative agent according to the Drug Interaction Probability Scale.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18505911_9_2837", "context": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale, and a possible causative agent according to the Drug Interaction Probability Scale.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18505911_9_2838", "context": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale, and a possible causative agent according to the Drug Interaction Probability Scale.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18505911_9_2839", "context": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale, and a possible causative agent according to the Drug Interaction Probability Scale.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18505911_9_2840", "context": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale, and a possible causative agent according to the Drug Interaction Probability Scale.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18505911_9_2841", "context": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale, and a possible causative agent according to the Drug Interaction Probability Scale.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18505911_9_2842", "context": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale, and a possible causative agent according to the Drug Interaction Probability Scale.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18505911_9_2843", "context": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale, and a possible causative agent according to the Drug Interaction Probability Scale.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8442800_2_2844", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "8442800_2_2845", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "8442800_2_2846", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "8442800_2_2847", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "8442800_2_2848", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "8442800_2_2849", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "8442800_2_2850", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8442800_2_2851", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8442800_2_2852", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8442800_2_2853", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8442800_2_2854", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8442800_2_2855", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "8442800_2_2856", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15507779_2_2857", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "15507779_2_2858", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "15507779_2_2859", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "15507779_2_2860", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "15507779_2_2861", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "15507779_2_2862", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "15507779_2_2863", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15507779_2_2864", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15507779_2_2865", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15507779_2_2866", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15507779_2_2867", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15507779_2_2868", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "15507779_2_2869", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8391300_2_2870", "context": "Vasospasm associated with ergotamine is a well-known phenomenon.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8391300_2_2871", "context": "Vasospasm associated with ergotamine is a well-known phenomenon.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8391300_2_2872", "context": "Vasospasm associated with ergotamine is a well-known phenomenon.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8391300_2_2873", "context": "Vasospasm associated with ergotamine is a well-known phenomenon.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8391300_2_2874", "context": "Vasospasm associated with ergotamine is a well-known phenomenon.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8391300_2_2875", "context": "Vasospasm associated with ergotamine is a well-known phenomenon.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8391300_2_2876", "context": "Vasospasm associated with ergotamine is a well-known phenomenon.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8391300_2_2877", "context": "Vasospasm associated with ergotamine is a well-known phenomenon.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3359700_1_2878", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3359700_1_2879", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3359700_1_2880", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3359700_1_2881", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3359700_1_2882", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3359700_1_2883", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3359700_1_2884", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3359700_1_2885", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3359700_1_2886", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3359700_1_2887", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3359700_1_2888", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3359700_1_2889", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3359700_1_2890", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21630612_4_2891", "context": "We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone to previously well-tolerated chronic statin therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21630612_4_2892", "context": "We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone to previously well-tolerated chronic statin therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21630612_4_2893", "context": "We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone to previously well-tolerated chronic statin therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21630612_4_2894", "context": "We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone to previously well-tolerated chronic statin therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21630612_4_2895", "context": "We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone to previously well-tolerated chronic statin therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21630612_4_2896", "context": "We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone to previously well-tolerated chronic statin therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21630612_4_2897", "context": "We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone to previously well-tolerated chronic statin therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21630612_4_2898", "context": "We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone to previously well-tolerated chronic statin therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23115227_3_2899", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "23115227_3_2900", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "23115227_3_2901", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "23115227_3_2902", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "23115227_3_2903", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "23115227_3_2904", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "23115227_3_2905", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "23115227_3_2906", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "23115227_3_2907", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "23115227_3_2908", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23115227_3_2909", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "23115227_3_2910", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "23115227_3_2911", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10870095_7_2912", "context": "In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of  S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10870095_7_2913", "context": "In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of  S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10870095_7_2914", "context": "In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of  S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10870095_7_2915", "context": "In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of  S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10870095_7_2916", "context": "In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of  S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10870095_7_2917", "context": "In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of  S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10870095_7_2918", "context": "In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of  S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10870095_7_2919", "context": "In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of  S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18755414_6_2920", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18755414_6_2921", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18755414_6_2922", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18755414_6_2923", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18755414_6_2924", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18755414_6_2925", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18755414_6_2926", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18755414_6_2927", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18755414_6_2928", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18755414_6_2929", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18755414_6_2930", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18755414_6_2931", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18755414_6_2932", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18751717_3_2933", "context": "CONCLUSIONS: The fundus picture shown in these cases may be typical of ASPPC after IVTA injection.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18751717_3_2934", "context": "CONCLUSIONS: The fundus picture shown in these cases may be typical of ASPPC after IVTA injection.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18751717_3_2935", "context": "CONCLUSIONS: The fundus picture shown in these cases may be typical of ASPPC after IVTA injection.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18751717_3_2936", "context": "CONCLUSIONS: The fundus picture shown in these cases may be typical of ASPPC after IVTA injection.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18751717_3_2937", "context": "CONCLUSIONS: The fundus picture shown in these cases may be typical of ASPPC after IVTA injection.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18751717_3_2938", "context": "CONCLUSIONS: The fundus picture shown in these cases may be typical of ASPPC after IVTA injection.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18751717_3_2939", "context": "CONCLUSIONS: The fundus picture shown in these cases may be typical of ASPPC after IVTA injection.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18751717_3_2940", "context": "CONCLUSIONS: The fundus picture shown in these cases may be typical of ASPPC after IVTA injection.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9149614_3_2941", "context": "The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9149614_3_2942", "context": "The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9149614_3_2943", "context": "The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9149614_3_2944", "context": "The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9149614_3_2945", "context": "The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9149614_3_2946", "context": "The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9149614_3_2947", "context": "The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9149614_3_2948", "context": "The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21658326_4_2949", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "21658326_4_2950", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "21658326_4_2951", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "21658326_4_2952", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "21658326_4_2953", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "21658326_4_2954", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21658326_4_2955", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21658326_4_2956", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21658326_4_2957", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21658326_4_2958", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21658326_4_2959", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21658326_4_2960", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21658326_4_2961", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3964363_1_2962", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3964363_1_2963", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3964363_1_2964", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3964363_1_2965", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3964363_1_2966", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3964363_1_2967", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3964363_1_2968", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3964363_1_2969", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4063627_2_2970", "context": "Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "4063627_2_2971", "context": "Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4063627_2_2972", "context": "Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4063627_2_2973", "context": "Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4063627_2_2974", "context": "Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4063627_2_2975", "context": "Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4063627_2_2976", "context": "Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4063627_2_2977", "context": "Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10082597_2_2978", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10082597_2_2979", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10082597_2_2980", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10082597_2_2981", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10082597_2_2982", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10082597_2_2983", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10082597_2_2984", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10082597_2_2985", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10082597_2_2986", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10082597_2_2987", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10082597_2_2988", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10082597_2_2989", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10082597_2_2990", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10870095_2_2991", "context": "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "10870095_2_2992", "context": "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10870095_2_2993", "context": "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10870095_2_2994", "context": "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10870095_2_2995", "context": "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10870095_2_2996", "context": "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10870095_2_2997", "context": "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "10870095_2_2998", "context": "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18364401_3_2999", "context": "Rapidly developing hyperglycemia during treatment with olanzapine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18364401_3_3000", "context": "Rapidly developing hyperglycemia during treatment with olanzapine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18364401_3_3001", "context": "Rapidly developing hyperglycemia during treatment with olanzapine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18364401_3_3002", "context": "Rapidly developing hyperglycemia during treatment with olanzapine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18364401_3_3003", "context": "Rapidly developing hyperglycemia during treatment with olanzapine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18364401_3_3004", "context": "Rapidly developing hyperglycemia during treatment with olanzapine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18364401_3_3005", "context": "Rapidly developing hyperglycemia during treatment with olanzapine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18364401_3_3006", "context": "Rapidly developing hyperglycemia during treatment with olanzapine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10579985_1_3007", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10579985_1_3008", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10579985_1_3009", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10579985_1_3010", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10579985_1_3011", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10579985_1_3012", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10579985_1_3013", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10579985_1_3014", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10579985_1_3015", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10579985_1_3016", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10579985_1_3017", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10579985_1_3018", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10579985_1_3019", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7761316_2_3020", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7761316_2_3021", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7761316_2_3022", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7761316_2_3023", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7761316_2_3024", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7761316_2_3025", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7761316_2_3026", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7761316_2_3027", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7761316_2_3028", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7761316_2_3029", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7761316_2_3030", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7761316_2_3031", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7761316_2_3032", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10225085_3_3033", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10225085_3_3034", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10225085_3_3035", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10225085_3_3036", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10225085_3_3037", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10225085_3_3038", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10225085_3_3039", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10225085_3_3040", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10225085_3_3041", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10225085_3_3042", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10225085_3_3043", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10225085_3_3044", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10225085_3_3045", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19884751_1_3046", "context": "Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19884751_1_3047", "context": "Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19884751_1_3048", "context": "Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19884751_1_3049", "context": "Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19884751_1_3050", "context": "Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19884751_1_3051", "context": "Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19884751_1_3052", "context": "Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19884751_1_3053", "context": "Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15368548_2_3054", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "15368548_2_3055", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15368548_2_3056", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15368548_2_3057", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15368548_2_3058", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15368548_2_3059", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15368548_2_3060", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "15368548_2_3061", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "4014301_4_3062", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "4014301_4_3063", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "4014301_4_3064", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "4014301_4_3065", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "4014301_4_3066", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "4014301_4_3067", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "4014301_4_3068", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4014301_4_3069", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4014301_4_3070", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4014301_4_3071", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4014301_4_3072", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4014301_4_3073", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4014301_4_3074", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11352235_4_3075", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11352235_4_3076", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11352235_4_3077", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11352235_4_3078", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11352235_4_3079", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11352235_4_3080", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11352235_4_3081", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11352235_4_3082", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11352235_4_3083", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11352235_4_3084", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11352235_4_3085", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11352235_4_3086", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11352235_4_3087", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11804071_1_3088", "context": "INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11804071_1_3089", "context": "INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11804071_1_3090", "context": "INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11804071_1_3091", "context": "INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11804071_1_3092", "context": "INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11804071_1_3093", "context": "INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11804071_1_3094", "context": "INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11804071_1_3095", "context": "INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19266307_1_3096", "context": "Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19266307_1_3097", "context": "Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19266307_1_3098", "context": "Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19266307_1_3099", "context": "Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19266307_1_3100", "context": "Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19266307_1_3101", "context": "Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19266307_1_3102", "context": "Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19266307_1_3103", "context": "Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11724089_5_3104", "context": "Ofloxacin: a probable cause of toxic epidermal necrolysis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11724089_5_3105", "context": "Ofloxacin: a probable cause of toxic epidermal necrolysis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11724089_5_3106", "context": "Ofloxacin: a probable cause of toxic epidermal necrolysis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11724089_5_3107", "context": "Ofloxacin: a probable cause of toxic epidermal necrolysis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11724089_5_3108", "context": "Ofloxacin: a probable cause of toxic epidermal necrolysis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11724089_5_3109", "context": "Ofloxacin: a probable cause of toxic epidermal necrolysis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11724089_5_3110", "context": "Ofloxacin: a probable cause of toxic epidermal necrolysis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11724089_5_3111", "context": "Ofloxacin: a probable cause of toxic epidermal necrolysis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16515630_1_3112", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16515630_1_3113", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16515630_1_3114", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16515630_1_3115", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16515630_1_3116", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16515630_1_3117", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16515630_1_3118", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16515630_1_3119", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16515630_1_3120", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16515630_1_3121", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16515630_1_3122", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16515630_1_3123", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16515630_1_3124", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9704170_1_3125", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9704170_1_3126", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9704170_1_3127", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9704170_1_3128", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9704170_1_3129", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9704170_1_3130", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9704170_1_3131", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9704170_1_3132", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9704170_1_3133", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9704170_1_3134", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9704170_1_3135", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9704170_1_3136", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9704170_1_3137", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20349794_1_3138", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20349794_1_3139", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20349794_1_3140", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20349794_1_3141", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20349794_1_3142", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20349794_1_3143", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20349794_1_3144", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20349794_1_3145", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20349794_1_3146", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20349794_1_3147", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20349794_1_3148", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20349794_1_3149", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20349794_1_3150", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6610943_1_3151", "context": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6610943_1_3152", "context": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6610943_1_3153", "context": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6610943_1_3154", "context": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6610943_1_3155", "context": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6610943_1_3156", "context": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6610943_1_3157", "context": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6610943_1_3158", "context": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18371508_2_3159", "context": "We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18371508_2_3160", "context": "We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18371508_2_3161", "context": "We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18371508_2_3162", "context": "We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18371508_2_3163", "context": "We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18371508_2_3164", "context": "We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18371508_2_3165", "context": "We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18371508_2_3166", "context": "We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "681921_1_3167", "context": "Catatonia associated with disulfiram therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "681921_1_3168", "context": "Catatonia associated with disulfiram therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "681921_1_3169", "context": "Catatonia associated with disulfiram therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "681921_1_3170", "context": "Catatonia associated with disulfiram therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "681921_1_3171", "context": "Catatonia associated with disulfiram therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "681921_1_3172", "context": "Catatonia associated with disulfiram therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "681921_1_3173", "context": "Catatonia associated with disulfiram therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "681921_1_3174", "context": "Catatonia associated with disulfiram therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21658326_5_3175", "context": "To date, no relation has ever been suggested between TNF-alpha inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21658326_5_3176", "context": "To date, no relation has ever been suggested between TNF-alpha inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21658326_5_3177", "context": "To date, no relation has ever been suggested between TNF-alpha inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21658326_5_3178", "context": "To date, no relation has ever been suggested between TNF-alpha inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21658326_5_3179", "context": "To date, no relation has ever been suggested between TNF-alpha inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21658326_5_3180", "context": "To date, no relation has ever been suggested between TNF-alpha inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21658326_5_3181", "context": "To date, no relation has ever been suggested between TNF-alpha inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21658326_5_3182", "context": "To date, no relation has ever been suggested between TNF-alpha inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10492493_2_3183", "context": "Losartan-induced angioedema.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10492493_2_3184", "context": "Losartan-induced angioedema.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10492493_2_3185", "context": "Losartan-induced angioedema.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10492493_2_3186", "context": "Losartan-induced angioedema.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10492493_2_3187", "context": "Losartan-induced angioedema.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10492493_2_3188", "context": "Losartan-induced angioedema.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10492493_2_3189", "context": "Losartan-induced angioedema.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10492493_2_3190", "context": "Losartan-induced angioedema.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8850251_1_3191", "context": "However, dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine-derivative drugs.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8850251_1_3192", "context": "However, dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine-derivative drugs.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8850251_1_3193", "context": "However, dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine-derivative drugs.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8850251_1_3194", "context": "However, dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine-derivative drugs.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8850251_1_3195", "context": "However, dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine-derivative drugs.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8850251_1_3196", "context": "However, dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine-derivative drugs.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8850251_1_3197", "context": "However, dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine-derivative drugs.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8850251_1_3198", "context": "However, dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine-derivative drugs.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18262450_10_3199", "context": "Oxycodone-gabapentin also significantly improved pain relief vs gabapentin alone (P = 0.003).", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "18262450_10_3200", "context": "Oxycodone-gabapentin also significantly improved pain relief vs gabapentin alone (P = 0.003).", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18262450_10_3201", "context": "Oxycodone-gabapentin also significantly improved pain relief vs gabapentin alone (P = 0.003).", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18262450_10_3202", "context": "Oxycodone-gabapentin also significantly improved pain relief vs gabapentin alone (P = 0.003).", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18262450_10_3203", "context": "Oxycodone-gabapentin also significantly improved pain relief vs gabapentin alone (P = 0.003).", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18262450_10_3204", "context": "Oxycodone-gabapentin also significantly improved pain relief vs gabapentin alone (P = 0.003).", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18262450_10_3205", "context": "Oxycodone-gabapentin also significantly improved pain relief vs gabapentin alone (P = 0.003).", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "18262450_10_3206", "context": "Oxycodone-gabapentin also significantly improved pain relief vs gabapentin alone (P = 0.003).", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11147747_1_3207", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11147747_1_3208", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11147747_1_3209", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11147747_1_3210", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11147747_1_3211", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11147747_1_3212", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11147747_1_3213", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11147747_1_3214", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11147747_1_3215", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11147747_1_3216", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11147747_1_3217", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11147747_1_3218", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11147747_1_3219", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15286697_2_3220", "context": "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15286697_2_3221", "context": "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15286697_2_3222", "context": "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15286697_2_3223", "context": "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15286697_2_3224", "context": "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15286697_2_3225", "context": "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15286697_2_3226", "context": "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15286697_2_3227", "context": "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15286697_5_3228", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15286697_5_3229", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15286697_5_3230", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15286697_5_3231", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15286697_5_3232", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15286697_5_3233", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15286697_5_3234", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15286697_5_3235", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15286697_5_3236", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15286697_5_3237", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15286697_5_3238", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15286697_5_3239", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15286697_5_3240", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6865827_2_3241", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6865827_2_3242", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6865827_2_3243", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6865827_2_3244", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6865827_2_3245", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6865827_2_3246", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6865827_2_3247", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6865827_2_3248", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6865827_2_3249", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6865827_2_3250", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6865827_2_3251", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6865827_2_3252", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6865827_2_3253", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18675768_6_3254", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18675768_6_3255", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18675768_6_3256", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18675768_6_3257", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18675768_6_3258", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18675768_6_3259", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18675768_6_3260", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18675768_6_3261", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18675768_6_3262", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18675768_6_3263", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18675768_6_3264", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18675768_6_3265", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18675768_6_3266", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3171334_2_3267", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3171334_2_3268", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3171334_2_3269", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3171334_2_3270", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3171334_2_3271", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3171334_2_3272", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3171334_2_3273", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3171334_2_3274", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3171334_2_3275", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3171334_2_3276", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3171334_2_3277", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3171334_2_3278", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3171334_2_3279", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18042092_3_3280", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18042092_3_3281", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18042092_3_3282", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18042092_3_3283", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18042092_3_3284", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18042092_3_3285", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18042092_3_3286", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18042092_3_3287", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18042092_3_3288", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18042092_3_3289", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18042092_3_3290", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18042092_3_3291", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18042092_3_3292", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15522120_4_3293", "context": "SSRI-drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15522120_4_3294", "context": "SSRI-drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15522120_4_3295", "context": "SSRI-drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15522120_4_3296", "context": "SSRI-drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15522120_4_3297", "context": "SSRI-drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15522120_4_3298", "context": "SSRI-drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15522120_4_3299", "context": "SSRI-drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15522120_4_3300", "context": "SSRI-drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22552763_1_3301", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "22552763_1_3302", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "22552763_1_3303", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "22552763_1_3304", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "22552763_1_3305", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "22552763_1_3306", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "22552763_1_3307", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22552763_1_3308", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22552763_1_3309", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22552763_1_3310", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22552763_1_3311", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22552763_1_3312", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22552763_1_3313", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16393774_7_3314", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16393774_7_3315", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16393774_7_3316", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16393774_7_3317", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16393774_7_3318", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16393774_7_3319", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16393774_7_3320", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16393774_7_3321", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16393774_7_3322", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16393774_7_3323", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16393774_7_3324", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16393774_7_3325", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16393774_7_3326", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7056119_5_3327", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7056119_5_3328", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7056119_5_3329", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7056119_5_3330", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7056119_5_3331", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7056119_5_3332", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7056119_5_3333", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7056119_5_3334", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9865241_3_3335", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9865241_3_3336", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9865241_3_3337", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9865241_3_3338", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9865241_3_3339", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9865241_3_3340", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9865241_3_3341", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9865241_3_3342", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9865241_3_3343", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9865241_3_3344", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9865241_3_3345", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9865241_3_3346", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9865241_3_3347", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21729965_4_3348", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "21729965_4_3349", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "21729965_4_3350", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "21729965_4_3351", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "21729965_4_3352", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "21729965_4_3353", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21729965_4_3354", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21729965_4_3355", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21729965_4_3356", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21729965_4_3357", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21729965_4_3358", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21729965_4_3359", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21729965_4_3360", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15595320_4_3361", "context": "We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15595320_4_3362", "context": "We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15595320_4_3363", "context": "We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15595320_4_3364", "context": "We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15595320_4_3365", "context": "We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15595320_4_3366", "context": "We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15595320_4_3367", "context": "We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15595320_4_3368", "context": "We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19212144_2_3369", "context": "Temsirolimus-induced glomerulopathy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19212144_2_3370", "context": "Temsirolimus-induced glomerulopathy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19212144_2_3371", "context": "Temsirolimus-induced glomerulopathy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19212144_2_3372", "context": "Temsirolimus-induced glomerulopathy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19212144_2_3373", "context": "Temsirolimus-induced glomerulopathy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19212144_2_3374", "context": "Temsirolimus-induced glomerulopathy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19212144_2_3375", "context": "Temsirolimus-induced glomerulopathy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19212144_2_3376", "context": "Temsirolimus-induced glomerulopathy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11485141_4_3377", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11485141_4_3378", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11485141_4_3379", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11485141_4_3380", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11485141_4_3381", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11485141_4_3382", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11485141_4_3383", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11485141_4_3384", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7949255_2_3385", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7949255_2_3386", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7949255_2_3387", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7949255_2_3388", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7949255_2_3389", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7949255_2_3390", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7949255_2_3391", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7949255_2_3392", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7949255_2_3393", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7949255_2_3394", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7949255_2_3395", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7949255_2_3396", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7949255_2_3397", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16685007_5_3398", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16685007_5_3399", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16685007_5_3400", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16685007_5_3401", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16685007_5_3402", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16685007_5_3403", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16685007_5_3404", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16685007_5_3405", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16685007_5_3406", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16685007_5_3407", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16685007_5_3408", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16685007_5_3409", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16685007_5_3410", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17090724_1_3411", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17090724_1_3412", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17090724_1_3413", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17090724_1_3414", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17090724_1_3415", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17090724_1_3416", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17090724_1_3417", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17090724_1_3418", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17090724_1_3419", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17090724_1_3420", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17090724_1_3421", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17090724_1_3422", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17090724_1_3423", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11510798_2_3424", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11510798_2_3425", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11510798_2_3426", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11510798_2_3427", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11510798_2_3428", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11510798_2_3429", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11510798_2_3430", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11510798_2_3431", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11510798_2_3432", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11510798_2_3433", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11510798_2_3434", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11510798_2_3435", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11510798_2_3436", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18580694_2_3437", "context": "Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18580694_2_3438", "context": "Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18580694_2_3439", "context": "Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18580694_2_3440", "context": "Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18580694_2_3441", "context": "Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18580694_2_3442", "context": "Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18580694_2_3443", "context": "Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18580694_2_3444", "context": "Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6873616_1_3445", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6873616_1_3446", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6873616_1_3447", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6873616_1_3448", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6873616_1_3449", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6873616_1_3450", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6873616_1_3451", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6873616_1_3452", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6873616_1_3453", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6873616_1_3454", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6873616_1_3455", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6873616_1_3456", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6873616_1_3457", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17182354_3_3458", "context": "Methylphenidate (Ritalin)-associated cataract and glaucoma.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17182354_3_3459", "context": "Methylphenidate (Ritalin)-associated cataract and glaucoma.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17182354_3_3460", "context": "Methylphenidate (Ritalin)-associated cataract and glaucoma.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17182354_3_3461", "context": "Methylphenidate (Ritalin)-associated cataract and glaucoma.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17182354_3_3462", "context": "Methylphenidate (Ritalin)-associated cataract and glaucoma.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17182354_3_3463", "context": "Methylphenidate (Ritalin)-associated cataract and glaucoma.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17182354_3_3464", "context": "Methylphenidate (Ritalin)-associated cataract and glaucoma.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17182354_3_3465", "context": "Methylphenidate (Ritalin)-associated cataract and glaucoma.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12410494_1_3466", "context": "Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12410494_1_3467", "context": "Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12410494_1_3468", "context": "Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12410494_1_3469", "context": "Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12410494_1_3470", "context": "Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12410494_1_3471", "context": "Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12410494_1_3472", "context": "Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12410494_1_3473", "context": "Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17955169_2_3474", "context": "Uncontrolled headache induced by oxcarbazepine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17955169_2_3475", "context": "Uncontrolled headache induced by oxcarbazepine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17955169_2_3476", "context": "Uncontrolled headache induced by oxcarbazepine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17955169_2_3477", "context": "Uncontrolled headache induced by oxcarbazepine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17955169_2_3478", "context": "Uncontrolled headache induced by oxcarbazepine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17955169_2_3479", "context": "Uncontrolled headache induced by oxcarbazepine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17955169_2_3480", "context": "Uncontrolled headache induced by oxcarbazepine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17955169_2_3481", "context": "Uncontrolled headache induced by oxcarbazepine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14697943_3_3482", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14697943_3_3483", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14697943_3_3484", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14697943_3_3485", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14697943_3_3486", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14697943_3_3487", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14697943_3_3488", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14697943_3_3489", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14697943_3_3490", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14697943_3_3491", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14697943_3_3492", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14697943_3_3493", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14697943_3_3494", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7949255_3_3495", "context": "Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7949255_3_3496", "context": "Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7949255_3_3497", "context": "Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7949255_3_3498", "context": "Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7949255_3_3499", "context": "Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7949255_3_3500", "context": "Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7949255_3_3501", "context": "Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7949255_3_3502", "context": "Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22372628_1_3503", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "22372628_1_3504", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "22372628_1_3505", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "22372628_1_3506", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "22372628_1_3507", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "22372628_1_3508", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "22372628_1_3509", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "22372628_1_3510", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "22372628_1_3511", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "22372628_1_3512", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22372628_1_3513", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "22372628_1_3514", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "22372628_1_3515", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8404753_2_3516", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8404753_2_3517", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8404753_2_3518", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8404753_2_3519", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8404753_2_3520", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8404753_2_3521", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8404753_2_3522", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8404753_2_3523", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8404753_2_3524", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8404753_2_3525", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8404753_2_3526", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8404753_2_3527", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8404753_2_3528", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21515865_4_3529", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "21515865_4_3530", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "21515865_4_3531", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "21515865_4_3532", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "21515865_4_3533", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "21515865_4_3534", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "21515865_4_3535", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "21515865_4_3536", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "21515865_4_3537", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "21515865_4_3538", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21515865_4_3539", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "21515865_4_3540", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "21515865_4_3541", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7056119_3_3542", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "7056119_3_3543", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "7056119_3_3544", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "7056119_3_3545", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "7056119_3_3546", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "7056119_3_3547", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "7056119_3_3548", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "7056119_3_3549", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "7056119_3_3550", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "7056119_3_3551", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7056119_3_3552", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "7056119_3_3553", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "7056119_3_3554", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "3720318_2_3555", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3720318_2_3556", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3720318_2_3557", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3720318_2_3558", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3720318_2_3559", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3720318_2_3560", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3720318_2_3561", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3720318_2_3562", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3720318_2_3563", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3720318_2_3564", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3720318_2_3565", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3720318_2_3566", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3720318_2_3567", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12166705_2_3568", "context": "Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12166705_2_3569", "context": "Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12166705_2_3570", "context": "Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12166705_2_3571", "context": "Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12166705_2_3572", "context": "Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12166705_2_3573", "context": "Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12166705_2_3574", "context": "Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12166705_2_3575", "context": "Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1414247_2_3576", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1414247_2_3577", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1414247_2_3578", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1414247_2_3579", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1414247_2_3580", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1414247_2_3581", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1414247_2_3582", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1414247_2_3583", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1414247_2_3584", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1414247_2_3585", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1414247_2_3586", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1414247_2_3587", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1414247_2_3588", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7355327_4_3589", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7355327_4_3590", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7355327_4_3591", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7355327_4_3592", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7355327_4_3593", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7355327_4_3594", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7355327_4_3595", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7355327_4_3596", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7355327_4_3597", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7355327_4_3598", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7355327_4_3599", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7355327_4_3600", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7355327_4_3601", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10573314_2_3602", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10573314_2_3603", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10573314_2_3604", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10573314_2_3605", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10573314_2_3606", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10573314_2_3607", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10573314_2_3608", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10573314_2_3609", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10573314_2_3610", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10573314_2_3611", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10573314_2_3612", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10573314_2_3613", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10573314_2_3614", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8850251_2_3615", "context": "In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8850251_2_3616", "context": "In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8850251_2_3617", "context": "In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8850251_2_3618", "context": "In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8850251_2_3619", "context": "In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8850251_2_3620", "context": "In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8850251_2_3621", "context": "In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8850251_2_3622", "context": "In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "879939_1_3623", "context": "Acetazolamide-accelerated anticonvulsant osteomalacia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "879939_1_3624", "context": "Acetazolamide-accelerated anticonvulsant osteomalacia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "879939_1_3625", "context": "Acetazolamide-accelerated anticonvulsant osteomalacia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "879939_1_3626", "context": "Acetazolamide-accelerated anticonvulsant osteomalacia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "879939_1_3627", "context": "Acetazolamide-accelerated anticonvulsant osteomalacia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "879939_1_3628", "context": "Acetazolamide-accelerated anticonvulsant osteomalacia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "879939_1_3629", "context": "Acetazolamide-accelerated anticonvulsant osteomalacia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "879939_1_3630", "context": "Acetazolamide-accelerated anticonvulsant osteomalacia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "129501_2_3631", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "129501_2_3632", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "129501_2_3633", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "129501_2_3634", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "129501_2_3635", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "129501_2_3636", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "129501_2_3637", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "129501_2_3638", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "129501_2_3639", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "129501_2_3640", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "129501_2_3641", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "129501_2_3642", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "129501_2_3643", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17182354_2_3644", "context": "Large dose of methylphenidate may cause cataract and glaucoma.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17182354_2_3645", "context": "Large dose of methylphenidate may cause cataract and glaucoma.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17182354_2_3646", "context": "Large dose of methylphenidate may cause cataract and glaucoma.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17182354_2_3647", "context": "Large dose of methylphenidate may cause cataract and glaucoma.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17182354_2_3648", "context": "Large dose of methylphenidate may cause cataract and glaucoma.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17182354_2_3649", "context": "Large dose of methylphenidate may cause cataract and glaucoma.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17182354_2_3650", "context": "Large dose of methylphenidate may cause cataract and glaucoma.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17182354_2_3651", "context": "Large dose of methylphenidate may cause cataract and glaucoma.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7369302_3_3652", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7369302_3_3653", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7369302_3_3654", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7369302_3_3655", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7369302_3_3656", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7369302_3_3657", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7369302_3_3658", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7369302_3_3659", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7369302_3_3660", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7369302_3_3661", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7369302_3_3662", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7369302_3_3663", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7369302_3_3664", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8404753_1_3665", "context": "Carbamazepine-induced tics.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8404753_1_3666", "context": "Carbamazepine-induced tics.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8404753_1_3667", "context": "Carbamazepine-induced tics.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8404753_1_3668", "context": "Carbamazepine-induced tics.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8404753_1_3669", "context": "Carbamazepine-induced tics.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8404753_1_3670", "context": "Carbamazepine-induced tics.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8404753_1_3671", "context": "Carbamazepine-induced tics.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8404753_1_3672", "context": "Carbamazepine-induced tics.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1655228_3_3673", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1655228_3_3674", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1655228_3_3675", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1655228_3_3676", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1655228_3_3677", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1655228_3_3678", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1655228_3_3679", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1655228_3_3680", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1655228_3_3681", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1655228_3_3682", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1655228_3_3683", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1655228_3_3684", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1655228_3_3685", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "25298587_1_3686", "context": "A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "25298587_1_3687", "context": "A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "25298587_1_3688", "context": "A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "25298587_1_3689", "context": "A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "25298587_1_3690", "context": "A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "25298587_1_3691", "context": "A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "25298587_1_3692", "context": "A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "25298587_1_3693", "context": "A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16046172_3_3694", "context": "Septic knee arthritis after intra-articular hyaluronate injection.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16046172_3_3695", "context": "Septic knee arthritis after intra-articular hyaluronate injection.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16046172_3_3696", "context": "Septic knee arthritis after intra-articular hyaluronate injection.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16046172_3_3697", "context": "Septic knee arthritis after intra-articular hyaluronate injection.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16046172_3_3698", "context": "Septic knee arthritis after intra-articular hyaluronate injection.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16046172_3_3699", "context": "Septic knee arthritis after intra-articular hyaluronate injection.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16046172_3_3700", "context": "Septic knee arthritis after intra-articular hyaluronate injection.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16046172_3_3701", "context": "Septic knee arthritis after intra-articular hyaluronate injection.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17921794_3_3702", "context": "The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17921794_3_3703", "context": "The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17921794_3_3704", "context": "The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17921794_3_3705", "context": "The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17921794_3_3706", "context": "The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17921794_3_3707", "context": "The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17921794_3_3708", "context": "The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17921794_3_3709", "context": "The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15588385_3_3710", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "15588385_3_3711", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "15588385_3_3712", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "15588385_3_3713", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "15588385_3_3714", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "15588385_3_3715", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "15588385_3_3716", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15588385_3_3717", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15588385_3_3718", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15588385_3_3719", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15588385_3_3720", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15588385_3_3721", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "15588385_3_3722", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "21330680_1_3723", "context": "Olanzapine-induced parkinsonism associated with smoking cessation.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21330680_1_3724", "context": "Olanzapine-induced parkinsonism associated with smoking cessation.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21330680_1_3725", "context": "Olanzapine-induced parkinsonism associated with smoking cessation.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21330680_1_3726", "context": "Olanzapine-induced parkinsonism associated with smoking cessation.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21330680_1_3727", "context": "Olanzapine-induced parkinsonism associated with smoking cessation.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21330680_1_3728", "context": "Olanzapine-induced parkinsonism associated with smoking cessation.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21330680_1_3729", "context": "Olanzapine-induced parkinsonism associated with smoking cessation.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21330680_1_3730", "context": "Olanzapine-induced parkinsonism associated with smoking cessation.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20465622_4_3731", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20465622_4_3732", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20465622_4_3733", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20465622_4_3734", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20465622_4_3735", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20465622_4_3736", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20465622_4_3737", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20465622_4_3738", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20465622_4_3739", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20465622_4_3740", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20465622_4_3741", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20465622_4_3742", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20465622_4_3743", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10190739_2_3744", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10190739_2_3745", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10190739_2_3746", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10190739_2_3747", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10190739_2_3748", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10190739_2_3749", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10190739_2_3750", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10190739_2_3751", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10190739_2_3752", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10190739_2_3753", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10190739_2_3754", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10190739_2_3755", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10190739_2_3756", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20628041_1_3757", "context": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20628041_1_3758", "context": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20628041_1_3759", "context": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20628041_1_3760", "context": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20628041_1_3761", "context": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20628041_1_3762", "context": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20628041_1_3763", "context": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20628041_1_3764", "context": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10573314_14_3765", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10573314_14_3766", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10573314_14_3767", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10573314_14_3768", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10573314_14_3769", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10573314_14_3770", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10573314_14_3771", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10573314_14_3772", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10573314_14_3773", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10573314_14_3774", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10573314_14_3775", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10573314_14_3776", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10573314_14_3777", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15522120_13_3778", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "15522120_13_3779", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "15522120_13_3780", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "15522120_13_3781", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "15522120_13_3782", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "15522120_13_3783", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "15522120_13_3784", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15522120_13_3785", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15522120_13_3786", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15522120_13_3787", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15522120_13_3788", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15522120_13_3789", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "15522120_13_3790", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8391300_3_3791", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8391300_3_3792", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8391300_3_3793", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8391300_3_3794", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8391300_3_3795", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8391300_3_3796", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8391300_3_3797", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8391300_3_3798", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8391300_3_3799", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8391300_3_3800", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8391300_3_3801", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8391300_3_3802", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8391300_3_3803", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16978752_2_3804", "context": "Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16978752_2_3805", "context": "Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16978752_2_3806", "context": "Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16978752_2_3807", "context": "Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16978752_2_3808", "context": "Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16978752_2_3809", "context": "Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16978752_2_3810", "context": "Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16978752_2_3811", "context": "Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1695794_4_3812", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "1695794_4_3813", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "1695794_4_3814", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "1695794_4_3815", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "1695794_4_3816", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "1695794_4_3817", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "1695794_4_3818", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "1695794_4_3819", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "1695794_4_3820", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "1695794_4_3821", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1695794_4_3822", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "1695794_4_3823", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "1695794_4_3824", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "6572542_3_3825", "context": "The responsibility of CCNU in the pathogenesis of pulmonary fibrosis seems very likely.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6572542_3_3826", "context": "The responsibility of CCNU in the pathogenesis of pulmonary fibrosis seems very likely.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6572542_3_3827", "context": "The responsibility of CCNU in the pathogenesis of pulmonary fibrosis seems very likely.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6572542_3_3828", "context": "The responsibility of CCNU in the pathogenesis of pulmonary fibrosis seems very likely.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6572542_3_3829", "context": "The responsibility of CCNU in the pathogenesis of pulmonary fibrosis seems very likely.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6572542_3_3830", "context": "The responsibility of CCNU in the pathogenesis of pulmonary fibrosis seems very likely.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6572542_3_3831", "context": "The responsibility of CCNU in the pathogenesis of pulmonary fibrosis seems very likely.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6572542_3_3832", "context": "The responsibility of CCNU in the pathogenesis of pulmonary fibrosis seems very likely.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15863610_1_3833", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15863610_1_3834", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15863610_1_3835", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15863610_1_3836", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15863610_1_3837", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15863610_1_3838", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15863610_1_3839", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15863610_1_3840", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15863610_1_3841", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15863610_1_3842", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15863610_1_3843", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15863610_1_3844", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15863610_1_3845", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15516308_1_3846", "context": "Fatal overdoses associated with quetiapine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15516308_1_3847", "context": "Fatal overdoses associated with quetiapine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15516308_1_3848", "context": "Fatal overdoses associated with quetiapine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15516308_1_3849", "context": "Fatal overdoses associated with quetiapine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15516308_1_3850", "context": "Fatal overdoses associated with quetiapine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15516308_1_3851", "context": "Fatal overdoses associated with quetiapine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15516308_1_3852", "context": "Fatal overdoses associated with quetiapine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15516308_1_3853", "context": "Fatal overdoses associated with quetiapine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16685112_3_3854", "context": "Gemcitabine-induced rectus abdominus radiation recall.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16685112_3_3855", "context": "Gemcitabine-induced rectus abdominus radiation recall.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16685112_3_3856", "context": "Gemcitabine-induced rectus abdominus radiation recall.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16685112_3_3857", "context": "Gemcitabine-induced rectus abdominus radiation recall.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16685112_3_3858", "context": "Gemcitabine-induced rectus abdominus radiation recall.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16685112_3_3859", "context": "Gemcitabine-induced rectus abdominus radiation recall.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16685112_3_3860", "context": "Gemcitabine-induced rectus abdominus radiation recall.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16685112_3_3861", "context": "Gemcitabine-induced rectus abdominus radiation recall.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19754002_2_3862", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19754002_2_3863", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19754002_2_3864", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19754002_2_3865", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19754002_2_3866", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19754002_2_3867", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19754002_2_3868", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19754002_2_3869", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19754002_2_3870", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19754002_2_3871", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19754002_2_3872", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19754002_2_3873", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19754002_2_3874", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15588385_4_3875", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15588385_4_3876", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15588385_4_3877", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15588385_4_3878", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15588385_4_3879", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15588385_4_3880", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15588385_4_3881", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15588385_4_3882", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15588385_4_3883", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15588385_4_3884", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15588385_4_3885", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15588385_4_3886", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15588385_4_3887", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11283125_2_3888", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "11283125_2_3889", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "11283125_2_3890", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "11283125_2_3891", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "11283125_2_3892", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "11283125_2_3893", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "11283125_2_3894", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11283125_2_3895", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11283125_2_3896", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11283125_2_3897", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11283125_2_3898", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11283125_2_3899", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "11283125_2_3900", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "6113770_2_3901", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6113770_2_3902", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6113770_2_3903", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6113770_2_3904", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6113770_2_3905", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6113770_2_3906", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6113770_2_3907", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6113770_2_3908", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1711090_1_3909", "context": "Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "1711090_1_3910", "context": "Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "1711090_1_3911", "context": "Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "1711090_1_3912", "context": "Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "1711090_1_3913", "context": "Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1711090_1_3914", "context": "Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "1711090_1_3915", "context": "Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "1711090_1_3916", "context": "Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "6693840_2_3917", "context": "Gynecomastia associated with theophylline.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6693840_2_3918", "context": "Gynecomastia associated with theophylline.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6693840_2_3919", "context": "Gynecomastia associated with theophylline.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6693840_2_3920", "context": "Gynecomastia associated with theophylline.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6693840_2_3921", "context": "Gynecomastia associated with theophylline.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6693840_2_3922", "context": "Gynecomastia associated with theophylline.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6693840_2_3923", "context": "Gynecomastia associated with theophylline.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6693840_2_3924", "context": "Gynecomastia associated with theophylline.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16393774_1_3925", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16393774_1_3926", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16393774_1_3927", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16393774_1_3928", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16393774_1_3929", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16393774_1_3930", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16393774_1_3931", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16393774_1_3932", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16393774_1_3933", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16393774_1_3934", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16393774_1_3935", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16393774_1_3936", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16393774_1_3937", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1888256_3_3938", "context": "To our knowledge, drug-induced fever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1888256_3_3939", "context": "To our knowledge, drug-induced fever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1888256_3_3940", "context": "To our knowledge, drug-induced fever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1888256_3_3941", "context": "To our knowledge, drug-induced fever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1888256_3_3942", "context": "To our knowledge, drug-induced fever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1888256_3_3943", "context": "To our knowledge, drug-induced fever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1888256_3_3944", "context": "To our knowledge, drug-induced fever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1888256_3_3945", "context": "To our knowledge, drug-induced fever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11155197_1_3946", "context": "Case studies in heparin-induced thrombocytopenia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11155197_1_3947", "context": "Case studies in heparin-induced thrombocytopenia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11155197_1_3948", "context": "Case studies in heparin-induced thrombocytopenia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11155197_1_3949", "context": "Case studies in heparin-induced thrombocytopenia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11155197_1_3950", "context": "Case studies in heparin-induced thrombocytopenia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11155197_1_3951", "context": "Case studies in heparin-induced thrombocytopenia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11155197_1_3952", "context": "Case studies in heparin-induced thrombocytopenia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11155197_1_3953", "context": "Case studies in heparin-induced thrombocytopenia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8316494_2_3954", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8316494_2_3955", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8316494_2_3956", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8316494_2_3957", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8316494_2_3958", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8316494_2_3959", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8316494_2_3960", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8316494_2_3961", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8316494_2_3962", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8316494_2_3963", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8316494_2_3964", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8316494_2_3965", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8316494_2_3966", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15061230_2_3967", "context": "Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15061230_2_3968", "context": "Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15061230_2_3969", "context": "Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15061230_2_3970", "context": "Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15061230_2_3971", "context": "Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15061230_2_3972", "context": "Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15061230_2_3973", "context": "Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15061230_2_3974", "context": "Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15663666_3_3975", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15663666_3_3976", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15663666_3_3977", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15663666_3_3978", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15663666_3_3979", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15663666_3_3980", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15663666_3_3981", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15663666_3_3982", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15663666_3_3983", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15663666_3_3984", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15663666_3_3985", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15663666_3_3986", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15663666_3_3987", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14684937_1_3988", "context": "After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "14684937_1_3989", "context": "After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "14684937_1_3990", "context": "After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "14684937_1_3991", "context": "After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "14684937_1_3992", "context": "After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14684937_1_3993", "context": "After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "14684937_1_3994", "context": "After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "14684937_1_3995", "context": "After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11485141_6_3996", "context": "Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11485141_6_3997", "context": "Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11485141_6_3998", "context": "Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11485141_6_3999", "context": "Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11485141_6_4000", "context": "Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11485141_6_4001", "context": "Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11485141_6_4002", "context": "Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11485141_6_4003", "context": "Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15623719_1_4004", "context": "Vision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15623719_1_4005", "context": "Vision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15623719_1_4006", "context": "Vision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15623719_1_4007", "context": "Vision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15623719_1_4008", "context": "Vision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15623719_1_4009", "context": "Vision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15623719_1_4010", "context": "Vision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15623719_1_4011", "context": "Vision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10682234_3_4012", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10682234_3_4013", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10682234_3_4014", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10682234_3_4015", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10682234_3_4016", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10682234_3_4017", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10682234_3_4018", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10682234_3_4019", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10682234_3_4020", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10682234_3_4021", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10682234_3_4022", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10682234_3_4023", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10682234_3_4024", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15895899_2_4025", "context": "Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15895899_2_4026", "context": "Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15895899_2_4027", "context": "Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15895899_2_4028", "context": "Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15895899_2_4029", "context": "Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15895899_2_4030", "context": "Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15895899_2_4031", "context": "Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15895899_2_4032", "context": "Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19555801_1_4033", "context": "Aripiprazole-induced hiccups: a case report.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19555801_1_4034", "context": "Aripiprazole-induced hiccups: a case report.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19555801_1_4035", "context": "Aripiprazole-induced hiccups: a case report.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19555801_1_4036", "context": "Aripiprazole-induced hiccups: a case report.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19555801_1_4037", "context": "Aripiprazole-induced hiccups: a case report.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19555801_1_4038", "context": "Aripiprazole-induced hiccups: a case report.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19555801_1_4039", "context": "Aripiprazole-induced hiccups: a case report.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19555801_1_4040", "context": "Aripiprazole-induced hiccups: a case report.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16728538_3_4041", "context": "The hepatic enzyme disturbances normalized after discontinuation of pegvisomant.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "16728538_3_4042", "context": "The hepatic enzyme disturbances normalized after discontinuation of pegvisomant.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16728538_3_4043", "context": "The hepatic enzyme disturbances normalized after discontinuation of pegvisomant.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16728538_3_4044", "context": "The hepatic enzyme disturbances normalized after discontinuation of pegvisomant.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "16728538_3_4045", "context": "The hepatic enzyme disturbances normalized after discontinuation of pegvisomant.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16728538_3_4046", "context": "The hepatic enzyme disturbances normalized after discontinuation of pegvisomant.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16728538_3_4047", "context": "The hepatic enzyme disturbances normalized after discontinuation of pegvisomant.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "16728538_3_4048", "context": "The hepatic enzyme disturbances normalized after discontinuation of pegvisomant.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9777751_4_4049", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9777751_4_4050", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9777751_4_4051", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9777751_4_4052", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9777751_4_4053", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9777751_4_4054", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9777751_4_4055", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9777751_4_4056", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9777751_4_4057", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9777751_4_4058", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9777751_4_4059", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9777751_4_4060", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9777751_4_4061", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16685112_2_4062", "context": "CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16685112_2_4063", "context": "CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16685112_2_4064", "context": "CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16685112_2_4065", "context": "CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16685112_2_4066", "context": "CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16685112_2_4067", "context": "CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16685112_2_4068", "context": "CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16685112_2_4069", "context": "CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16046172_2_4070", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16046172_2_4071", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16046172_2_4072", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16046172_2_4073", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16046172_2_4074", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16046172_2_4075", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16046172_2_4076", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16046172_2_4077", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16046172_2_4078", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16046172_2_4079", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16046172_2_4080", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16046172_2_4081", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16046172_2_4082", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6731466_5_4083", "context": "Association of zomepirac administration with renal cortical necrosis is not known to have been previously demonstrated.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6731466_5_4084", "context": "Association of zomepirac administration with renal cortical necrosis is not known to have been previously demonstrated.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6731466_5_4085", "context": "Association of zomepirac administration with renal cortical necrosis is not known to have been previously demonstrated.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6731466_5_4086", "context": "Association of zomepirac administration with renal cortical necrosis is not known to have been previously demonstrated.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6731466_5_4087", "context": "Association of zomepirac administration with renal cortical necrosis is not known to have been previously demonstrated.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6731466_5_4088", "context": "Association of zomepirac administration with renal cortical necrosis is not known to have been previously demonstrated.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6731466_5_4089", "context": "Association of zomepirac administration with renal cortical necrosis is not known to have been previously demonstrated.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6731466_5_4090", "context": "Association of zomepirac administration with renal cortical necrosis is not known to have been previously demonstrated.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6427463_2_4091", "context": "Vasomotor reactions after gold sodium thiomalate are well recognized.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6427463_2_4092", "context": "Vasomotor reactions after gold sodium thiomalate are well recognized.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6427463_2_4093", "context": "Vasomotor reactions after gold sodium thiomalate are well recognized.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6427463_2_4094", "context": "Vasomotor reactions after gold sodium thiomalate are well recognized.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6427463_2_4095", "context": "Vasomotor reactions after gold sodium thiomalate are well recognized.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6427463_2_4096", "context": "Vasomotor reactions after gold sodium thiomalate are well recognized.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6427463_2_4097", "context": "Vasomotor reactions after gold sodium thiomalate are well recognized.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6427463_2_4098", "context": "Vasomotor reactions after gold sodium thiomalate are well recognized.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21515865_1_4099", "context": "Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21515865_1_4100", "context": "Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21515865_1_4101", "context": "Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21515865_1_4102", "context": "Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21515865_1_4103", "context": "Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21515865_1_4104", "context": "Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21515865_1_4105", "context": "Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21515865_1_4106", "context": "Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15571949_1_4107", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15571949_1_4108", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15571949_1_4109", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15571949_1_4110", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15571949_1_4111", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15571949_1_4112", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15571949_1_4113", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15571949_1_4114", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15571949_1_4115", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15571949_1_4116", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15571949_1_4117", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15571949_1_4118", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15571949_1_4119", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7139589_1_4120", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7139589_1_4121", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7139589_1_4122", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7139589_1_4123", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7139589_1_4124", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7139589_1_4125", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7139589_1_4126", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7139589_1_4127", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7139589_1_4128", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7139589_1_4129", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7139589_1_4130", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7139589_1_4131", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7139589_1_4132", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17205927_1_4133", "context": "Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17205927_1_4134", "context": "Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17205927_1_4135", "context": "Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17205927_1_4136", "context": "Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17205927_1_4137", "context": "Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17205927_1_4138", "context": "Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17205927_1_4139", "context": "Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17205927_1_4140", "context": "Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9725786_1_4141", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9725786_1_4142", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9725786_1_4143", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9725786_1_4144", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9725786_1_4145", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9725786_1_4146", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9725786_1_4147", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9725786_1_4148", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9725786_1_4149", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9725786_1_4150", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9725786_1_4151", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9725786_1_4152", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9725786_1_4153", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15588385_2_4154", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15588385_2_4155", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15588385_2_4156", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15588385_2_4157", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15588385_2_4158", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15588385_2_4159", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15588385_2_4160", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15588385_2_4161", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15588385_2_4162", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15588385_2_4163", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15588385_2_4164", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15588385_2_4165", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15588385_2_4166", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12042592_1_4167", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12042592_1_4168", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12042592_1_4169", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12042592_1_4170", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12042592_1_4171", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12042592_1_4172", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12042592_1_4173", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12042592_1_4174", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12042592_1_4175", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12042592_1_4176", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12042592_1_4177", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12042592_1_4178", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12042592_1_4179", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9671138_3_4180", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9671138_3_4181", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9671138_3_4182", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9671138_3_4183", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9671138_3_4184", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9671138_3_4185", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9671138_3_4186", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9671138_3_4187", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9671138_3_4188", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9671138_3_4189", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9671138_3_4190", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9671138_3_4191", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9671138_3_4192", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10812579_1_4193", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10812579_1_4194", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10812579_1_4195", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10812579_1_4196", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10812579_1_4197", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10812579_1_4198", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10812579_1_4199", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10812579_1_4200", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10812579_1_4201", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10812579_1_4202", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10812579_1_4203", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10812579_1_4204", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10812579_1_4205", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16685007_2_4206", "context": "Oral corticosteroids (OCS) may be associated with systemic adverse events (AEs), which can be reduced by replacing OCS with inhaled corticosteroids (ICS).", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16685007_2_4207", "context": "Oral corticosteroids (OCS) may be associated with systemic adverse events (AEs), which can be reduced by replacing OCS with inhaled corticosteroids (ICS).", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16685007_2_4208", "context": "Oral corticosteroids (OCS) may be associated with systemic adverse events (AEs), which can be reduced by replacing OCS with inhaled corticosteroids (ICS).", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16685007_2_4209", "context": "Oral corticosteroids (OCS) may be associated with systemic adverse events (AEs), which can be reduced by replacing OCS with inhaled corticosteroids (ICS).", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16685007_2_4210", "context": "Oral corticosteroids (OCS) may be associated with systemic adverse events (AEs), which can be reduced by replacing OCS with inhaled corticosteroids (ICS).", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16685007_2_4211", "context": "Oral corticosteroids (OCS) may be associated with systemic adverse events (AEs), which can be reduced by replacing OCS with inhaled corticosteroids (ICS).", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16685007_2_4212", "context": "Oral corticosteroids (OCS) may be associated with systemic adverse events (AEs), which can be reduced by replacing OCS with inhaled corticosteroids (ICS).", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16685007_2_4213", "context": "Oral corticosteroids (OCS) may be associated with systemic adverse events (AEs), which can be reduced by replacing OCS with inhaled corticosteroids (ICS).", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15072497_1_4214", "context": "Development of Peyronie's disease during long-term colchicine treatment.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15072497_1_4215", "context": "Development of Peyronie's disease during long-term colchicine treatment.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15072497_1_4216", "context": "Development of Peyronie's disease during long-term colchicine treatment.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15072497_1_4217", "context": "Development of Peyronie's disease during long-term colchicine treatment.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15072497_1_4218", "context": "Development of Peyronie's disease during long-term colchicine treatment.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15072497_1_4219", "context": "Development of Peyronie's disease during long-term colchicine treatment.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15072497_1_4220", "context": "Development of Peyronie's disease during long-term colchicine treatment.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15072497_1_4221", "context": "Development of Peyronie's disease during long-term colchicine treatment.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9007910_6_4222", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "9007910_6_4223", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "9007910_6_4224", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "9007910_6_4225", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "9007910_6_4226", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "9007910_6_4227", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "9007910_6_4228", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9007910_6_4229", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9007910_6_4230", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9007910_6_4231", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9007910_6_4232", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9007910_6_4233", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "9007910_6_4234", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16599252_1_4235", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16599252_1_4236", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16599252_1_4237", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16599252_1_4238", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16599252_1_4239", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16599252_1_4240", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16599252_1_4241", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16599252_1_4242", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16599252_1_4243", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16599252_1_4244", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16599252_1_4245", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16599252_1_4246", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16599252_1_4247", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6788011_4_4248", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6788011_4_4249", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6788011_4_4250", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6788011_4_4251", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6788011_4_4252", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6788011_4_4253", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6788011_4_4254", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6788011_4_4255", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6788011_4_4256", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6788011_4_4257", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6788011_4_4258", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6788011_4_4259", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6788011_4_4260", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6731466_6_4261", "context": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti-inflammatory agents, especially zomepirac.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6731466_6_4262", "context": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti-inflammatory agents, especially zomepirac.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6731466_6_4263", "context": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti-inflammatory agents, especially zomepirac.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6731466_6_4264", "context": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti-inflammatory agents, especially zomepirac.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6731466_6_4265", "context": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti-inflammatory agents, especially zomepirac.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6731466_6_4266", "context": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti-inflammatory agents, especially zomepirac.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6731466_6_4267", "context": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti-inflammatory agents, especially zomepirac.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6731466_6_4268", "context": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti-inflammatory agents, especially zomepirac.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12488741_1_4269", "context": "Clinical, spectroscopic, and imaging abnormalities resolved with discontinuation of metronidazole.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "12488741_1_4270", "context": "Clinical, spectroscopic, and imaging abnormalities resolved with discontinuation of metronidazole.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12488741_1_4271", "context": "Clinical, spectroscopic, and imaging abnormalities resolved with discontinuation of metronidazole.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12488741_1_4272", "context": "Clinical, spectroscopic, and imaging abnormalities resolved with discontinuation of metronidazole.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12488741_1_4273", "context": "Clinical, spectroscopic, and imaging abnormalities resolved with discontinuation of metronidazole.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12488741_1_4274", "context": "Clinical, spectroscopic, and imaging abnormalities resolved with discontinuation of metronidazole.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12488741_1_4275", "context": "Clinical, spectroscopic, and imaging abnormalities resolved with discontinuation of metronidazole.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "12488741_1_4276", "context": "Clinical, spectroscopic, and imaging abnormalities resolved with discontinuation of metronidazole.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "20202988_8_4277", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "20202988_8_4278", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "20202988_8_4279", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "20202988_8_4280", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "20202988_8_4281", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "20202988_8_4282", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "20202988_8_4283", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "20202988_8_4284", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "20202988_8_4285", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "20202988_8_4286", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20202988_8_4287", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "20202988_8_4288", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "20202988_8_4289", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16265343_2_4290", "context": "Reversible cardiomyopathy caused by administration of interferon alpha.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16265343_2_4291", "context": "Reversible cardiomyopathy caused by administration of interferon alpha.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16265343_2_4292", "context": "Reversible cardiomyopathy caused by administration of interferon alpha.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16265343_2_4293", "context": "Reversible cardiomyopathy caused by administration of interferon alpha.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16265343_2_4294", "context": "Reversible cardiomyopathy caused by administration of interferon alpha.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16265343_2_4295", "context": "Reversible cardiomyopathy caused by administration of interferon alpha.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16265343_2_4296", "context": "Reversible cardiomyopathy caused by administration of interferon alpha.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16265343_2_4297", "context": "Reversible cardiomyopathy caused by administration of interferon alpha.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8696525_1_4298", "context": "Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8696525_1_4299", "context": "Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8696525_1_4300", "context": "Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8696525_1_4301", "context": "Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8696525_1_4302", "context": "Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8696525_1_4303", "context": "Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8696525_1_4304", "context": "Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8696525_1_4305", "context": "Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12851279_13_4306", "context": "There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR).", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12851279_13_4307", "context": "There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR).", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12851279_13_4308", "context": "There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR).", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12851279_13_4309", "context": "There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR).", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12851279_13_4310", "context": "There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR).", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12851279_13_4311", "context": "There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR).", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12851279_13_4312", "context": "There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR).", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12851279_13_4313", "context": "There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR).", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3318771_1_4314", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3318771_1_4315", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3318771_1_4316", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3318771_1_4317", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3318771_1_4318", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3318771_1_4319", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3318771_1_4320", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3318771_1_4321", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3318771_1_4322", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3318771_1_4323", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3318771_1_4324", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3318771_1_4325", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3318771_1_4326", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17016002_1_4327", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17016002_1_4328", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17016002_1_4329", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17016002_1_4330", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17016002_1_4331", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17016002_1_4332", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17016002_1_4333", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17016002_1_4334", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17016002_1_4335", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17016002_1_4336", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17016002_1_4337", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17016002_1_4338", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17016002_1_4339", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10212021_1_4340", "context": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10212021_1_4341", "context": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10212021_1_4342", "context": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10212021_1_4343", "context": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10212021_1_4344", "context": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10212021_1_4345", "context": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10212021_1_4346", "context": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10212021_1_4347", "context": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9253492_4_4348", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9253492_4_4349", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9253492_4_4350", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9253492_4_4351", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9253492_4_4352", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9253492_4_4353", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9253492_4_4354", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9253492_4_4355", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9253492_4_4356", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9253492_4_4357", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9253492_4_4358", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9253492_4_4359", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9253492_4_4360", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16317298_4_4361", "context": "Radiation recall related to gemcitabine has been reported in lung and breast cancer.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16317298_4_4362", "context": "Radiation recall related to gemcitabine has been reported in lung and breast cancer.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16317298_4_4363", "context": "Radiation recall related to gemcitabine has been reported in lung and breast cancer.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16317298_4_4364", "context": "Radiation recall related to gemcitabine has been reported in lung and breast cancer.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16317298_4_4365", "context": "Radiation recall related to gemcitabine has been reported in lung and breast cancer.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16317298_4_4366", "context": "Radiation recall related to gemcitabine has been reported in lung and breast cancer.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16317298_4_4367", "context": "Radiation recall related to gemcitabine has been reported in lung and breast cancer.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16317298_4_4368", "context": "Radiation recall related to gemcitabine has been reported in lung and breast cancer.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10435399_1_4369", "context": "It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10435399_1_4370", "context": "It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10435399_1_4371", "context": "It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10435399_1_4372", "context": "It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10435399_1_4373", "context": "It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10435399_1_4374", "context": "It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10435399_1_4375", "context": "It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10435399_1_4376", "context": "It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17827338_2_4377", "context": "Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "17827338_2_4378", "context": "Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17827338_2_4379", "context": "Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "17827338_2_4380", "context": "Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17827338_2_4381", "context": "Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17827338_2_4382", "context": "Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17827338_2_4383", "context": "Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "17827338_2_4384", "context": "Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9253492_2_4385", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9253492_2_4386", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9253492_2_4387", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9253492_2_4388", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9253492_2_4389", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9253492_2_4390", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9253492_2_4391", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9253492_2_4392", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9253492_2_4393", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9253492_2_4394", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9253492_2_4395", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9253492_2_4396", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9253492_2_4397", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11147747_3_4398", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11147747_3_4399", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11147747_3_4400", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11147747_3_4401", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11147747_3_4402", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11147747_3_4403", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11147747_3_4404", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11147747_3_4405", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11147747_3_4406", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11147747_3_4407", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11147747_3_4408", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11147747_3_4409", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11147747_3_4410", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1087773_2_4411", "context": "Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1087773_2_4412", "context": "Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1087773_2_4413", "context": "Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1087773_2_4414", "context": "Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1087773_2_4415", "context": "Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1087773_2_4416", "context": "Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1087773_2_4417", "context": "Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1087773_2_4418", "context": "Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15507779_4_4419", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15507779_4_4420", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15507779_4_4421", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15507779_4_4422", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15507779_4_4423", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15507779_4_4424", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15507779_4_4425", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15507779_4_4426", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15507779_4_4427", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15507779_4_4428", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15507779_4_4429", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15507779_4_4430", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15507779_4_4431", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18364401_2_4432", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18364401_2_4433", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18364401_2_4434", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18364401_2_4435", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18364401_2_4436", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18364401_2_4437", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18364401_2_4438", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18364401_2_4439", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18364401_2_4440", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18364401_2_4441", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18364401_2_4442", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18364401_2_4443", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18364401_2_4444", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12851279_15_4445", "context": "Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12851279_15_4446", "context": "Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12851279_15_4447", "context": "Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12851279_15_4448", "context": "Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12851279_15_4449", "context": "Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12851279_15_4450", "context": "Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12851279_15_4451", "context": "Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12851279_15_4452", "context": "Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6618859_1_4453", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6618859_1_4454", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6618859_1_4455", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6618859_1_4456", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6618859_1_4457", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6618859_1_4458", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6618859_1_4459", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6618859_1_4460", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6618859_1_4461", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6618859_1_4462", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6618859_1_4463", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6618859_1_4464", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6618859_1_4465", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6113770_1_4466", "context": "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6113770_1_4467", "context": "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6113770_1_4468", "context": "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6113770_1_4469", "context": "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6113770_1_4470", "context": "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6113770_1_4471", "context": "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6113770_1_4472", "context": "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6113770_1_4473", "context": "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17665812_3_4474", "context": "Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17665812_3_4475", "context": "Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17665812_3_4476", "context": "Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17665812_3_4477", "context": "Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17665812_3_4478", "context": "Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17665812_3_4479", "context": "Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17665812_3_4480", "context": "Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17665812_3_4481", "context": "Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7139589_4_4482", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7139589_4_4483", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7139589_4_4484", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7139589_4_4485", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7139589_4_4486", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7139589_4_4487", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7139589_4_4488", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7139589_4_4489", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7139589_4_4490", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7139589_4_4491", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7139589_4_4492", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7139589_4_4493", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7139589_4_4494", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17182354_4_4495", "context": "We report a case of Ritalin-associated cataract and glaucoma.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17182354_4_4496", "context": "We report a case of Ritalin-associated cataract and glaucoma.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17182354_4_4497", "context": "We report a case of Ritalin-associated cataract and glaucoma.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17182354_4_4498", "context": "We report a case of Ritalin-associated cataract and glaucoma.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17182354_4_4499", "context": "We report a case of Ritalin-associated cataract and glaucoma.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17182354_4_4500", "context": "We report a case of Ritalin-associated cataract and glaucoma.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17182354_4_4501", "context": "We report a case of Ritalin-associated cataract and glaucoma.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17182354_4_4502", "context": "We report a case of Ritalin-associated cataract and glaucoma.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19884751_3_4503", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19884751_3_4504", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19884751_3_4505", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19884751_3_4506", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19884751_3_4507", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19884751_3_4508", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19884751_3_4509", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19884751_3_4510", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19884751_3_4511", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19884751_3_4512", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19884751_3_4513", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19884751_3_4514", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19884751_3_4515", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1655228_1_4516", "context": "Cardiac toxicity related to BCNU has not been described well.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1655228_1_4517", "context": "Cardiac toxicity related to BCNU has not been described well.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1655228_1_4518", "context": "Cardiac toxicity related to BCNU has not been described well.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1655228_1_4519", "context": "Cardiac toxicity related to BCNU has not been described well.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1655228_1_4520", "context": "Cardiac toxicity related to BCNU has not been described well.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1655228_1_4521", "context": "Cardiac toxicity related to BCNU has not been described well.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1655228_1_4522", "context": "Cardiac toxicity related to BCNU has not been described well.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1655228_1_4523", "context": "Cardiac toxicity related to BCNU has not been described well.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12891225_2_4524", "context": "Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "12891225_2_4525", "context": "Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12891225_2_4526", "context": "Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12891225_2_4527", "context": "Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12891225_2_4528", "context": "Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12891225_2_4529", "context": "Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12891225_2_4530", "context": "Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "12891225_2_4531", "context": "Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17123120_2_4532", "context": "Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17123120_2_4533", "context": "Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17123120_2_4534", "context": "Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17123120_2_4535", "context": "Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17123120_2_4536", "context": "Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17123120_2_4537", "context": "Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17123120_2_4538", "context": "Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17123120_2_4539", "context": "Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15927910_3_4540", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15927910_3_4541", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15927910_3_4542", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15927910_3_4543", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15927910_3_4544", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15927910_3_4545", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15927910_3_4546", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15927910_3_4547", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15927910_3_4548", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15927910_3_4549", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15927910_3_4550", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15927910_3_4551", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15927910_3_4552", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14684937_3_4553", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14684937_3_4554", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14684937_3_4555", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14684937_3_4556", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14684937_3_4557", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14684937_3_4558", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14684937_3_4559", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14684937_3_4560", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11352235_1_4561", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11352235_1_4562", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11352235_1_4563", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11352235_1_4564", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11352235_1_4565", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11352235_1_4566", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11352235_1_4567", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11352235_1_4568", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11352235_1_4569", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11352235_1_4570", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11352235_1_4571", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11352235_1_4572", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11352235_1_4573", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7071645_2_4574", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7071645_2_4575", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7071645_2_4576", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7071645_2_4577", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7071645_2_4578", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7071645_2_4579", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7071645_2_4580", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7071645_2_4581", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7071645_2_4582", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7071645_2_4583", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7071645_2_4584", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7071645_2_4585", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7071645_2_4586", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "24531907_1_4587", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "24531907_1_4588", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "24531907_1_4589", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "24531907_1_4590", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "24531907_1_4591", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "24531907_1_4592", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "24531907_1_4593", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "24531907_1_4594", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "24531907_1_4595", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "24531907_1_4596", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "24531907_1_4597", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "24531907_1_4598", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "24531907_1_4599", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9352164_5_4600", "context": "We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9352164_5_4601", "context": "We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9352164_5_4602", "context": "We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9352164_5_4603", "context": "We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9352164_5_4604", "context": "We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9352164_5_4605", "context": "We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9352164_5_4606", "context": "We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9352164_5_4607", "context": "We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8430717_1_4608", "context": "Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8430717_1_4609", "context": "Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8430717_1_4610", "context": "Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8430717_1_4611", "context": "Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8430717_1_4612", "context": "Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8430717_1_4613", "context": "Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8430717_1_4614", "context": "Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8430717_1_4615", "context": "Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1680596_2_4616", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1680596_2_4617", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1680596_2_4618", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1680596_2_4619", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1680596_2_4620", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1680596_2_4621", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1680596_2_4622", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1680596_2_4623", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1680596_2_4624", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1680596_2_4625", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1680596_2_4626", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1680596_2_4627", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1680596_2_4628", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10579985_4_4629", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10579985_4_4630", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10579985_4_4631", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10579985_4_4632", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10579985_4_4633", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10579985_4_4634", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10579985_4_4635", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10579985_4_4636", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10579985_4_4637", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10579985_4_4638", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10579985_4_4639", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10579985_4_4640", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10579985_4_4641", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17275666_2_4642", "context": "Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies, including juvenile absence epilepsy.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "17275666_2_4643", "context": "Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies, including juvenile absence epilepsy.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17275666_2_4644", "context": "Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies, including juvenile absence epilepsy.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "17275666_2_4645", "context": "Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies, including juvenile absence epilepsy.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17275666_2_4646", "context": "Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies, including juvenile absence epilepsy.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17275666_2_4647", "context": "Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies, including juvenile absence epilepsy.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17275666_2_4648", "context": "Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies, including juvenile absence epilepsy.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "17275666_2_4649", "context": "Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies, including juvenile absence epilepsy.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "14561622_3_4650", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14561622_3_4651", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14561622_3_4652", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14561622_3_4653", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14561622_3_4654", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14561622_3_4655", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14561622_3_4656", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14561622_3_4657", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14561622_3_4658", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14561622_3_4659", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14561622_3_4660", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14561622_3_4661", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14561622_3_4662", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22677303_11_4663", "context": "According to the Drug Interaction Probability Scale, a causal relationship between the warfarin-cloxacillin interaction and increased INR value was rated \"probable\".", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "22677303_11_4664", "context": "According to the Drug Interaction Probability Scale, a causal relationship between the warfarin-cloxacillin interaction and increased INR value was rated \"probable\".", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22677303_11_4665", "context": "According to the Drug Interaction Probability Scale, a causal relationship between the warfarin-cloxacillin interaction and increased INR value was rated \"probable\".", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22677303_11_4666", "context": "According to the Drug Interaction Probability Scale, a causal relationship between the warfarin-cloxacillin interaction and increased INR value was rated \"probable\".", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22677303_11_4667", "context": "According to the Drug Interaction Probability Scale, a causal relationship between the warfarin-cloxacillin interaction and increased INR value was rated \"probable\".", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22677303_11_4668", "context": "According to the Drug Interaction Probability Scale, a causal relationship between the warfarin-cloxacillin interaction and increased INR value was rated \"probable\".", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22677303_11_4669", "context": "According to the Drug Interaction Probability Scale, a causal relationship between the warfarin-cloxacillin interaction and increased INR value was rated \"probable\".", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22677303_11_4670", "context": "According to the Drug Interaction Probability Scale, a causal relationship between the warfarin-cloxacillin interaction and increased INR value was rated \"probable\".", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16393774_4_4671", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16393774_4_4672", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16393774_4_4673", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16393774_4_4674", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16393774_4_4675", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16393774_4_4676", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16393774_4_4677", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16393774_4_4678", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16393774_4_4679", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16393774_4_4680", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16393774_4_4681", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16393774_4_4682", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16393774_4_4683", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "440873_1_4684", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "440873_1_4685", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "440873_1_4686", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "440873_1_4687", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "440873_1_4688", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "440873_1_4689", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "440873_1_4690", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "440873_1_4691", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "440873_1_4692", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "440873_1_4693", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "440873_1_4694", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "440873_1_4695", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "440873_1_4696", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20925534_10_4697", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20925534_10_4698", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20925534_10_4699", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20925534_10_4700", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20925534_10_4701", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20925534_10_4702", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20925534_10_4703", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20925534_10_4704", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20925534_10_4705", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20925534_10_4706", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20925534_10_4707", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20925534_10_4708", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20925534_10_4709", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9865241_1_4710", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9865241_1_4711", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9865241_1_4712", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9865241_1_4713", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9865241_1_4714", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9865241_1_4715", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9865241_1_4716", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9865241_1_4717", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20925534_1_4718", "context": "Clopidogrel with or without omeprazole in coronary artery disease.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "20925534_1_4719", "context": "Clopidogrel with or without omeprazole in coronary artery disease.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "20925534_1_4720", "context": "Clopidogrel with or without omeprazole in coronary artery disease.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "20925534_1_4721", "context": "Clopidogrel with or without omeprazole in coronary artery disease.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "20925534_1_4722", "context": "Clopidogrel with or without omeprazole in coronary artery disease.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20925534_1_4723", "context": "Clopidogrel with or without omeprazole in coronary artery disease.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "20925534_1_4724", "context": "Clopidogrel with or without omeprazole in coronary artery disease.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "20925534_1_4725", "context": "Clopidogrel with or without omeprazole in coronary artery disease.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11001600_1_4726", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11001600_1_4727", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11001600_1_4728", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11001600_1_4729", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11001600_1_4730", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11001600_1_4731", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11001600_1_4732", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11001600_1_4733", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11001600_1_4734", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11001600_1_4735", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11001600_1_4736", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11001600_1_4737", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11001600_1_4738", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18580694_1_4739", "context": "In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18580694_1_4740", "context": "In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18580694_1_4741", "context": "In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18580694_1_4742", "context": "In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18580694_1_4743", "context": "In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18580694_1_4744", "context": "In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18580694_1_4745", "context": "In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18580694_1_4746", "context": "In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10592946_2_4747", "context": "After abstinence from oolong tea his delirium resolved.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "10592946_2_4748", "context": "After abstinence from oolong tea his delirium resolved.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10592946_2_4749", "context": "After abstinence from oolong tea his delirium resolved.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10592946_2_4750", "context": "After abstinence from oolong tea his delirium resolved.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10592946_2_4751", "context": "After abstinence from oolong tea his delirium resolved.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10592946_2_4752", "context": "After abstinence from oolong tea his delirium resolved.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10592946_2_4753", "context": "After abstinence from oolong tea his delirium resolved.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "10592946_2_4754", "context": "After abstinence from oolong tea his delirium resolved.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16901609_1_4755", "context": "Anaphylaxis to intrathecal diamorphine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16901609_1_4756", "context": "Anaphylaxis to intrathecal diamorphine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16901609_1_4757", "context": "Anaphylaxis to intrathecal diamorphine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16901609_1_4758", "context": "Anaphylaxis to intrathecal diamorphine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16901609_1_4759", "context": "Anaphylaxis to intrathecal diamorphine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16901609_1_4760", "context": "Anaphylaxis to intrathecal diamorphine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16901609_1_4761", "context": "Anaphylaxis to intrathecal diamorphine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16901609_1_4762", "context": "Anaphylaxis to intrathecal diamorphine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8726608_3_4763", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8726608_3_4764", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8726608_3_4765", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8726608_3_4766", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8726608_3_4767", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8726608_3_4768", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8726608_3_4769", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8726608_3_4770", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8726608_3_4771", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8726608_3_4772", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8726608_3_4773", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8726608_3_4774", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8726608_3_4775", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15522120_12_4776", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15522120_12_4777", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15522120_12_4778", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15522120_12_4779", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15522120_12_4780", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15522120_12_4781", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15522120_12_4782", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15522120_12_4783", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15522120_12_4784", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15522120_12_4785", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15522120_12_4786", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15522120_12_4787", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15522120_12_4788", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8589490_2_4789", "context": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8589490_2_4790", "context": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8589490_2_4791", "context": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8589490_2_4792", "context": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8589490_2_4793", "context": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8589490_2_4794", "context": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8589490_2_4795", "context": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8589490_2_4796", "context": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7485371_1_4797", "context": "CONCLUSION: Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7485371_1_4798", "context": "CONCLUSION: Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7485371_1_4799", "context": "CONCLUSION: Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7485371_1_4800", "context": "CONCLUSION: Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7485371_1_4801", "context": "CONCLUSION: Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7485371_1_4802", "context": "CONCLUSION: Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7485371_1_4803", "context": "CONCLUSION: Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7485371_1_4804", "context": "CONCLUSION: Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10812579_2_4805", "context": "A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10812579_2_4806", "context": "A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10812579_2_4807", "context": "A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10812579_2_4808", "context": "A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10812579_2_4809", "context": "A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10812579_2_4810", "context": "A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10812579_2_4811", "context": "A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10812579_2_4812", "context": "A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7748076_1_4813", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7748076_1_4814", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7748076_1_4815", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7748076_1_4816", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7748076_1_4817", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7748076_1_4818", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7748076_1_4819", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7748076_1_4820", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7748076_1_4821", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7748076_1_4822", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7748076_1_4823", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7748076_1_4824", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7748076_1_4825", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6610943_4_4826", "context": "This association should be considered in the period after vasopressin-treated gastrointestinal hemorrhage.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6610943_4_4827", "context": "This association should be considered in the period after vasopressin-treated gastrointestinal hemorrhage.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6610943_4_4828", "context": "This association should be considered in the period after vasopressin-treated gastrointestinal hemorrhage.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6610943_4_4829", "context": "This association should be considered in the period after vasopressin-treated gastrointestinal hemorrhage.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6610943_4_4830", "context": "This association should be considered in the period after vasopressin-treated gastrointestinal hemorrhage.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6610943_4_4831", "context": "This association should be considered in the period after vasopressin-treated gastrointestinal hemorrhage.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6610943_4_4832", "context": "This association should be considered in the period after vasopressin-treated gastrointestinal hemorrhage.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6610943_4_4833", "context": "This association should be considered in the period after vasopressin-treated gastrointestinal hemorrhage.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6693840_4_4834", "context": "The gynecomastia regressed when the theophylline was discontinued.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "6693840_4_4835", "context": "The gynecomastia regressed when the theophylline was discontinued.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "6693840_4_4836", "context": "The gynecomastia regressed when the theophylline was discontinued.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "6693840_4_4837", "context": "The gynecomastia regressed when the theophylline was discontinued.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "6693840_4_4838", "context": "The gynecomastia regressed when the theophylline was discontinued.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6693840_4_4839", "context": "The gynecomastia regressed when the theophylline was discontinued.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "6693840_4_4840", "context": "The gynecomastia regressed when the theophylline was discontinued.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "6693840_4_4841", "context": "The gynecomastia regressed when the theophylline was discontinued.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "3277077_1_4842", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3277077_1_4843", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3277077_1_4844", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3277077_1_4845", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3277077_1_4846", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3277077_1_4847", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3277077_1_4848", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3277077_1_4849", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3277077_1_4850", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3277077_1_4851", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3277077_1_4852", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3277077_1_4853", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3277077_1_4854", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2297635_1_4855", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2297635_1_4856", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2297635_1_4857", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2297635_1_4858", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2297635_1_4859", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2297635_1_4860", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2297635_1_4861", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2297635_1_4862", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2297635_1_4863", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2297635_1_4864", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2297635_1_4865", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2297635_1_4866", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2297635_1_4867", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1087773_1_4868", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1087773_1_4869", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1087773_1_4870", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1087773_1_4871", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1087773_1_4872", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1087773_1_4873", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1087773_1_4874", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1087773_1_4875", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1087773_1_4876", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1087773_1_4877", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1087773_1_4878", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1087773_1_4879", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1087773_1_4880", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16609346_1_4881", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16609346_1_4882", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16609346_1_4883", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16609346_1_4884", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16609346_1_4885", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16609346_1_4886", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16609346_1_4887", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16609346_1_4888", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16609346_1_4889", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16609346_1_4890", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16609346_1_4891", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16609346_1_4892", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16609346_1_4893", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21658326_2_4894", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "21658326_2_4895", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "21658326_2_4896", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "21658326_2_4897", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "21658326_2_4898", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21658326_2_4899", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "21658326_2_4900", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "21658326_2_4901", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "6731466_1_4902", "context": "Focal renal cortical necrosis associated with zomepirac.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6731466_1_4903", "context": "Focal renal cortical necrosis associated with zomepirac.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6731466_1_4904", "context": "Focal renal cortical necrosis associated with zomepirac.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6731466_1_4905", "context": "Focal renal cortical necrosis associated with zomepirac.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6731466_1_4906", "context": "Focal renal cortical necrosis associated with zomepirac.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6731466_1_4907", "context": "Focal renal cortical necrosis associated with zomepirac.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6731466_1_4908", "context": "Focal renal cortical necrosis associated with zomepirac.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6731466_1_4909", "context": "Focal renal cortical necrosis associated with zomepirac.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8850251_6_4910", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8850251_6_4911", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8850251_6_4912", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8850251_6_4913", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8850251_6_4914", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8850251_6_4915", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8850251_6_4916", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8850251_6_4917", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8850251_6_4918", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8850251_6_4919", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8850251_6_4920", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8850251_6_4921", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8850251_6_4922", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20349794_4_4923", "context": "Carboplatin was substituted for cisplatin, and there were no further episodes of SIADH.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20349794_4_4924", "context": "Carboplatin was substituted for cisplatin, and there were no further episodes of SIADH.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20349794_4_4925", "context": "Carboplatin was substituted for cisplatin, and there were no further episodes of SIADH.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20349794_4_4926", "context": "Carboplatin was substituted for cisplatin, and there were no further episodes of SIADH.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20349794_4_4927", "context": "Carboplatin was substituted for cisplatin, and there were no further episodes of SIADH.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20349794_4_4928", "context": "Carboplatin was substituted for cisplatin, and there were no further episodes of SIADH.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20349794_4_4929", "context": "Carboplatin was substituted for cisplatin, and there were no further episodes of SIADH.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20349794_4_4930", "context": "Carboplatin was substituted for cisplatin, and there were no further episodes of SIADH.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16490518_3_4931", "context": "Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16490518_3_4932", "context": "Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16490518_3_4933", "context": "Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16490518_3_4934", "context": "Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16490518_3_4935", "context": "Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16490518_3_4936", "context": "Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16490518_3_4937", "context": "Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16490518_3_4938", "context": "Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16160485_1_4939", "context": "CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16160485_1_4940", "context": "CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16160485_1_4941", "context": "CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16160485_1_4942", "context": "CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16160485_1_4943", "context": "CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16160485_1_4944", "context": "CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16160485_1_4945", "context": "CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16160485_1_4946", "context": "CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10717401_2_4947", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10717401_2_4948", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10717401_2_4949", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10717401_2_4950", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10717401_2_4951", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10717401_2_4952", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10717401_2_4953", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10717401_2_4954", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10717401_2_4955", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10717401_2_4956", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10717401_2_4957", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10717401_2_4958", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10717401_2_4959", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16317298_1_4960", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16317298_1_4961", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16317298_1_4962", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16317298_1_4963", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16317298_1_4964", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16317298_1_4965", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16317298_1_4966", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16317298_1_4967", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16317298_1_4968", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16317298_1_4969", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16317298_1_4970", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16317298_1_4971", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16317298_1_4972", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8404753_7_4973", "context": "After development of the tics in 2, CBZ was continued at the same or higher dose, and the tics abated and then ceased spontaneously < or = 6 months.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "8404753_7_4974", "context": "After development of the tics in 2, CBZ was continued at the same or higher dose, and the tics abated and then ceased spontaneously < or = 6 months.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8404753_7_4975", "context": "After development of the tics in 2, CBZ was continued at the same or higher dose, and the tics abated and then ceased spontaneously < or = 6 months.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8404753_7_4976", "context": "After development of the tics in 2, CBZ was continued at the same or higher dose, and the tics abated and then ceased spontaneously < or = 6 months.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8404753_7_4977", "context": "After development of the tics in 2, CBZ was continued at the same or higher dose, and the tics abated and then ceased spontaneously < or = 6 months.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8404753_7_4978", "context": "After development of the tics in 2, CBZ was continued at the same or higher dose, and the tics abated and then ceased spontaneously < or = 6 months.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8404753_7_4979", "context": "After development of the tics in 2, CBZ was continued at the same or higher dose, and the tics abated and then ceased spontaneously < or = 6 months.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "8404753_7_4980", "context": "After development of the tics in 2, CBZ was continued at the same or higher dose, and the tics abated and then ceased spontaneously < or = 6 months.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16978752_4_4981", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16978752_4_4982", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16978752_4_4983", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16978752_4_4984", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16978752_4_4985", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16978752_4_4986", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16978752_4_4987", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16978752_4_4988", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16978752_4_4989", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16978752_4_4990", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16978752_4_4991", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16978752_4_4992", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16978752_4_4993", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18203308_4_4994", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18203308_4_4995", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18203308_4_4996", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18203308_4_4997", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18203308_4_4998", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18203308_4_4999", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18203308_4_5000", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18203308_4_5001", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18203308_4_5002", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18203308_4_5003", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18203308_4_5004", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18203308_4_5005", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18203308_4_5006", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11510798_5_5007", "context": "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11510798_5_5008", "context": "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11510798_5_5009", "context": "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11510798_5_5010", "context": "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11510798_5_5011", "context": "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11510798_5_5012", "context": "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11510798_5_5013", "context": "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11510798_5_5014", "context": "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17619811_2_5015", "context": "A case of colchicine-induced rhabdomyolysis is reported.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17619811_2_5016", "context": "A case of colchicine-induced rhabdomyolysis is reported.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17619811_2_5017", "context": "A case of colchicine-induced rhabdomyolysis is reported.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17619811_2_5018", "context": "A case of colchicine-induced rhabdomyolysis is reported.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17619811_2_5019", "context": "A case of colchicine-induced rhabdomyolysis is reported.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17619811_2_5020", "context": "A case of colchicine-induced rhabdomyolysis is reported.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17619811_2_5021", "context": "A case of colchicine-induced rhabdomyolysis is reported.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17619811_2_5022", "context": "A case of colchicine-induced rhabdomyolysis is reported.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7056119_4_5023", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7056119_4_5024", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7056119_4_5025", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7056119_4_5026", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7056119_4_5027", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7056119_4_5028", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7056119_4_5029", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7056119_4_5030", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17167851_2_5031", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17167851_2_5032", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17167851_2_5033", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17167851_2_5034", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17167851_2_5035", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17167851_2_5036", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17167851_2_5037", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17167851_2_5038", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17167851_2_5039", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17167851_2_5040", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17167851_2_5041", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17167851_2_5042", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17167851_2_5043", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "172214_2_5044", "context": "Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559).", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "172214_2_5045", "context": "Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559).", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "172214_2_5046", "context": "Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559).", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "172214_2_5047", "context": "Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559).", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "172214_2_5048", "context": "Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559).", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "172214_2_5049", "context": "Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559).", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "172214_2_5050", "context": "Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559).", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "172214_2_5051", "context": "Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559).", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18347524_1_5052", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18347524_1_5053", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18347524_1_5054", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18347524_1_5055", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18347524_1_5056", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18347524_1_5057", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18347524_1_5058", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18347524_1_5059", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18347524_1_5060", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18347524_1_5061", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18347524_1_5062", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18347524_1_5063", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18347524_1_5064", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15836666_2_5065", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15836666_2_5066", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15836666_2_5067", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15836666_2_5068", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15836666_2_5069", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15836666_2_5070", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15836666_2_5071", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15836666_2_5072", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15836666_2_5073", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15836666_2_5074", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15836666_2_5075", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15836666_2_5076", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15836666_2_5077", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6440806_1_5078", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6440806_1_5079", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6440806_1_5080", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6440806_1_5081", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6440806_1_5082", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6440806_1_5083", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6440806_1_5084", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6440806_1_5085", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6440806_1_5086", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6440806_1_5087", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6440806_1_5088", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6440806_1_5089", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6440806_1_5090", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12786839_1_5091", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12786839_1_5092", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12786839_1_5093", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12786839_1_5094", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12786839_1_5095", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12786839_1_5096", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12786839_1_5097", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12786839_1_5098", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12659609_2_5099", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12659609_2_5100", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12659609_2_5101", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12659609_2_5102", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12659609_2_5103", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12659609_2_5104", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12659609_2_5105", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12659609_2_5106", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15857283_4_5107", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15857283_4_5108", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15857283_4_5109", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15857283_4_5110", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15857283_4_5111", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15857283_4_5112", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15857283_4_5113", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15857283_4_5114", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15857283_4_5115", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15857283_4_5116", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15857283_4_5117", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15857283_4_5118", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15857283_4_5119", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3136101_2_5120", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3136101_2_5121", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3136101_2_5122", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3136101_2_5123", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3136101_2_5124", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3136101_2_5125", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3136101_2_5126", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3136101_2_5127", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3136101_2_5128", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3136101_2_5129", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3136101_2_5130", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3136101_2_5131", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3136101_2_5132", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19318596_2_5133", "context": "In this case, CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19318596_2_5134", "context": "In this case, CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19318596_2_5135", "context": "In this case, CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19318596_2_5136", "context": "In this case, CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19318596_2_5137", "context": "In this case, CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19318596_2_5138", "context": "In this case, CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19318596_2_5139", "context": "In this case, CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19318596_2_5140", "context": "In this case, CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18751717_1_5141", "context": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18751717_1_5142", "context": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18751717_1_5143", "context": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18751717_1_5144", "context": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18751717_1_5145", "context": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18751717_1_5146", "context": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18751717_1_5147", "context": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18751717_1_5148", "context": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7139589_2_5149", "context": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7139589_2_5150", "context": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7139589_2_5151", "context": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7139589_2_5152", "context": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7139589_2_5153", "context": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7139589_2_5154", "context": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7139589_2_5155", "context": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7139589_2_5156", "context": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7783891_3_5157", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7783891_3_5158", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7783891_3_5159", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7783891_3_5160", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7783891_3_5161", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7783891_3_5162", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7783891_3_5163", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7783891_3_5164", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7783891_3_5165", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7783891_3_5166", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7783891_3_5167", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7783891_3_5168", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7783891_3_5169", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10332990_2_5170", "context": "Epoprostenol (prostacyclin) is currently approved for treatment of primary pulmonary hypertension; however, it is being evaluated in other forms of pulmonary hypertension, particularly scleroderma.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "10332990_2_5171", "context": "Epoprostenol (prostacyclin) is currently approved for treatment of primary pulmonary hypertension; however, it is being evaluated in other forms of pulmonary hypertension, particularly scleroderma.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10332990_2_5172", "context": "Epoprostenol (prostacyclin) is currently approved for treatment of primary pulmonary hypertension; however, it is being evaluated in other forms of pulmonary hypertension, particularly scleroderma.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10332990_2_5173", "context": "Epoprostenol (prostacyclin) is currently approved for treatment of primary pulmonary hypertension; however, it is being evaluated in other forms of pulmonary hypertension, particularly scleroderma.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10332990_2_5174", "context": "Epoprostenol (prostacyclin) is currently approved for treatment of primary pulmonary hypertension; however, it is being evaluated in other forms of pulmonary hypertension, particularly scleroderma.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10332990_2_5175", "context": "Epoprostenol (prostacyclin) is currently approved for treatment of primary pulmonary hypertension; however, it is being evaluated in other forms of pulmonary hypertension, particularly scleroderma.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10332990_2_5176", "context": "Epoprostenol (prostacyclin) is currently approved for treatment of primary pulmonary hypertension; however, it is being evaluated in other forms of pulmonary hypertension, particularly scleroderma.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "10332990_2_5177", "context": "Epoprostenol (prostacyclin) is currently approved for treatment of primary pulmonary hypertension; however, it is being evaluated in other forms of pulmonary hypertension, particularly scleroderma.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11724089_4_5178", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11724089_4_5179", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11724089_4_5180", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11724089_4_5181", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11724089_4_5182", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11724089_4_5183", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11724089_4_5184", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11724089_4_5185", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11724089_4_5186", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11724089_4_5187", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11724089_4_5188", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11724089_4_5189", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11724089_4_5190", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12869178_1_5191", "context": "Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12869178_1_5192", "context": "Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12869178_1_5193", "context": "Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12869178_1_5194", "context": "Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12869178_1_5195", "context": "Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12869178_1_5196", "context": "Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12869178_1_5197", "context": "Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12869178_1_5198", "context": "Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11283125_1_5199", "context": "Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "11283125_1_5200", "context": "Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "11283125_1_5201", "context": "Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "11283125_1_5202", "context": "Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "11283125_1_5203", "context": "Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "11450788_4_5204", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11450788_4_5205", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11450788_4_5206", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11450788_4_5207", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11450788_4_5208", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11450788_4_5209", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11450788_4_5210", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11450788_4_5211", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16537817_10_5212", "context": "An objective causal assessment suggests that rhabdomyolysis, renal failure, and possibly hepatotoxicity were probably related to an amiodarone-simvastatin interaction.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16537817_10_5213", "context": "An objective causal assessment suggests that rhabdomyolysis, renal failure, and possibly hepatotoxicity were probably related to an amiodarone-simvastatin interaction.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16537817_10_5214", "context": "An objective causal assessment suggests that rhabdomyolysis, renal failure, and possibly hepatotoxicity were probably related to an amiodarone-simvastatin interaction.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16537817_10_5215", "context": "An objective causal assessment suggests that rhabdomyolysis, renal failure, and possibly hepatotoxicity were probably related to an amiodarone-simvastatin interaction.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16537817_10_5216", "context": "An objective causal assessment suggests that rhabdomyolysis, renal failure, and possibly hepatotoxicity were probably related to an amiodarone-simvastatin interaction.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16537817_10_5217", "context": "An objective causal assessment suggests that rhabdomyolysis, renal failure, and possibly hepatotoxicity were probably related to an amiodarone-simvastatin interaction.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16537817_10_5218", "context": "An objective causal assessment suggests that rhabdomyolysis, renal failure, and possibly hepatotoxicity were probably related to an amiodarone-simvastatin interaction.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16537817_10_5219", "context": "An objective causal assessment suggests that rhabdomyolysis, renal failure, and possibly hepatotoxicity were probably related to an amiodarone-simvastatin interaction.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11105373_2_5220", "context": "Nail staining from hydroquinone cream.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11105373_2_5221", "context": "Nail staining from hydroquinone cream.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11105373_2_5222", "context": "Nail staining from hydroquinone cream.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11105373_2_5223", "context": "Nail staining from hydroquinone cream.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11105373_2_5224", "context": "Nail staining from hydroquinone cream.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11105373_2_5225", "context": "Nail staining from hydroquinone cream.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11105373_2_5226", "context": "Nail staining from hydroquinone cream.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11105373_2_5227", "context": "Nail staining from hydroquinone cream.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "748238_2_5228", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "748238_2_5229", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "748238_2_5230", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "748238_2_5231", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "748238_2_5232", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "748238_2_5233", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "748238_2_5234", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "748238_2_5235", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "748238_2_5236", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "748238_2_5237", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "748238_2_5238", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "748238_2_5239", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "748238_2_5240", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10698143_2_5241", "context": "Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10698143_2_5242", "context": "Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10698143_2_5243", "context": "Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10698143_2_5244", "context": "Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10698143_2_5245", "context": "Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10698143_2_5246", "context": "Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10698143_2_5247", "context": "Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10698143_2_5248", "context": "Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20628041_5_5249", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "20628041_5_5250", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "20628041_5_5251", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "20628041_5_5252", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "20628041_5_5253", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20628041_5_5254", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "20628041_5_5255", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "20628041_5_5256", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18675768_15_5257", "context": "CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18675768_15_5258", "context": "CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18675768_15_5259", "context": "CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18675768_15_5260", "context": "CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18675768_15_5261", "context": "CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18675768_15_5262", "context": "CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18675768_15_5263", "context": "CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18675768_15_5264", "context": "CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14614357_2_5265", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14614357_2_5266", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14614357_2_5267", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14614357_2_5268", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14614357_2_5269", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14614357_2_5270", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14614357_2_5271", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14614357_2_5272", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14614357_2_5273", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14614357_2_5274", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14614357_2_5275", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14614357_2_5276", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14614357_2_5277", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3708949_2_5278", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3708949_2_5279", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3708949_2_5280", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3708949_2_5281", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3708949_2_5282", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3708949_2_5283", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3708949_2_5284", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3708949_2_5285", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3708949_2_5286", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3708949_2_5287", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3708949_2_5288", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3708949_2_5289", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3708949_2_5290", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18364401_4_5291", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18364401_4_5292", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18364401_4_5293", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18364401_4_5294", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18364401_4_5295", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18364401_4_5296", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18364401_4_5297", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18364401_4_5298", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18364401_4_5299", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18364401_4_5300", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18364401_4_5301", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18364401_4_5302", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18364401_4_5303", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8151270_1_5304", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8151270_1_5305", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8151270_1_5306", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8151270_1_5307", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8151270_1_5308", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8151270_1_5309", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8151270_1_5310", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8151270_1_5311", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8151270_1_5312", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8151270_1_5313", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8151270_1_5314", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8151270_1_5315", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8151270_1_5316", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18425523_4_5317", "context": "Persisent ocular hypertension following intravitreal ranibizumab.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18425523_4_5318", "context": "Persisent ocular hypertension following intravitreal ranibizumab.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18425523_4_5319", "context": "Persisent ocular hypertension following intravitreal ranibizumab.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18425523_4_5320", "context": "Persisent ocular hypertension following intravitreal ranibizumab.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18425523_4_5321", "context": "Persisent ocular hypertension following intravitreal ranibizumab.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18425523_4_5322", "context": "Persisent ocular hypertension following intravitreal ranibizumab.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18425523_4_5323", "context": "Persisent ocular hypertension following intravitreal ranibizumab.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18425523_4_5324", "context": "Persisent ocular hypertension following intravitreal ranibizumab.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14968106_4_5325", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14968106_4_5326", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14968106_4_5327", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14968106_4_5328", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14968106_4_5329", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14968106_4_5330", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14968106_4_5331", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14968106_4_5332", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14968106_4_5333", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14968106_4_5334", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14968106_4_5335", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14968106_4_5336", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14968106_4_5337", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18166746_4_5338", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18166746_4_5339", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18166746_4_5340", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18166746_4_5341", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18166746_4_5342", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18166746_4_5343", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18166746_4_5344", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18166746_4_5345", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18166746_4_5346", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18166746_4_5347", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18166746_4_5348", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18166746_4_5349", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18166746_4_5350", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9704170_2_5351", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9704170_2_5352", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9704170_2_5353", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9704170_2_5354", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9704170_2_5355", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9704170_2_5356", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9704170_2_5357", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9704170_2_5358", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9704170_2_5359", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9704170_2_5360", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9704170_2_5361", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9704170_2_5362", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9704170_2_5363", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11485141_2_5364", "context": "CONCLUSIONS: We report the first case of gemcitabine-induced LABD.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11485141_2_5365", "context": "CONCLUSIONS: We report the first case of gemcitabine-induced LABD.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11485141_2_5366", "context": "CONCLUSIONS: We report the first case of gemcitabine-induced LABD.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11485141_2_5367", "context": "CONCLUSIONS: We report the first case of gemcitabine-induced LABD.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11485141_2_5368", "context": "CONCLUSIONS: We report the first case of gemcitabine-induced LABD.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11485141_2_5369", "context": "CONCLUSIONS: We report the first case of gemcitabine-induced LABD.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11485141_2_5370", "context": "CONCLUSIONS: We report the first case of gemcitabine-induced LABD.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11485141_2_5371", "context": "CONCLUSIONS: We report the first case of gemcitabine-induced LABD.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10752888_1_5372", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10752888_1_5373", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10752888_1_5374", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10752888_1_5375", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10752888_1_5376", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10752888_1_5377", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10752888_1_5378", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10752888_1_5379", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10752888_1_5380", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10752888_1_5381", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10752888_1_5382", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10752888_1_5383", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10752888_1_5384", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2012922_2_5385", "context": "Trazodone-induced transient hypomanic symptoms and their management.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2012922_2_5386", "context": "Trazodone-induced transient hypomanic symptoms and their management.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2012922_2_5387", "context": "Trazodone-induced transient hypomanic symptoms and their management.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2012922_2_5388", "context": "Trazodone-induced transient hypomanic symptoms and their management.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2012922_2_5389", "context": "Trazodone-induced transient hypomanic symptoms and their management.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2012922_2_5390", "context": "Trazodone-induced transient hypomanic symptoms and their management.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2012922_2_5391", "context": "Trazodone-induced transient hypomanic symptoms and their management.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2012922_2_5392", "context": "Trazodone-induced transient hypomanic symptoms and their management.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2219619_1_5393", "context": "Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2219619_1_5394", "context": "Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2219619_1_5395", "context": "Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2219619_1_5396", "context": "Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2219619_1_5397", "context": "Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2219619_1_5398", "context": "Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2219619_1_5399", "context": "Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2219619_1_5400", "context": "Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18076602_1_5401", "context": "Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18076602_1_5402", "context": "Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18076602_1_5403", "context": "Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18076602_1_5404", "context": "Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18076602_1_5405", "context": "Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18076602_1_5406", "context": "Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18076602_1_5407", "context": "Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18076602_1_5408", "context": "Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8726608_5_5409", "context": "When measured, the serum lithium level had increased 4-fold during acyclovir therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8726608_5_5410", "context": "When measured, the serum lithium level had increased 4-fold during acyclovir therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8726608_5_5411", "context": "When measured, the serum lithium level had increased 4-fold during acyclovir therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8726608_5_5412", "context": "When measured, the serum lithium level had increased 4-fold during acyclovir therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8726608_5_5413", "context": "When measured, the serum lithium level had increased 4-fold during acyclovir therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8726608_5_5414", "context": "When measured, the serum lithium level had increased 4-fold during acyclovir therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8726608_5_5415", "context": "When measured, the serum lithium level had increased 4-fold during acyclovir therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8726608_5_5416", "context": "When measured, the serum lithium level had increased 4-fold during acyclovir therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17504225_3_5417", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17504225_3_5418", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17504225_3_5419", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17504225_3_5420", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17504225_3_5421", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17504225_3_5422", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17504225_3_5423", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17504225_3_5424", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17504225_3_5425", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17504225_3_5426", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17504225_3_5427", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17504225_3_5428", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17504225_3_5429", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12847760_1_5430", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12847760_1_5431", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12847760_1_5432", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12847760_1_5433", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12847760_1_5434", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12847760_1_5435", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12847760_1_5436", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12847760_1_5437", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12847760_1_5438", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12847760_1_5439", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12847760_1_5440", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12847760_1_5441", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12847760_1_5442", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15516308_15_5443", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15516308_15_5444", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15516308_15_5445", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15516308_15_5446", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15516308_15_5447", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15516308_15_5448", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15516308_15_5449", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15516308_15_5450", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17275666_4_5451", "context": "Similar to antiarrhythmic drugs aggravating particular arrhythmias, antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17275666_4_5452", "context": "Similar to antiarrhythmic drugs aggravating particular arrhythmias, antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17275666_4_5453", "context": "Similar to antiarrhythmic drugs aggravating particular arrhythmias, antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17275666_4_5454", "context": "Similar to antiarrhythmic drugs aggravating particular arrhythmias, antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17275666_4_5455", "context": "Similar to antiarrhythmic drugs aggravating particular arrhythmias, antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17275666_4_5456", "context": "Similar to antiarrhythmic drugs aggravating particular arrhythmias, antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17275666_4_5457", "context": "Similar to antiarrhythmic drugs aggravating particular arrhythmias, antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17275666_4_5458", "context": "Similar to antiarrhythmic drugs aggravating particular arrhythmias, antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16192734_3_5459", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16192734_3_5460", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16192734_3_5461", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16192734_3_5462", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16192734_3_5463", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16192734_3_5464", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16192734_3_5465", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16192734_3_5466", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16192734_3_5467", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16192734_3_5468", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16192734_3_5469", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16192734_3_5470", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16192734_3_5471", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7748076_2_5472", "context": "OBJECTIVE: To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7748076_2_5473", "context": "OBJECTIVE: To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7748076_2_5474", "context": "OBJECTIVE: To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7748076_2_5475", "context": "OBJECTIVE: To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7748076_2_5476", "context": "OBJECTIVE: To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7748076_2_5477", "context": "OBJECTIVE: To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7748076_2_5478", "context": "OBJECTIVE: To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7748076_2_5479", "context": "OBJECTIVE: To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9007910_8_5480", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9007910_8_5481", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9007910_8_5482", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9007910_8_5483", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9007910_8_5484", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9007910_8_5485", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9007910_8_5486", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9007910_8_5487", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9007910_8_5488", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9007910_8_5489", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9007910_8_5490", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9007910_8_5491", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9007910_8_5492", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8912599_2_5493", "context": "Methotrexate is an effective but potentially toxic treatment for psoriasis.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "8912599_2_5494", "context": "Methotrexate is an effective but potentially toxic treatment for psoriasis.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8912599_2_5495", "context": "Methotrexate is an effective but potentially toxic treatment for psoriasis.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8912599_2_5496", "context": "Methotrexate is an effective but potentially toxic treatment for psoriasis.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8912599_2_5497", "context": "Methotrexate is an effective but potentially toxic treatment for psoriasis.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8912599_2_5498", "context": "Methotrexate is an effective but potentially toxic treatment for psoriasis.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8912599_2_5499", "context": "Methotrexate is an effective but potentially toxic treatment for psoriasis.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "8912599_2_5500", "context": "Methotrexate is an effective but potentially toxic treatment for psoriasis.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18203308_3_5501", "context": "Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18203308_3_5502", "context": "Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18203308_3_5503", "context": "Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18203308_3_5504", "context": "Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18203308_3_5505", "context": "Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18203308_3_5506", "context": "Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18203308_3_5507", "context": "Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18203308_3_5508", "context": "Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "53128_3_5509", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "53128_3_5510", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "53128_3_5511", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "53128_3_5512", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "53128_3_5513", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "53128_3_5514", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "53128_3_5515", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "53128_3_5516", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "53128_3_5517", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "53128_3_5518", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "53128_3_5519", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "53128_3_5520", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "53128_3_5521", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9533061_2_5522", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9533061_2_5523", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9533061_2_5524", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9533061_2_5525", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9533061_2_5526", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9533061_2_5527", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9533061_2_5528", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9533061_2_5529", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9533061_2_5530", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9533061_2_5531", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9533061_2_5532", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9533061_2_5533", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9533061_2_5534", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20234160_1_5535", "context": "Severe vancomycin-induced anaphylactic reaction.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20234160_1_5536", "context": "Severe vancomycin-induced anaphylactic reaction.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20234160_1_5537", "context": "Severe vancomycin-induced anaphylactic reaction.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20234160_1_5538", "context": "Severe vancomycin-induced anaphylactic reaction.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20234160_1_5539", "context": "Severe vancomycin-induced anaphylactic reaction.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20234160_1_5540", "context": "Severe vancomycin-induced anaphylactic reaction.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20234160_1_5541", "context": "Severe vancomycin-induced anaphylactic reaction.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20234160_1_5542", "context": "Severe vancomycin-induced anaphylactic reaction.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8876616_2_5543", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8876616_2_5544", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8876616_2_5545", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8876616_2_5546", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8876616_2_5547", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8876616_2_5548", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8876616_2_5549", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8876616_2_5550", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8876616_2_5551", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8876616_2_5552", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8876616_2_5553", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8876616_2_5554", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8876616_2_5555", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16192734_2_5556", "context": "Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16192734_2_5557", "context": "Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16192734_2_5558", "context": "Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16192734_2_5559", "context": "Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16192734_2_5560", "context": "Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16192734_2_5561", "context": "Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16192734_2_5562", "context": "Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16192734_2_5563", "context": "Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18628507_5_5564", "context": "Voriconazole (VRC) has not previously been reported to cause angio-oedema.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18628507_5_5565", "context": "Voriconazole (VRC) has not previously been reported to cause angio-oedema.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18628507_5_5566", "context": "Voriconazole (VRC) has not previously been reported to cause angio-oedema.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18628507_5_5567", "context": "Voriconazole (VRC) has not previously been reported to cause angio-oedema.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18628507_5_5568", "context": "Voriconazole (VRC) has not previously been reported to cause angio-oedema.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18628507_5_5569", "context": "Voriconazole (VRC) has not previously been reported to cause angio-oedema.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18628507_5_5570", "context": "Voriconazole (VRC) has not previously been reported to cause angio-oedema.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18628507_5_5571", "context": "Voriconazole (VRC) has not previously been reported to cause angio-oedema.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12477460_3_5572", "context": "CONCLUSION: Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12477460_3_5573", "context": "CONCLUSION: Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12477460_3_5574", "context": "CONCLUSION: Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12477460_3_5575", "context": "CONCLUSION: Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12477460_3_5576", "context": "CONCLUSION: Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12477460_3_5577", "context": "CONCLUSION: Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12477460_3_5578", "context": "CONCLUSION: Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12477460_3_5579", "context": "CONCLUSION: Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10573314_5_5580", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "10573314_5_5581", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "10573314_5_5582", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "10573314_5_5583", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "10573314_5_5584", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "10573314_5_5585", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "10573314_5_5586", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10573314_5_5587", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10573314_5_5588", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10573314_5_5589", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10573314_5_5590", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10573314_5_5591", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "10573314_5_5592", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16393774_5_5593", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16393774_5_5594", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16393774_5_5595", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16393774_5_5596", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16393774_5_5597", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16393774_5_5598", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16393774_5_5599", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16393774_5_5600", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16393774_5_5601", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16393774_5_5602", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16393774_5_5603", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16393774_5_5604", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16393774_5_5605", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10682234_9_5606", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10682234_9_5607", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10682234_9_5608", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10682234_9_5609", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10682234_9_5610", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10682234_9_5611", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10682234_9_5612", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10682234_9_5613", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10682234_9_5614", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10682234_9_5615", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10682234_9_5616", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10682234_9_5617", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10682234_9_5618", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18837734_1_5619", "context": "Rosaceiform eruption induced by erlotinib.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18837734_1_5620", "context": "Rosaceiform eruption induced by erlotinib.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18837734_1_5621", "context": "Rosaceiform eruption induced by erlotinib.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18837734_1_5622", "context": "Rosaceiform eruption induced by erlotinib.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18837734_1_5623", "context": "Rosaceiform eruption induced by erlotinib.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18837734_1_5624", "context": "Rosaceiform eruption induced by erlotinib.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18837734_1_5625", "context": "Rosaceiform eruption induced by erlotinib.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18837734_1_5626", "context": "Rosaceiform eruption induced by erlotinib.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6697887_2_5627", "context": "The incidence of oral-verapamil-induced hypotension in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6697887_2_5628", "context": "The incidence of oral-verapamil-induced hypotension in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6697887_2_5629", "context": "The incidence of oral-verapamil-induced hypotension in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6697887_2_5630", "context": "The incidence of oral-verapamil-induced hypotension in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6697887_2_5631", "context": "The incidence of oral-verapamil-induced hypotension in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6697887_2_5632", "context": "The incidence of oral-verapamil-induced hypotension in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6697887_2_5633", "context": "The incidence of oral-verapamil-induced hypotension in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6697887_2_5634", "context": "The incidence of oral-verapamil-induced hypotension in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8726608_4_5635", "context": "Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "8726608_4_5636", "context": "Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8726608_4_5637", "context": "Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8726608_4_5638", "context": "Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8726608_4_5639", "context": "Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8726608_4_5640", "context": "Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8726608_4_5641", "context": "Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "8726608_4_5642", "context": "Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11283125_9_5643", "context": "Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "11283125_9_5644", "context": "Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11283125_9_5645", "context": "Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11283125_9_5646", "context": "Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11283125_9_5647", "context": "Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11283125_9_5648", "context": "Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11283125_9_5649", "context": "Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "11283125_9_5650", "context": "Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "3732375_1_5651", "context": "Theophylline intoxication following viloxazine induced decrease in clearance.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3732375_1_5652", "context": "Theophylline intoxication following viloxazine induced decrease in clearance.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3732375_1_5653", "context": "Theophylline intoxication following viloxazine induced decrease in clearance.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3732375_1_5654", "context": "Theophylline intoxication following viloxazine induced decrease in clearance.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3732375_1_5655", "context": "Theophylline intoxication following viloxazine induced decrease in clearance.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3732375_1_5656", "context": "Theophylline intoxication following viloxazine induced decrease in clearance.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3732375_1_5657", "context": "Theophylline intoxication following viloxazine induced decrease in clearance.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3732375_1_5658", "context": "Theophylline intoxication following viloxazine induced decrease in clearance.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11197767_3_5659", "context": "Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals; however, at lower concentrations only zinc demonstrated toxicity.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11197767_3_5660", "context": "Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals; however, at lower concentrations only zinc demonstrated toxicity.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11197767_3_5661", "context": "Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals; however, at lower concentrations only zinc demonstrated toxicity.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11197767_3_5662", "context": "Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals; however, at lower concentrations only zinc demonstrated toxicity.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11197767_3_5663", "context": "Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals; however, at lower concentrations only zinc demonstrated toxicity.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11197767_3_5664", "context": "Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals; however, at lower concentrations only zinc demonstrated toxicity.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11197767_3_5665", "context": "Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals; however, at lower concentrations only zinc demonstrated toxicity.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11197767_3_5666", "context": "Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals; however, at lower concentrations only zinc demonstrated toxicity.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12504711_3_5667", "context": "PURPOSE: We report an unusual paradoxical effect of brimonidine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12504711_3_5668", "context": "PURPOSE: We report an unusual paradoxical effect of brimonidine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12504711_3_5669", "context": "PURPOSE: We report an unusual paradoxical effect of brimonidine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12504711_3_5670", "context": "PURPOSE: We report an unusual paradoxical effect of brimonidine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12504711_3_5671", "context": "PURPOSE: We report an unusual paradoxical effect of brimonidine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12504711_3_5672", "context": "PURPOSE: We report an unusual paradoxical effect of brimonidine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12504711_3_5673", "context": "PURPOSE: We report an unusual paradoxical effect of brimonidine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12504711_3_5674", "context": "PURPOSE: We report an unusual paradoxical effect of brimonidine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17387702_1_5675", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17387702_1_5676", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17387702_1_5677", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17387702_1_5678", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17387702_1_5679", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17387702_1_5680", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17387702_1_5681", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17387702_1_5682", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17387702_1_5683", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17387702_1_5684", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17387702_1_5685", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17387702_1_5686", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17387702_1_5687", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19131789_2_5688", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19131789_2_5689", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19131789_2_5690", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19131789_2_5691", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19131789_2_5692", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19131789_2_5693", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19131789_2_5694", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19131789_2_5695", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19131789_2_5696", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19131789_2_5697", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19131789_2_5698", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19131789_2_5699", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19131789_2_5700", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10646879_2_5701", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10646879_2_5702", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10646879_2_5703", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10646879_2_5704", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10646879_2_5705", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10646879_2_5706", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10646879_2_5707", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10646879_2_5708", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10646879_2_5709", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10646879_2_5710", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10646879_2_5711", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10646879_2_5712", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10646879_2_5713", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11352235_3_5714", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11352235_3_5715", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11352235_3_5716", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11352235_3_5717", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11352235_3_5718", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11352235_3_5719", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11352235_3_5720", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11352235_3_5721", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11352235_3_5722", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11352235_3_5723", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11352235_3_5724", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11352235_3_5725", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11352235_3_5726", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "681921_3_5727", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "681921_3_5728", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "681921_3_5729", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "681921_3_5730", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "681921_3_5731", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "681921_3_5732", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "681921_3_5733", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "681921_3_5734", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "681921_3_5735", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "681921_3_5736", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "681921_3_5737", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "681921_3_5738", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "681921_3_5739", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11096051_2_5740", "context": "Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11096051_2_5741", "context": "Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11096051_2_5742", "context": "Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11096051_2_5743", "context": "Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11096051_2_5744", "context": "Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11096051_2_5745", "context": "Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11096051_2_5746", "context": "Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11096051_2_5747", "context": "Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18569796_4_5748", "context": "Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18569796_4_5749", "context": "Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18569796_4_5750", "context": "Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18569796_4_5751", "context": "Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18569796_4_5752", "context": "Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18569796_4_5753", "context": "Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18569796_4_5754", "context": "Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18569796_4_5755", "context": "Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16901609_2_5756", "context": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16901609_2_5757", "context": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16901609_2_5758", "context": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16901609_2_5759", "context": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16901609_2_5760", "context": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16901609_2_5761", "context": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16901609_2_5762", "context": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16901609_2_5763", "context": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15811174_2_5764", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15811174_2_5765", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15811174_2_5766", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15811174_2_5767", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15811174_2_5768", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15811174_2_5769", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15811174_2_5770", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15811174_2_5771", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15811174_2_5772", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15811174_2_5773", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15811174_2_5774", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15811174_2_5775", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15811174_2_5776", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18505911_13_5777", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18505911_13_5778", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18505911_13_5779", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18505911_13_5780", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18505911_13_5781", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18505911_13_5782", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18505911_13_5783", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18505911_13_5784", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18505911_13_5785", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18505911_13_5786", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18505911_13_5787", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18505911_13_5788", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18505911_13_5789", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18569796_3_5790", "context": "PURPOSE: To report a case of nodular scleritis following alendronate sodium.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18569796_3_5791", "context": "PURPOSE: To report a case of nodular scleritis following alendronate sodium.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18569796_3_5792", "context": "PURPOSE: To report a case of nodular scleritis following alendronate sodium.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18569796_3_5793", "context": "PURPOSE: To report a case of nodular scleritis following alendronate sodium.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18569796_3_5794", "context": "PURPOSE: To report a case of nodular scleritis following alendronate sodium.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18569796_3_5795", "context": "PURPOSE: To report a case of nodular scleritis following alendronate sodium.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18569796_3_5796", "context": "PURPOSE: To report a case of nodular scleritis following alendronate sodium.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18569796_3_5797", "context": "PURPOSE: To report a case of nodular scleritis following alendronate sodium.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12869178_2_5798", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12869178_2_5799", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12869178_2_5800", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12869178_2_5801", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12869178_2_5802", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12869178_2_5803", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12869178_2_5804", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12869178_2_5805", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12869178_2_5806", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12869178_2_5807", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12869178_2_5808", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12869178_2_5809", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12869178_2_5810", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7485371_2_5811", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7485371_2_5812", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7485371_2_5813", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7485371_2_5814", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7485371_2_5815", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7485371_2_5816", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7485371_2_5817", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7485371_2_5818", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7485371_2_5819", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7485371_2_5820", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7485371_2_5821", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7485371_2_5822", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7485371_2_5823", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16216617_2_5824", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16216617_2_5825", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16216617_2_5826", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16216617_2_5827", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16216617_2_5828", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16216617_2_5829", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16216617_2_5830", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16216617_2_5831", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16216617_2_5832", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16216617_2_5833", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16216617_2_5834", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16216617_2_5835", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16216617_2_5836", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18751717_4_5837", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18751717_4_5838", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18751717_4_5839", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18751717_4_5840", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18751717_4_5841", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18751717_4_5842", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18751717_4_5843", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18751717_4_5844", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18751717_4_5845", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18751717_4_5846", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18751717_4_5847", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18751717_4_5848", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18751717_4_5849", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1695794_5_5850", "context": "Disopyramide was started on admission for supraventricular tachycardia.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "1695794_5_5851", "context": "Disopyramide was started on admission for supraventricular tachycardia.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "1695794_5_5852", "context": "Disopyramide was started on admission for supraventricular tachycardia.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "1695794_5_5853", "context": "Disopyramide was started on admission for supraventricular tachycardia.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "1695794_5_5854", "context": "Disopyramide was started on admission for supraventricular tachycardia.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1695794_5_5855", "context": "Disopyramide was started on admission for supraventricular tachycardia.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "1695794_5_5856", "context": "Disopyramide was started on admission for supraventricular tachycardia.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "1695794_5_5857", "context": "Disopyramide was started on admission for supraventricular tachycardia.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10759907_1_5858", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10759907_1_5859", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10759907_1_5860", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10759907_1_5861", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10759907_1_5862", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10759907_1_5863", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10759907_1_5864", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10759907_1_5865", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10759907_1_5866", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10759907_1_5867", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10759907_1_5868", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10759907_1_5869", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10759907_1_5870", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19754002_3_5871", "context": "The skin rash effect was most probably due, in first line, to olanzapine, but the cutaneous skin condition was triggered and aggravated by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium medication.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19754002_3_5872", "context": "The skin rash effect was most probably due, in first line, to olanzapine, but the cutaneous skin condition was triggered and aggravated by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium medication.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19754002_3_5873", "context": "The skin rash effect was most probably due, in first line, to olanzapine, but the cutaneous skin condition was triggered and aggravated by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium medication.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19754002_3_5874", "context": "The skin rash effect was most probably due, in first line, to olanzapine, but the cutaneous skin condition was triggered and aggravated by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium medication.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19754002_3_5875", "context": "The skin rash effect was most probably due, in first line, to olanzapine, but the cutaneous skin condition was triggered and aggravated by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium medication.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19754002_3_5876", "context": "The skin rash effect was most probably due, in first line, to olanzapine, but the cutaneous skin condition was triggered and aggravated by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium medication.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19754002_3_5877", "context": "The skin rash effect was most probably due, in first line, to olanzapine, but the cutaneous skin condition was triggered and aggravated by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium medication.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19754002_3_5878", "context": "The skin rash effect was most probably due, in first line, to olanzapine, but the cutaneous skin condition was triggered and aggravated by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium medication.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7639655_2_5879", "context": "CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7639655_2_5880", "context": "CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7639655_2_5881", "context": "CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7639655_2_5882", "context": "CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7639655_2_5883", "context": "CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7639655_2_5884", "context": "CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7639655_2_5885", "context": "CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7639655_2_5886", "context": "CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14742791_2_5887", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14742791_2_5888", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14742791_2_5889", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14742791_2_5890", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14742791_2_5891", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14742791_2_5892", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14742791_2_5893", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14742791_2_5894", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14742791_2_5895", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14742791_2_5896", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14742791_2_5897", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14742791_2_5898", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14742791_2_5899", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9865241_5_5900", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "9865241_5_5901", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9865241_5_5902", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9865241_5_5903", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9865241_5_5904", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9865241_5_5905", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9865241_5_5906", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "9865241_5_5907", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11485141_1_5908", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11485141_1_5909", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11485141_1_5910", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11485141_1_5911", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11485141_1_5912", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11485141_1_5913", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11485141_1_5914", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11485141_1_5915", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11485141_1_5916", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11485141_1_5917", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11485141_1_5918", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11485141_1_5919", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11485141_1_5920", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18166746_3_5921", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "18166746_3_5922", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "18166746_3_5923", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "18166746_3_5924", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "18166746_3_5925", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "18166746_3_5926", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "18166746_3_5927", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18166746_3_5928", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18166746_3_5929", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18166746_3_5930", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18166746_3_5931", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18166746_3_5932", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "18166746_3_5933", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7712052_3_5934", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7712052_3_5935", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7712052_3_5936", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7712052_3_5937", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7712052_3_5938", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7712052_3_5939", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7712052_3_5940", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7712052_3_5941", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7712052_3_5942", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7712052_3_5943", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7712052_3_5944", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7712052_3_5945", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7712052_3_5946", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15773973_2_5947", "context": "It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15773973_2_5948", "context": "It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15773973_2_5949", "context": "It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15773973_2_5950", "context": "It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15773973_2_5951", "context": "It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15773973_2_5952", "context": "It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15773973_2_5953", "context": "It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15773973_2_5954", "context": "It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2943526_1_5955", "context": "Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2943526_1_5956", "context": "Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2943526_1_5957", "context": "Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2943526_1_5958", "context": "Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2943526_1_5959", "context": "Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2943526_1_5960", "context": "Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2943526_1_5961", "context": "Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2943526_1_5962", "context": "Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3136101_1_5963", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3136101_1_5964", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3136101_1_5965", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3136101_1_5966", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3136101_1_5967", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3136101_1_5968", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3136101_1_5969", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3136101_1_5970", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10082597_1_5971", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10082597_1_5972", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10082597_1_5973", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10082597_1_5974", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10082597_1_5975", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10082597_1_5976", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10082597_1_5977", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10082597_1_5978", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10082597_1_5979", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10082597_1_5980", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10082597_1_5981", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10082597_1_5982", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10082597_1_5983", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18505911_4_5984", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "18505911_4_5985", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "18505911_4_5986", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "18505911_4_5987", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "18505911_4_5988", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "18505911_4_5989", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "18505911_4_5990", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18505911_4_5991", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18505911_4_5992", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18505911_4_5993", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18505911_4_5994", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18505911_4_5995", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "18505911_4_5996", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9279731_1_5997", "context": "When the disease recurred conventional amphotericin B was used again, but had to be stopped because of severe side effects.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9279731_1_5998", "context": "When the disease recurred conventional amphotericin B was used again, but had to be stopped because of severe side effects.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9279731_1_5999", "context": "When the disease recurred conventional amphotericin B was used again, but had to be stopped because of severe side effects.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9279731_1_6000", "context": "When the disease recurred conventional amphotericin B was used again, but had to be stopped because of severe side effects.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9279731_1_6001", "context": "When the disease recurred conventional amphotericin B was used again, but had to be stopped because of severe side effects.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9279731_1_6002", "context": "When the disease recurred conventional amphotericin B was used again, but had to be stopped because of severe side effects.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9279731_1_6003", "context": "When the disease recurred conventional amphotericin B was used again, but had to be stopped because of severe side effects.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9279731_1_6004", "context": "When the disease recurred conventional amphotericin B was used again, but had to be stopped because of severe side effects.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3211830_2_6005", "context": "Widespread cutaneous vasculitis associated with diltiazem.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3211830_2_6006", "context": "Widespread cutaneous vasculitis associated with diltiazem.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3211830_2_6007", "context": "Widespread cutaneous vasculitis associated with diltiazem.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3211830_2_6008", "context": "Widespread cutaneous vasculitis associated with diltiazem.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3211830_2_6009", "context": "Widespread cutaneous vasculitis associated with diltiazem.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3211830_2_6010", "context": "Widespread cutaneous vasculitis associated with diltiazem.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3211830_2_6011", "context": "Widespread cutaneous vasculitis associated with diltiazem.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3211830_2_6012", "context": "Widespread cutaneous vasculitis associated with diltiazem.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9726762_2_6013", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9726762_2_6014", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9726762_2_6015", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9726762_2_6016", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9726762_2_6017", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9726762_2_6018", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9726762_2_6019", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9726762_2_6020", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9726762_2_6021", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9726762_2_6022", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9726762_2_6023", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9726762_2_6024", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9726762_2_6025", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15773973_3_6026", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15773973_3_6027", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15773973_3_6028", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15773973_3_6029", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15773973_3_6030", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15773973_3_6031", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15773973_3_6032", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15773973_3_6033", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15773973_3_6034", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15773973_3_6035", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15773973_3_6036", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15773973_3_6037", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15773973_3_6038", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16697705_2_6039", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16697705_2_6040", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16697705_2_6041", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16697705_2_6042", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16697705_2_6043", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16697705_2_6044", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16697705_2_6045", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16697705_2_6046", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16697705_2_6047", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16697705_2_6048", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16697705_2_6049", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16697705_2_6050", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16697705_2_6051", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7212107_2_6052", "context": "These results indicate that lithium may cause biochemical hyperparathyroidism.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7212107_2_6053", "context": "These results indicate that lithium may cause biochemical hyperparathyroidism.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7212107_2_6054", "context": "These results indicate that lithium may cause biochemical hyperparathyroidism.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7212107_2_6055", "context": "These results indicate that lithium may cause biochemical hyperparathyroidism.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7212107_2_6056", "context": "These results indicate that lithium may cause biochemical hyperparathyroidism.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7212107_2_6057", "context": "These results indicate that lithium may cause biochemical hyperparathyroidism.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7212107_2_6058", "context": "These results indicate that lithium may cause biochemical hyperparathyroidism.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7212107_2_6059", "context": "These results indicate that lithium may cause biochemical hyperparathyroidism.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10579985_2_6060", "context": "The relationship between infliximab treatment and lymphoma in Crohn's disease.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10579985_2_6061", "context": "The relationship between infliximab treatment and lymphoma in Crohn's disease.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10579985_2_6062", "context": "The relationship between infliximab treatment and lymphoma in Crohn's disease.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10579985_2_6063", "context": "The relationship between infliximab treatment and lymphoma in Crohn's disease.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10579985_2_6064", "context": "The relationship between infliximab treatment and lymphoma in Crohn's disease.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10579985_2_6065", "context": "The relationship between infliximab treatment and lymphoma in Crohn's disease.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10579985_2_6066", "context": "The relationship between infliximab treatment and lymphoma in Crohn's disease.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10579985_2_6067", "context": "The relationship between infliximab treatment and lymphoma in Crohn's disease.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15863610_7_6068", "context": "CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15863610_7_6069", "context": "CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15863610_7_6070", "context": "CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15863610_7_6071", "context": "CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15863610_7_6072", "context": "CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15863610_7_6073", "context": "CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15863610_7_6074", "context": "CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15863610_7_6075", "context": "CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19131789_3_6076", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19131789_3_6077", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19131789_3_6078", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19131789_3_6079", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19131789_3_6080", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19131789_3_6081", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19131789_3_6082", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19131789_3_6083", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19131789_3_6084", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19131789_3_6085", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19131789_3_6086", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19131789_3_6087", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19131789_3_6088", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8467620_2_6089", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8467620_2_6090", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8467620_2_6091", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8467620_2_6092", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8467620_2_6093", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8467620_2_6094", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8467620_2_6095", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8467620_2_6096", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8467620_2_6097", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8467620_2_6098", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8467620_2_6099", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8467620_2_6100", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8467620_2_6101", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14561622_2_6102", "context": "We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal methotrexate.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14561622_2_6103", "context": "We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal methotrexate.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14561622_2_6104", "context": "We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal methotrexate.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14561622_2_6105", "context": "We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal methotrexate.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14561622_2_6106", "context": "We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal methotrexate.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14561622_2_6107", "context": "We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal methotrexate.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14561622_2_6108", "context": "We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal methotrexate.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14561622_2_6109", "context": "We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal methotrexate.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16843118_2_6110", "context": "Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16843118_2_6111", "context": "Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16843118_2_6112", "context": "Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16843118_2_6113", "context": "Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16843118_2_6114", "context": "Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16843118_2_6115", "context": "Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16843118_2_6116", "context": "Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16843118_2_6117", "context": "Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20465622_1_6118", "context": "Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20465622_1_6119", "context": "Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20465622_1_6120", "context": "Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20465622_1_6121", "context": "Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20465622_1_6122", "context": "Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20465622_1_6123", "context": "Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20465622_1_6124", "context": "Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20465622_1_6125", "context": "Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17619811_1_6126", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17619811_1_6127", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17619811_1_6128", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17619811_1_6129", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17619811_1_6130", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17619811_1_6131", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17619811_1_6132", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17619811_1_6133", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17619811_1_6134", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17619811_1_6135", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17619811_1_6136", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17619811_1_6137", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17619811_1_6138", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17275666_6_6139", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17275666_6_6140", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17275666_6_6141", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17275666_6_6142", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17275666_6_6143", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17275666_6_6144", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17275666_6_6145", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17275666_6_6146", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17275666_6_6147", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17275666_6_6148", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17275666_6_6149", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17275666_6_6150", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17275666_6_6151", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18277922_1_6152", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18277922_1_6153", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18277922_1_6154", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18277922_1_6155", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18277922_1_6156", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18277922_1_6157", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18277922_1_6158", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18277922_1_6159", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18277922_1_6160", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18277922_1_6161", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18277922_1_6162", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18277922_1_6163", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18277922_1_6164", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15857283_1_6165", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15857283_1_6166", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15857283_1_6167", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15857283_1_6168", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15857283_1_6169", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15857283_1_6170", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15857283_1_6171", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15857283_1_6172", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15857283_1_6173", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15857283_1_6174", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15857283_1_6175", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15857283_1_6176", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15857283_1_6177", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7978578_1_6178", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7978578_1_6179", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7978578_1_6180", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7978578_1_6181", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7978578_1_6182", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7978578_1_6183", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7978578_1_6184", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7978578_1_6185", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16978752_1_6186", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16978752_1_6187", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16978752_1_6188", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16978752_1_6189", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16978752_1_6190", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16978752_1_6191", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16978752_1_6192", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16978752_1_6193", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8250714_2_6194", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8250714_2_6195", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8250714_2_6196", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8250714_2_6197", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8250714_2_6198", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8250714_2_6199", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8250714_2_6200", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8250714_2_6201", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8250714_2_6202", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8250714_2_6203", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8250714_2_6204", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8250714_2_6205", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8250714_2_6206", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1695794_3_6207", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1695794_3_6208", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1695794_3_6209", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1695794_3_6210", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1695794_3_6211", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1695794_3_6212", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1695794_3_6213", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1695794_3_6214", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6239881_1_6215", "context": "Allergic contact dermatitis to compound tincture of benzoin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6239881_1_6216", "context": "Allergic contact dermatitis to compound tincture of benzoin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6239881_1_6217", "context": "Allergic contact dermatitis to compound tincture of benzoin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6239881_1_6218", "context": "Allergic contact dermatitis to compound tincture of benzoin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6239881_1_6219", "context": "Allergic contact dermatitis to compound tincture of benzoin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6239881_1_6220", "context": "Allergic contact dermatitis to compound tincture of benzoin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6239881_1_6221", "context": "Allergic contact dermatitis to compound tincture of benzoin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6239881_1_6222", "context": "Allergic contact dermatitis to compound tincture of benzoin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8610807_3_6223", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8610807_3_6224", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8610807_3_6225", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8610807_3_6226", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8610807_3_6227", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8610807_3_6228", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8610807_3_6229", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8610807_3_6230", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8610807_3_6231", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8610807_3_6232", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8610807_3_6233", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8610807_3_6234", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8610807_3_6235", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23970584_4_6236", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "23970584_4_6237", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "23970584_4_6238", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "23970584_4_6239", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "23970584_4_6240", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "23970584_4_6241", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "23970584_4_6242", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "23970584_4_6243", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "23970584_4_6244", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "23970584_4_6245", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23970584_4_6246", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "23970584_4_6247", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "23970584_4_6248", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11341670_2_6249", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11341670_2_6250", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11341670_2_6251", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11341670_2_6252", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11341670_2_6253", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11341670_2_6254", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11341670_2_6255", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11341670_2_6256", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11341670_2_6257", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11341670_2_6258", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11341670_2_6259", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11341670_2_6260", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11341670_2_6261", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18855892_5_6262", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18855892_5_6263", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18855892_5_6264", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18855892_5_6265", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18855892_5_6266", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18855892_5_6267", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18855892_5_6268", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18855892_5_6269", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18855892_5_6270", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18855892_5_6271", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18855892_5_6272", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18855892_5_6273", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18855892_5_6274", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17823522_5_6275", "context": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17823522_5_6276", "context": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17823522_5_6277", "context": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17823522_5_6278", "context": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17823522_5_6279", "context": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17823522_5_6280", "context": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17823522_5_6281", "context": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17823522_5_6282", "context": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18569796_1_6283", "context": "CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18569796_1_6284", "context": "CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18569796_1_6285", "context": "CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18569796_1_6286", "context": "CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18569796_1_6287", "context": "CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18569796_1_6288", "context": "CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18569796_1_6289", "context": "CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18569796_1_6290", "context": "CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1469187_2_6291", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "1469187_2_6292", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "1469187_2_6293", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "1469187_2_6294", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "1469187_2_6295", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "1469187_2_6296", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "1469187_2_6297", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "1469187_2_6298", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "1469187_2_6299", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "1469187_2_6300", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1469187_2_6301", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "1469187_2_6302", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "1469187_2_6303", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "6788011_3_6304", "context": "Gold-salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6788011_3_6305", "context": "Gold-salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6788011_3_6306", "context": "Gold-salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6788011_3_6307", "context": "Gold-salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6788011_3_6308", "context": "Gold-salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6788011_3_6309", "context": "Gold-salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6788011_3_6310", "context": "Gold-salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6788011_3_6311", "context": "Gold-salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20199429_1_6312", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20199429_1_6313", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20199429_1_6314", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20199429_1_6315", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20199429_1_6316", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20199429_1_6317", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20199429_1_6318", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20199429_1_6319", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20199429_1_6320", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20199429_1_6321", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20199429_1_6322", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20199429_1_6323", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20199429_1_6324", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16160485_2_6325", "context": "Recently, CD20-negative tumors have been described after Rituximab therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16160485_2_6326", "context": "Recently, CD20-negative tumors have been described after Rituximab therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16160485_2_6327", "context": "Recently, CD20-negative tumors have been described after Rituximab therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16160485_2_6328", "context": "Recently, CD20-negative tumors have been described after Rituximab therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16160485_2_6329", "context": "Recently, CD20-negative tumors have been described after Rituximab therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16160485_2_6330", "context": "Recently, CD20-negative tumors have been described after Rituximab therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16160485_2_6331", "context": "Recently, CD20-negative tumors have been described after Rituximab therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16160485_2_6332", "context": "Recently, CD20-negative tumors have been described after Rituximab therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10560960_1_6333", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10560960_1_6334", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10560960_1_6335", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10560960_1_6336", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10560960_1_6337", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10560960_1_6338", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10560960_1_6339", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10560960_1_6340", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10560960_1_6341", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10560960_1_6342", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10560960_1_6343", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10560960_1_6344", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10560960_1_6345", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10646879_1_6346", "context": "Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10646879_1_6347", "context": "Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10646879_1_6348", "context": "Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10646879_1_6349", "context": "Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10646879_1_6350", "context": "Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10646879_1_6351", "context": "Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10646879_1_6352", "context": "Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10646879_1_6353", "context": "Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15863610_4_6354", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15863610_4_6355", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15863610_4_6356", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15863610_4_6357", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15863610_4_6358", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15863610_4_6359", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15863610_4_6360", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15863610_4_6361", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15863610_4_6362", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15863610_4_6363", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15863610_4_6364", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15863610_4_6365", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15863610_4_6366", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22677303_12_6367", "context": "Interactions between warfarin and cloxacillin can result in serious adverse reactions.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "22677303_12_6368", "context": "Interactions between warfarin and cloxacillin can result in serious adverse reactions.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22677303_12_6369", "context": "Interactions between warfarin and cloxacillin can result in serious adverse reactions.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22677303_12_6370", "context": "Interactions between warfarin and cloxacillin can result in serious adverse reactions.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22677303_12_6371", "context": "Interactions between warfarin and cloxacillin can result in serious adverse reactions.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22677303_12_6372", "context": "Interactions between warfarin and cloxacillin can result in serious adverse reactions.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22677303_12_6373", "context": "Interactions between warfarin and cloxacillin can result in serious adverse reactions.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22677303_12_6374", "context": "Interactions between warfarin and cloxacillin can result in serious adverse reactions.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11724089_2_6375", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11724089_2_6376", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11724089_2_6377", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11724089_2_6378", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11724089_2_6379", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11724089_2_6380", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11724089_2_6381", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11724089_2_6382", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "879939_5_6383", "context": "Acetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "879939_5_6384", "context": "Acetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "879939_5_6385", "context": "Acetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "879939_5_6386", "context": "Acetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "879939_5_6387", "context": "Acetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "879939_5_6388", "context": "Acetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "879939_5_6389", "context": "Acetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "879939_5_6390", "context": "Acetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14697943_1_6391", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14697943_1_6392", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14697943_1_6393", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14697943_1_6394", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14697943_1_6395", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14697943_1_6396", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14697943_1_6397", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14697943_1_6398", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14697943_1_6399", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14697943_1_6400", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14697943_1_6401", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14697943_1_6402", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14697943_1_6403", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14742791_5_6404", "context": "There have been several reported cases of omeprazole-induced AIN.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14742791_5_6405", "context": "There have been several reported cases of omeprazole-induced AIN.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14742791_5_6406", "context": "There have been several reported cases of omeprazole-induced AIN.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14742791_5_6407", "context": "There have been several reported cases of omeprazole-induced AIN.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14742791_5_6408", "context": "There have been several reported cases of omeprazole-induced AIN.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14742791_5_6409", "context": "There have been several reported cases of omeprazole-induced AIN.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14742791_5_6410", "context": "There have been several reported cases of omeprazole-induced AIN.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14742791_5_6411", "context": "There have been several reported cases of omeprazole-induced AIN.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9726762_4_6412", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9726762_4_6413", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9726762_4_6414", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9726762_4_6415", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9726762_4_6416", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9726762_4_6417", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9726762_4_6418", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9726762_4_6419", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9726762_4_6420", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9726762_4_6421", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9726762_4_6422", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9726762_4_6423", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9726762_4_6424", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1966850_1_6425", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1966850_1_6426", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1966850_1_6427", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1966850_1_6428", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1966850_1_6429", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1966850_1_6430", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1966850_1_6431", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1966850_1_6432", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8145359_1_6433", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8145359_1_6434", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8145359_1_6435", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8145359_1_6436", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8145359_1_6437", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8145359_1_6438", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8145359_1_6439", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8145359_1_6440", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8145359_1_6441", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8145359_1_6442", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8145359_1_6443", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8145359_1_6444", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8145359_1_6445", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11762672_1_6446", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11762672_1_6447", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11762672_1_6448", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11762672_1_6449", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11762672_1_6450", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11762672_1_6451", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11762672_1_6452", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11762672_1_6453", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11762672_1_6454", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11762672_1_6455", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11762672_1_6456", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11762672_1_6457", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11762672_1_6458", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8523340_1_6459", "context": "All developed mucocutaneous side effects within 20 weeks of beginning im gold therapy, at a time when RA had improved markedly compared to pretreatment status.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8523340_1_6460", "context": "All developed mucocutaneous side effects within 20 weeks of beginning im gold therapy, at a time when RA had improved markedly compared to pretreatment status.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8523340_1_6461", "context": "All developed mucocutaneous side effects within 20 weeks of beginning im gold therapy, at a time when RA had improved markedly compared to pretreatment status.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8523340_1_6462", "context": "All developed mucocutaneous side effects within 20 weeks of beginning im gold therapy, at a time when RA had improved markedly compared to pretreatment status.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8523340_1_6463", "context": "All developed mucocutaneous side effects within 20 weeks of beginning im gold therapy, at a time when RA had improved markedly compared to pretreatment status.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8523340_1_6464", "context": "All developed mucocutaneous side effects within 20 weeks of beginning im gold therapy, at a time when RA had improved markedly compared to pretreatment status.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8523340_1_6465", "context": "All developed mucocutaneous side effects within 20 weeks of beginning im gold therapy, at a time when RA had improved markedly compared to pretreatment status.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8523340_1_6466", "context": "All developed mucocutaneous side effects within 20 weeks of beginning im gold therapy, at a time when RA had improved markedly compared to pretreatment status.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1868481_2_6467", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1868481_2_6468", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1868481_2_6469", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1868481_2_6470", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1868481_2_6471", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1868481_2_6472", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1868481_2_6473", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1868481_2_6474", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1868481_2_6475", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1868481_2_6476", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1868481_2_6477", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1868481_2_6478", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1868481_2_6479", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12836099_1_6480", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12836099_1_6481", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12836099_1_6482", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12836099_1_6483", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12836099_1_6484", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12836099_1_6485", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12836099_1_6486", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12836099_1_6487", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12836099_1_6488", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12836099_1_6489", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12836099_1_6490", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12836099_1_6491", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12836099_1_6492", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18628507_4_6493", "context": "To our knowledge, this is the first report of an angio-oedema associated with VRC.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18628507_4_6494", "context": "To our knowledge, this is the first report of an angio-oedema associated with VRC.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18628507_4_6495", "context": "To our knowledge, this is the first report of an angio-oedema associated with VRC.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18628507_4_6496", "context": "To our knowledge, this is the first report of an angio-oedema associated with VRC.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18628507_4_6497", "context": "To our knowledge, this is the first report of an angio-oedema associated with VRC.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18628507_4_6498", "context": "To our knowledge, this is the first report of an angio-oedema associated with VRC.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18628507_4_6499", "context": "To our knowledge, this is the first report of an angio-oedema associated with VRC.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18628507_4_6500", "context": "To our knowledge, this is the first report of an angio-oedema associated with VRC.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4014301_1_6501", "context": "Insulin-induced cardiac failure.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "4014301_1_6502", "context": "Insulin-induced cardiac failure.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4014301_1_6503", "context": "Insulin-induced cardiac failure.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4014301_1_6504", "context": "Insulin-induced cardiac failure.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4014301_1_6505", "context": "Insulin-induced cardiac failure.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4014301_1_6506", "context": "Insulin-induced cardiac failure.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4014301_1_6507", "context": "Insulin-induced cardiac failure.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4014301_1_6508", "context": "Insulin-induced cardiac failure.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15522120_10_6509", "context": "The symptoms disappeared with clemastine and betametasone treatment.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "15522120_10_6510", "context": "The symptoms disappeared with clemastine and betametasone treatment.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15522120_10_6511", "context": "The symptoms disappeared with clemastine and betametasone treatment.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15522120_10_6512", "context": "The symptoms disappeared with clemastine and betametasone treatment.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15522120_10_6513", "context": "The symptoms disappeared with clemastine and betametasone treatment.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15522120_10_6514", "context": "The symptoms disappeared with clemastine and betametasone treatment.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15522120_10_6515", "context": "The symptoms disappeared with clemastine and betametasone treatment.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "15522120_10_6516", "context": "The symptoms disappeared with clemastine and betametasone treatment.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11724089_6_6517", "context": "This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11724089_6_6518", "context": "This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11724089_6_6519", "context": "This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11724089_6_6520", "context": "This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11724089_6_6521", "context": "This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11724089_6_6522", "context": "This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11724089_6_6523", "context": "This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11724089_6_6524", "context": "This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3917429_1_6525", "context": "Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3917429_1_6526", "context": "Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3917429_1_6527", "context": "Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3917429_1_6528", "context": "Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3917429_1_6529", "context": "Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3917429_1_6530", "context": "Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3917429_1_6531", "context": "Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3917429_1_6532", "context": "Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6738830_1_6533", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6738830_1_6534", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6738830_1_6535", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6738830_1_6536", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6738830_1_6537", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6738830_1_6538", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6738830_1_6539", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6738830_1_6540", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6738830_1_6541", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6738830_1_6542", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6738830_1_6543", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6738830_1_6544", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6738830_1_6545", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "440873_3_6546", "context": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "440873_3_6547", "context": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "440873_3_6548", "context": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "440873_3_6549", "context": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "440873_3_6550", "context": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "440873_3_6551", "context": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "440873_3_6552", "context": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "440873_3_6553", "context": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12042592_2_6554", "context": "Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12042592_2_6555", "context": "Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12042592_2_6556", "context": "Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12042592_2_6557", "context": "Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12042592_2_6558", "context": "Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12042592_2_6559", "context": "Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12042592_2_6560", "context": "Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12042592_2_6561", "context": "Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9777751_6_6562", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9777751_6_6563", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9777751_6_6564", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9777751_6_6565", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9777751_6_6566", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9777751_6_6567", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9777751_6_6568", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9777751_6_6569", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8696525_2_6570", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8696525_2_6571", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8696525_2_6572", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8696525_2_6573", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8696525_2_6574", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8696525_2_6575", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8696525_2_6576", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8696525_2_6577", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8696525_2_6578", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8696525_2_6579", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8696525_2_6580", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8696525_2_6581", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8696525_2_6582", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7355327_2_6583", "context": "Regardless of a negative history of asthma, therefore, life-threatening bronchospasm must be considered a possible complication of propranolol therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7355327_2_6584", "context": "Regardless of a negative history of asthma, therefore, life-threatening bronchospasm must be considered a possible complication of propranolol therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7355327_2_6585", "context": "Regardless of a negative history of asthma, therefore, life-threatening bronchospasm must be considered a possible complication of propranolol therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7355327_2_6586", "context": "Regardless of a negative history of asthma, therefore, life-threatening bronchospasm must be considered a possible complication of propranolol therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7355327_2_6587", "context": "Regardless of a negative history of asthma, therefore, life-threatening bronchospasm must be considered a possible complication of propranolol therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7355327_2_6588", "context": "Regardless of a negative history of asthma, therefore, life-threatening bronchospasm must be considered a possible complication of propranolol therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7355327_2_6589", "context": "Regardless of a negative history of asthma, therefore, life-threatening bronchospasm must be considered a possible complication of propranolol therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7355327_2_6590", "context": "Regardless of a negative history of asthma, therefore, life-threatening bronchospasm must be considered a possible complication of propranolol therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11147747_2_6591", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11147747_2_6592", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11147747_2_6593", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11147747_2_6594", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11147747_2_6595", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11147747_2_6596", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11147747_2_6597", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11147747_2_6598", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11147747_2_6599", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11147747_2_6600", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11147747_2_6601", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11147747_2_6602", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11147747_2_6603", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1680596_1_6604", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1680596_1_6605", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1680596_1_6606", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1680596_1_6607", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1680596_1_6608", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1680596_1_6609", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1680596_1_6610", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1680596_1_6611", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1680596_1_6612", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1680596_1_6613", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1680596_1_6614", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1680596_1_6615", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1680596_1_6616", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19112808_1_6617", "context": "Interstitial granulomatous dermatitis associated with darifenacin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19112808_1_6618", "context": "Interstitial granulomatous dermatitis associated with darifenacin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19112808_1_6619", "context": "Interstitial granulomatous dermatitis associated with darifenacin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19112808_1_6620", "context": "Interstitial granulomatous dermatitis associated with darifenacin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19112808_1_6621", "context": "Interstitial granulomatous dermatitis associated with darifenacin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19112808_1_6622", "context": "Interstitial granulomatous dermatitis associated with darifenacin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19112808_1_6623", "context": "Interstitial granulomatous dermatitis associated with darifenacin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19112808_1_6624", "context": "Interstitial granulomatous dermatitis associated with darifenacin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11762672_2_6625", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11762672_2_6626", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11762672_2_6627", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11762672_2_6628", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11762672_2_6629", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11762672_2_6630", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11762672_2_6631", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11762672_2_6632", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11762672_2_6633", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "11762672_2_6634", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11762672_2_6635", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11762672_2_6636", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11762672_2_6637", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11762672_2_6638", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11762672_2_6639", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "11762672_2_6640", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "20925534_3_6641", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20925534_3_6642", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20925534_3_6643", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20925534_3_6644", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20925534_3_6645", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20925534_3_6646", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20925534_3_6647", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20925534_3_6648", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20925534_3_6649", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20925534_3_6650", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20925534_3_6651", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20925534_3_6652", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20925534_3_6653", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10592946_4_6654", "context": "The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10592946_4_6655", "context": "The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10592946_4_6656", "context": "The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10592946_4_6657", "context": "The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10592946_4_6658", "context": "The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10592946_4_6659", "context": "The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10592946_4_6660", "context": "The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10592946_4_6661", "context": "The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11283125_8_6662", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "11283125_8_6663", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "11283125_8_6664", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "11283125_8_6665", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "11283125_8_6666", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "11283125_8_6667", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "11283125_8_6668", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11283125_8_6669", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11283125_8_6670", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11283125_8_6671", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11283125_8_6672", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11283125_8_6673", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "11283125_8_6674", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17823522_1_6675", "context": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17823522_1_6676", "context": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17823522_1_6677", "context": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17823522_1_6678", "context": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17823522_1_6679", "context": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17823522_1_6680", "context": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17823522_1_6681", "context": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17823522_1_6682", "context": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1422497_2_6683", "context": "Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1422497_2_6684", "context": "Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1422497_2_6685", "context": "Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1422497_2_6686", "context": "Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1422497_2_6687", "context": "Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1422497_2_6688", "context": "Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1422497_2_6689", "context": "Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1422497_2_6690", "context": "Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7212107_1_6691", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7212107_1_6692", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7212107_1_6693", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7212107_1_6694", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7212107_1_6695", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7212107_1_6696", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7212107_1_6697", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7212107_1_6698", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7212107_1_6699", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7212107_1_6700", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7212107_1_6701", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7212107_1_6702", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7212107_1_6703", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18755414_2_6704", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18755414_2_6705", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18755414_2_6706", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18755414_2_6707", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18755414_2_6708", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18755414_2_6709", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18755414_2_6710", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18755414_2_6711", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "589261_3_6712", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "589261_3_6713", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "589261_3_6714", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "589261_3_6715", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "589261_3_6716", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "589261_3_6717", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "589261_3_6718", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "589261_3_6719", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "589261_3_6720", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "589261_3_6721", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "589261_3_6722", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "589261_3_6723", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "589261_3_6724", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19754002_4_6725", "context": "The allergic reaction started to develop after co-administration of pravastatin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19754002_4_6726", "context": "The allergic reaction started to develop after co-administration of pravastatin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19754002_4_6727", "context": "The allergic reaction started to develop after co-administration of pravastatin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19754002_4_6728", "context": "The allergic reaction started to develop after co-administration of pravastatin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19754002_4_6729", "context": "The allergic reaction started to develop after co-administration of pravastatin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19754002_4_6730", "context": "The allergic reaction started to develop after co-administration of pravastatin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19754002_4_6731", "context": "The allergic reaction started to develop after co-administration of pravastatin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19754002_4_6732", "context": "The allergic reaction started to develop after co-administration of pravastatin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11202801_3_6733", "context": "We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11202801_3_6734", "context": "We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11202801_3_6735", "context": "We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11202801_3_6736", "context": "We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11202801_3_6737", "context": "We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11202801_3_6738", "context": "We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11202801_3_6739", "context": "We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11202801_3_6740", "context": "We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "868978_2_6741", "context": "The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "868978_2_6742", "context": "The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "868978_2_6743", "context": "The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "868978_2_6744", "context": "The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "868978_2_6745", "context": "The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "868978_2_6746", "context": "The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "868978_2_6747", "context": "The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "868978_2_6748", "context": "The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1966850_2_6749", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1966850_2_6750", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1966850_2_6751", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1966850_2_6752", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1966850_2_6753", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1966850_2_6754", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1966850_2_6755", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1966850_2_6756", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1966850_2_6757", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1966850_2_6758", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1966850_2_6759", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1966850_2_6760", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1966850_2_6761", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17504225_2_6762", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17504225_2_6763", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17504225_2_6764", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17504225_2_6765", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17504225_2_6766", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17504225_2_6767", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17504225_2_6768", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17504225_2_6769", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17504225_2_6770", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17504225_2_6771", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17504225_2_6772", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17504225_2_6773", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17504225_2_6774", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16685007_12_6775", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "16685007_12_6776", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "16685007_12_6777", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "16685007_12_6778", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "16685007_12_6779", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "16685007_12_6780", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "16685007_12_6781", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16685007_12_6782", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16685007_12_6783", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "16685007_12_6784", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16685007_12_6785", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16685007_12_6786", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "16685007_12_6787", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "14968106_1_6788", "context": "CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14968106_1_6789", "context": "CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14968106_1_6790", "context": "CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14968106_1_6791", "context": "CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14968106_1_6792", "context": "CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14968106_1_6793", "context": "CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14968106_1_6794", "context": "CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14968106_1_6795", "context": "CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12854039_5_6796", "context": "Multiple sclerosis-like disease secondary to alpha interferon.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12854039_5_6797", "context": "Multiple sclerosis-like disease secondary to alpha interferon.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12854039_5_6798", "context": "Multiple sclerosis-like disease secondary to alpha interferon.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12854039_5_6799", "context": "Multiple sclerosis-like disease secondary to alpha interferon.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12854039_5_6800", "context": "Multiple sclerosis-like disease secondary to alpha interferon.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12854039_5_6801", "context": "Multiple sclerosis-like disease secondary to alpha interferon.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12854039_5_6802", "context": "Multiple sclerosis-like disease secondary to alpha interferon.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12854039_5_6803", "context": "Multiple sclerosis-like disease secondary to alpha interferon.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17921794_4_6804", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17921794_4_6805", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17921794_4_6806", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17921794_4_6807", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17921794_4_6808", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17921794_4_6809", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17921794_4_6810", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17921794_4_6811", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17921794_4_6812", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17921794_4_6813", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17921794_4_6814", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17921794_4_6815", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17921794_4_6816", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16603845_1_6817", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16603845_1_6818", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16603845_1_6819", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16603845_1_6820", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16603845_1_6821", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16603845_1_6822", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16603845_1_6823", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16603845_1_6824", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16603845_1_6825", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16603845_1_6826", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16603845_1_6827", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16603845_1_6828", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16603845_1_6829", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20628041_2_6830", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20628041_2_6831", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20628041_2_6832", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20628041_2_6833", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20628041_2_6834", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20628041_2_6835", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20628041_2_6836", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20628041_2_6837", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20628041_2_6838", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20628041_2_6839", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20628041_2_6840", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20628041_2_6841", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20628041_2_6842", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16978752_3_6843", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16978752_3_6844", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16978752_3_6845", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16978752_3_6846", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16978752_3_6847", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16978752_3_6848", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16978752_3_6849", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16978752_3_6850", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16978752_3_6851", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16978752_3_6852", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16978752_3_6853", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16978752_3_6854", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16978752_3_6855", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21658326_3_6856", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21658326_3_6857", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21658326_3_6858", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21658326_3_6859", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21658326_3_6860", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21658326_3_6861", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21658326_3_6862", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21658326_3_6863", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6239881_2_6864", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6239881_2_6865", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6239881_2_6866", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6239881_2_6867", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6239881_2_6868", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6239881_2_6869", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6239881_2_6870", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6239881_2_6871", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6239881_2_6872", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6239881_2_6873", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6239881_2_6874", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6239881_2_6875", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6239881_2_6876", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8404753_3_6877", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8404753_3_6878", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8404753_3_6879", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8404753_3_6880", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8404753_3_6881", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8404753_3_6882", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8404753_3_6883", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8404753_3_6884", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8404753_3_6885", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8404753_3_6886", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8404753_3_6887", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8404753_3_6888", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8404753_3_6889", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11197767_2_6890", "context": "The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11197767_2_6891", "context": "The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11197767_2_6892", "context": "The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11197767_2_6893", "context": "The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11197767_2_6894", "context": "The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11197767_2_6895", "context": "The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11197767_2_6896", "context": "The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11197767_2_6897", "context": "The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18354950_3_6898", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18354950_3_6899", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18354950_3_6900", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18354950_3_6901", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18354950_3_6902", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18354950_3_6903", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18354950_3_6904", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18354950_3_6905", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18354950_3_6906", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18354950_3_6907", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18354950_3_6908", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18354950_3_6909", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18354950_3_6910", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11310527_2_6911", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "11310527_2_6912", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "11310527_2_6913", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "11310527_2_6914", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "11310527_2_6915", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "11310527_2_6916", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "11310527_2_6917", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11310527_2_6918", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11310527_2_6919", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11310527_2_6920", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11310527_2_6921", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11310527_2_6922", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "11310527_2_6923", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "19754002_1_6924", "context": "Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19754002_1_6925", "context": "Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19754002_1_6926", "context": "Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19754002_1_6927", "context": "Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19754002_1_6928", "context": "Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19754002_1_6929", "context": "Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19754002_1_6930", "context": "Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19754002_1_6931", "context": "Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1602800_1_6932", "context": "Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1602800_1_6933", "context": "Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1602800_1_6934", "context": "Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1602800_1_6935", "context": "Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1602800_1_6936", "context": "Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1602800_1_6937", "context": "Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1602800_1_6938", "context": "Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1602800_1_6939", "context": "Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15811174_1_6940", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15811174_1_6941", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15811174_1_6942", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15811174_1_6943", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15811174_1_6944", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15811174_1_6945", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15811174_1_6946", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15811174_1_6947", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15811174_1_6948", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15811174_1_6949", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15811174_1_6950", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15811174_1_6951", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15811174_1_6952", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7081289_3_6953", "context": "There have been only two reports of cimetidine-induced hepatitis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7081289_3_6954", "context": "There have been only two reports of cimetidine-induced hepatitis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7081289_3_6955", "context": "There have been only two reports of cimetidine-induced hepatitis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7081289_3_6956", "context": "There have been only two reports of cimetidine-induced hepatitis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7081289_3_6957", "context": "There have been only two reports of cimetidine-induced hepatitis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7081289_3_6958", "context": "There have been only two reports of cimetidine-induced hepatitis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7081289_3_6959", "context": "There have been only two reports of cimetidine-induced hepatitis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7081289_3_6960", "context": "There have been only two reports of cimetidine-induced hepatitis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3732375_2_6961", "context": "A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3732375_2_6962", "context": "A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3732375_2_6963", "context": "A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3732375_2_6964", "context": "A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3732375_2_6965", "context": "A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3732375_2_6966", "context": "A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3732375_2_6967", "context": "A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3732375_2_6968", "context": "A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7639655_1_6969", "context": "Anterior ischemic optic neuropathy secondary to interferon alfa.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7639655_1_6970", "context": "Anterior ischemic optic neuropathy secondary to interferon alfa.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7639655_1_6971", "context": "Anterior ischemic optic neuropathy secondary to interferon alfa.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7639655_1_6972", "context": "Anterior ischemic optic neuropathy secondary to interferon alfa.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7639655_1_6973", "context": "Anterior ischemic optic neuropathy secondary to interferon alfa.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7639655_1_6974", "context": "Anterior ischemic optic neuropathy secondary to interferon alfa.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7639655_1_6975", "context": "Anterior ischemic optic neuropathy secondary to interferon alfa.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7639655_1_6976", "context": "Anterior ischemic optic neuropathy secondary to interferon alfa.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12854039_6_6977", "context": "PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12854039_6_6978", "context": "PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12854039_6_6979", "context": "PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12854039_6_6980", "context": "PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12854039_6_6981", "context": "PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12854039_6_6982", "context": "PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12854039_6_6983", "context": "PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12854039_6_6984", "context": "PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12234159_2_6985", "context": "Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12234159_2_6986", "context": "Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12234159_2_6987", "context": "Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12234159_2_6988", "context": "Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12234159_2_6989", "context": "Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12234159_2_6990", "context": "Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12234159_2_6991", "context": "Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12234159_2_6992", "context": "Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16609346_2_6993", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16609346_2_6994", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16609346_2_6995", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16609346_2_6996", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16609346_2_6997", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16609346_2_6998", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16609346_2_6999", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16609346_2_7000", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4075534_3_7001", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "4075534_3_7002", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4075534_3_7003", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4075534_3_7004", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4075534_3_7005", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4075534_3_7006", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4075534_3_7007", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4075534_3_7008", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3003260_2_7009", "context": "Cataracts induced by intermittent Decadron used as an antiemetic.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3003260_2_7010", "context": "Cataracts induced by intermittent Decadron used as an antiemetic.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3003260_2_7011", "context": "Cataracts induced by intermittent Decadron used as an antiemetic.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3003260_2_7012", "context": "Cataracts induced by intermittent Decadron used as an antiemetic.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3003260_2_7013", "context": "Cataracts induced by intermittent Decadron used as an antiemetic.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3003260_2_7014", "context": "Cataracts induced by intermittent Decadron used as an antiemetic.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3003260_2_7015", "context": "Cataracts induced by intermittent Decadron used as an antiemetic.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3003260_2_7016", "context": "Cataracts induced by intermittent Decadron used as an antiemetic.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "879939_2_7017", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "879939_2_7018", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "879939_2_7019", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "879939_2_7020", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "879939_2_7021", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "879939_2_7022", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "879939_2_7023", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "879939_2_7024", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "879939_2_7025", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "879939_2_7026", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "879939_2_7027", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "879939_2_7028", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "879939_2_7029", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3969689_4_7030", "context": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3969689_4_7031", "context": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3969689_4_7032", "context": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3969689_4_7033", "context": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3969689_4_7034", "context": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3969689_4_7035", "context": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3969689_4_7036", "context": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3969689_4_7037", "context": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8912599_6_7038", "context": "Erosion of psoriatic plaques: an early sign of methotrexate toxicity.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8912599_6_7039", "context": "Erosion of psoriatic plaques: an early sign of methotrexate toxicity.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8912599_6_7040", "context": "Erosion of psoriatic plaques: an early sign of methotrexate toxicity.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8912599_6_7041", "context": "Erosion of psoriatic plaques: an early sign of methotrexate toxicity.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8912599_6_7042", "context": "Erosion of psoriatic plaques: an early sign of methotrexate toxicity.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8912599_6_7043", "context": "Erosion of psoriatic plaques: an early sign of methotrexate toxicity.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8912599_6_7044", "context": "Erosion of psoriatic plaques: an early sign of methotrexate toxicity.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8912599_6_7045", "context": "Erosion of psoriatic plaques: an early sign of methotrexate toxicity.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11696132_1_7046", "context": "After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11696132_1_7047", "context": "After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11696132_1_7048", "context": "After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11696132_1_7049", "context": "After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11696132_1_7050", "context": "After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11696132_1_7051", "context": "After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11696132_1_7052", "context": "After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11696132_1_7053", "context": "After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12851279_1_7054", "context": "Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "12851279_1_7055", "context": "Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12851279_1_7056", "context": "Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12851279_1_7057", "context": "Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12851279_1_7058", "context": "Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12851279_1_7059", "context": "Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12851279_1_7060", "context": "Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "12851279_1_7061", "context": "Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15863610_5_7062", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15863610_5_7063", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15863610_5_7064", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15863610_5_7065", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15863610_5_7066", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15863610_5_7067", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15863610_5_7068", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15863610_5_7069", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15863610_5_7070", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15863610_5_7071", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15863610_5_7072", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15863610_5_7073", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15863610_5_7074", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16728538_1_7075", "context": "After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16728538_1_7076", "context": "After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16728538_1_7077", "context": "After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16728538_1_7078", "context": "After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16728538_1_7079", "context": "After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16728538_1_7080", "context": "After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16728538_1_7081", "context": "After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16728538_1_7082", "context": "After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22372628_2_7083", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "22372628_2_7084", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "22372628_2_7085", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "22372628_2_7086", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "22372628_2_7087", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "22372628_2_7088", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "22372628_2_7089", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "22372628_2_7090", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "22372628_2_7091", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "22372628_2_7092", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22372628_2_7093", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "22372628_2_7094", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "22372628_2_7095", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7071645_3_7096", "context": "Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7071645_3_7097", "context": "Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7071645_3_7098", "context": "Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7071645_3_7099", "context": "Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7071645_3_7100", "context": "Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7071645_3_7101", "context": "Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7071645_3_7102", "context": "Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7071645_3_7103", "context": "Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18364401_1_7104", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18364401_1_7105", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18364401_1_7106", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18364401_1_7107", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18364401_1_7108", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18364401_1_7109", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18364401_1_7110", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18364401_1_7111", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18364401_1_7112", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18364401_1_7113", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18364401_1_7114", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18364401_1_7115", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18364401_1_7116", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18661248_2_7117", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18661248_2_7118", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18661248_2_7119", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18661248_2_7120", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18661248_2_7121", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18661248_2_7122", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18661248_2_7123", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18661248_2_7124", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18661248_2_7125", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18661248_2_7126", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18661248_2_7127", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18661248_2_7128", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18661248_2_7129", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12022905_3_7130", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12022905_3_7131", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12022905_3_7132", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12022905_3_7133", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12022905_3_7134", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12022905_3_7135", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12022905_3_7136", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12022905_3_7137", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12022905_3_7138", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12022905_3_7139", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12022905_3_7140", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12022905_3_7141", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12022905_3_7142", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11202801_2_7143", "context": "Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11202801_2_7144", "context": "Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11202801_2_7145", "context": "Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11202801_2_7146", "context": "Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11202801_2_7147", "context": "Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11202801_2_7148", "context": "Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11202801_2_7149", "context": "Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11202801_2_7150", "context": "Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11283125_3_7151", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "11283125_3_7152", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "11283125_3_7153", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "11283125_3_7154", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "11283125_3_7155", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "11283125_3_7156", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "11283125_3_7157", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11283125_3_7158", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11283125_3_7159", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11283125_3_7160", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11283125_3_7161", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11283125_3_7162", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "11283125_3_7163", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7756684_1_7164", "context": "The dose-limiting toxicity of KW-2149 is pulmonary toxicity.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7756684_1_7165", "context": "The dose-limiting toxicity of KW-2149 is pulmonary toxicity.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7756684_1_7166", "context": "The dose-limiting toxicity of KW-2149 is pulmonary toxicity.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7756684_1_7167", "context": "The dose-limiting toxicity of KW-2149 is pulmonary toxicity.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7756684_1_7168", "context": "The dose-limiting toxicity of KW-2149 is pulmonary toxicity.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7756684_1_7169", "context": "The dose-limiting toxicity of KW-2149 is pulmonary toxicity.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7756684_1_7170", "context": "The dose-limiting toxicity of KW-2149 is pulmonary toxicity.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7756684_1_7171", "context": "The dose-limiting toxicity of KW-2149 is pulmonary toxicity.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15773973_1_7172", "context": "Flucloxacillin-induced aplastic anaemia and liver failure.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15773973_1_7173", "context": "Flucloxacillin-induced aplastic anaemia and liver failure.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15773973_1_7174", "context": "Flucloxacillin-induced aplastic anaemia and liver failure.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15773973_1_7175", "context": "Flucloxacillin-induced aplastic anaemia and liver failure.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15773973_1_7176", "context": "Flucloxacillin-induced aplastic anaemia and liver failure.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15773973_1_7177", "context": "Flucloxacillin-induced aplastic anaemia and liver failure.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15773973_1_7178", "context": "Flucloxacillin-induced aplastic anaemia and liver failure.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15773973_1_7179", "context": "Flucloxacillin-induced aplastic anaemia and liver failure.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18855892_8_7180", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18855892_8_7181", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18855892_8_7182", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18855892_8_7183", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18855892_8_7184", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18855892_8_7185", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18855892_8_7186", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18855892_8_7187", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18855892_8_7188", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18855892_8_7189", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18855892_8_7190", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18855892_8_7191", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18855892_8_7192", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15286697_4_7193", "context": "We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of BCNU-related pulmonary fibrosis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15286697_4_7194", "context": "We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of BCNU-related pulmonary fibrosis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15286697_4_7195", "context": "We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of BCNU-related pulmonary fibrosis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15286697_4_7196", "context": "We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of BCNU-related pulmonary fibrosis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15286697_4_7197", "context": "We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of BCNU-related pulmonary fibrosis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15286697_4_7198", "context": "We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of BCNU-related pulmonary fibrosis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15286697_4_7199", "context": "We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of BCNU-related pulmonary fibrosis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15286697_4_7200", "context": "We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of BCNU-related pulmonary fibrosis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2241449_1_7201", "context": "Physicians using this \"new\" drug must be aware of the potential danger of sulfonamide-induced injury to the urinary tract.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2241449_1_7202", "context": "Physicians using this \"new\" drug must be aware of the potential danger of sulfonamide-induced injury to the urinary tract.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2241449_1_7203", "context": "Physicians using this \"new\" drug must be aware of the potential danger of sulfonamide-induced injury to the urinary tract.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2241449_1_7204", "context": "Physicians using this \"new\" drug must be aware of the potential danger of sulfonamide-induced injury to the urinary tract.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2241449_1_7205", "context": "Physicians using this \"new\" drug must be aware of the potential danger of sulfonamide-induced injury to the urinary tract.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2241449_1_7206", "context": "Physicians using this \"new\" drug must be aware of the potential danger of sulfonamide-induced injury to the urinary tract.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2241449_1_7207", "context": "Physicians using this \"new\" drug must be aware of the potential danger of sulfonamide-induced injury to the urinary tract.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2241449_1_7208", "context": "Physicians using this \"new\" drug must be aware of the potential danger of sulfonamide-induced injury to the urinary tract.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12504711_4_7209", "context": "RESULTS: Brimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12504711_4_7210", "context": "RESULTS: Brimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12504711_4_7211", "context": "RESULTS: Brimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12504711_4_7212", "context": "RESULTS: Brimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12504711_4_7213", "context": "RESULTS: Brimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12504711_4_7214", "context": "RESULTS: Brimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12504711_4_7215", "context": "RESULTS: Brimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12504711_4_7216", "context": "RESULTS: Brimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15507779_1_7217", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15507779_1_7218", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15507779_1_7219", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15507779_1_7220", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15507779_1_7221", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15507779_1_7222", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15507779_1_7223", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15507779_1_7224", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15507779_1_7225", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15507779_1_7226", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15507779_1_7227", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15507779_1_7228", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15507779_1_7229", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1711090_2_7230", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "1711090_2_7231", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "1711090_2_7232", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "1711090_2_7233", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "1711090_2_7234", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "1711090_2_7235", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "1711090_2_7236", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "1711090_2_7237", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "1711090_2_7238", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "1711090_2_7239", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1711090_2_7240", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "1711090_2_7241", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "1711090_2_7242", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "3806824_1_7243", "context": "Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3806824_1_7244", "context": "Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3806824_1_7245", "context": "Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3806824_1_7246", "context": "Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3806824_1_7247", "context": "Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3806824_1_7248", "context": "Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3806824_1_7249", "context": "Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3806824_1_7250", "context": "Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "440873_4_7251", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "440873_4_7252", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "440873_4_7253", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "440873_4_7254", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "440873_4_7255", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "440873_4_7256", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "440873_4_7257", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "440873_4_7258", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "440873_4_7259", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "440873_4_7260", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "440873_4_7261", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "440873_4_7262", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "440873_4_7263", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17275666_1_7264", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17275666_1_7265", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17275666_1_7266", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17275666_1_7267", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17275666_1_7268", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17275666_1_7269", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17275666_1_7270", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17275666_1_7271", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15516308_10_7272", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15516308_10_7273", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15516308_10_7274", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15516308_10_7275", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15516308_10_7276", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15516308_10_7277", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15516308_10_7278", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15516308_10_7279", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15516308_10_7280", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15516308_10_7281", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15516308_10_7282", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15516308_10_7283", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15516308_10_7284", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16599252_2_7285", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16599252_2_7286", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16599252_2_7287", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16599252_2_7288", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16599252_2_7289", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16599252_2_7290", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16599252_2_7291", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16599252_2_7292", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18855892_3_7293", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18855892_3_7294", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18855892_3_7295", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18855892_3_7296", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18855892_3_7297", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18855892_3_7298", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18855892_3_7299", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18855892_3_7300", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18855892_3_7301", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18855892_3_7302", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18855892_3_7303", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18855892_3_7304", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18855892_3_7305", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9737132_3_7306", "context": "Pentazocine-induced fibrous myopathy and localized neuropathy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9737132_3_7307", "context": "Pentazocine-induced fibrous myopathy and localized neuropathy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9737132_3_7308", "context": "Pentazocine-induced fibrous myopathy and localized neuropathy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9737132_3_7309", "context": "Pentazocine-induced fibrous myopathy and localized neuropathy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9737132_3_7310", "context": "Pentazocine-induced fibrous myopathy and localized neuropathy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9737132_3_7311", "context": "Pentazocine-induced fibrous myopathy and localized neuropathy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9737132_3_7312", "context": "Pentazocine-induced fibrous myopathy and localized neuropathy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9737132_3_7313", "context": "Pentazocine-induced fibrous myopathy and localized neuropathy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11096051_1_7314", "context": "Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "11096051_1_7315", "context": "Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11096051_1_7316", "context": "Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11096051_1_7317", "context": "Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11096051_1_7318", "context": "Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11096051_1_7319", "context": "Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11096051_1_7320", "context": "Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "11096051_1_7321", "context": "Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17823522_3_7322", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17823522_3_7323", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17823522_3_7324", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17823522_3_7325", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17823522_3_7326", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17823522_3_7327", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17823522_3_7328", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17823522_3_7329", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17823522_3_7330", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17823522_3_7331", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17823522_3_7332", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17823522_3_7333", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17823522_3_7334", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6810714_1_7335", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6810714_1_7336", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6810714_1_7337", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6810714_1_7338", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6810714_1_7339", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6810714_1_7340", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6810714_1_7341", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6810714_1_7342", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6810714_1_7343", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6810714_1_7344", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6810714_1_7345", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6810714_1_7346", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6810714_1_7347", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16132305_2_7348", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16132305_2_7349", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16132305_2_7350", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16132305_2_7351", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16132305_2_7352", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16132305_2_7353", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16132305_2_7354", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16132305_2_7355", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16132305_2_7356", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16132305_2_7357", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16132305_2_7358", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16132305_2_7359", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16132305_2_7360", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3084231_1_7361", "context": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3084231_1_7362", "context": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3084231_1_7363", "context": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3084231_1_7364", "context": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3084231_1_7365", "context": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3084231_1_7366", "context": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3084231_1_7367", "context": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3084231_1_7368", "context": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19583682_3_7369", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19583682_3_7370", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19583682_3_7371", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19583682_3_7372", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19583682_3_7373", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19583682_3_7374", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19583682_3_7375", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19583682_3_7376", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19583682_3_7377", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19583682_3_7378", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19583682_3_7379", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19583682_3_7380", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19583682_3_7381", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12218252_1_7382", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12218252_1_7383", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12218252_1_7384", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12218252_1_7385", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12218252_1_7386", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12218252_1_7387", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12218252_1_7388", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12218252_1_7389", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10592946_1_7390", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10592946_1_7391", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10592946_1_7392", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10592946_1_7393", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10592946_1_7394", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10592946_1_7395", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10592946_1_7396", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10592946_1_7397", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10592946_1_7398", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10592946_1_7399", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10592946_1_7400", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10592946_1_7401", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10592946_1_7402", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3242521_1_7403", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3242521_1_7404", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3242521_1_7405", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3242521_1_7406", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3242521_1_7407", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3242521_1_7408", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3242521_1_7409", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3242521_1_7410", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3242521_1_7411", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3242521_1_7412", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3242521_1_7413", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3242521_1_7414", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3242521_1_7415", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6671350_4_7416", "context": "Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the cephalosporin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6671350_4_7417", "context": "Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the cephalosporin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6671350_4_7418", "context": "Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the cephalosporin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6671350_4_7419", "context": "Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the cephalosporin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6671350_4_7420", "context": "Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the cephalosporin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6671350_4_7421", "context": "Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the cephalosporin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6671350_4_7422", "context": "Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the cephalosporin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6671350_4_7423", "context": "Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the cephalosporin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6873616_2_7424", "context": "Intrahepatic cholestasis and sicca complex after thiabendazole.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6873616_2_7425", "context": "Intrahepatic cholestasis and sicca complex after thiabendazole.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6873616_2_7426", "context": "Intrahepatic cholestasis and sicca complex after thiabendazole.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6873616_2_7427", "context": "Intrahepatic cholestasis and sicca complex after thiabendazole.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6873616_2_7428", "context": "Intrahepatic cholestasis and sicca complex after thiabendazole.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6873616_2_7429", "context": "Intrahepatic cholestasis and sicca complex after thiabendazole.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6873616_2_7430", "context": "Intrahepatic cholestasis and sicca complex after thiabendazole.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6873616_2_7431", "context": "Intrahepatic cholestasis and sicca complex after thiabendazole.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "748238_3_7432", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "748238_3_7433", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "748238_3_7434", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "748238_3_7435", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "748238_3_7436", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "748238_3_7437", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "748238_3_7438", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "748238_3_7439", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "748238_3_7440", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "748238_3_7441", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "748238_3_7442", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "748238_3_7443", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "748238_3_7444", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6671350_3_7445", "context": "Moxalactam is more likely to be associated with platelet dysfunction.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6671350_3_7446", "context": "Moxalactam is more likely to be associated with platelet dysfunction.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6671350_3_7447", "context": "Moxalactam is more likely to be associated with platelet dysfunction.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6671350_3_7448", "context": "Moxalactam is more likely to be associated with platelet dysfunction.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6671350_3_7449", "context": "Moxalactam is more likely to be associated with platelet dysfunction.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6671350_3_7450", "context": "Moxalactam is more likely to be associated with platelet dysfunction.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6671350_3_7451", "context": "Moxalactam is more likely to be associated with platelet dysfunction.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6671350_3_7452", "context": "Moxalactam is more likely to be associated with platelet dysfunction.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8151270_2_7453", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8151270_2_7454", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8151270_2_7455", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8151270_2_7456", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8151270_2_7457", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8151270_2_7458", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8151270_2_7459", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8151270_2_7460", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8151270_2_7461", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8151270_2_7462", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8151270_2_7463", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8151270_2_7464", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8151270_2_7465", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10573314_3_7466", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10573314_3_7467", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10573314_3_7468", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10573314_3_7469", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10573314_3_7470", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10573314_3_7471", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10573314_3_7472", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10573314_3_7473", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10573314_3_7474", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10573314_3_7475", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10573314_3_7476", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10573314_3_7477", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10573314_3_7478", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16288069_2_7479", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16288069_2_7480", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16288069_2_7481", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16288069_2_7482", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16288069_2_7483", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16288069_2_7484", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16288069_2_7485", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16288069_2_7486", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16288069_2_7487", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16288069_2_7488", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16288069_2_7489", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16288069_2_7490", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16288069_2_7491", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16393774_6_7492", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16393774_6_7493", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16393774_6_7494", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16393774_6_7495", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16393774_6_7496", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16393774_6_7497", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16393774_6_7498", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16393774_6_7499", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16393774_6_7500", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16393774_6_7501", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16393774_6_7502", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16393774_6_7503", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16393774_6_7504", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3156465_3_7505", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3156465_3_7506", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3156465_3_7507", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3156465_3_7508", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3156465_3_7509", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3156465_3_7510", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3156465_3_7511", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3156465_3_7512", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3156465_3_7513", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3156465_3_7514", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3156465_3_7515", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3156465_3_7516", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3156465_3_7517", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "13680140_1_7518", "context": "Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "13680140_1_7519", "context": "Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "13680140_1_7520", "context": "Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "13680140_1_7521", "context": "Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "13680140_1_7522", "context": "Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "13680140_1_7523", "context": "Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "13680140_1_7524", "context": "Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "13680140_1_7525", "context": "Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6725214_1_7526", "context": "A case of priapism associated with trazodone is described.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6725214_1_7527", "context": "A case of priapism associated with trazodone is described.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6725214_1_7528", "context": "A case of priapism associated with trazodone is described.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6725214_1_7529", "context": "A case of priapism associated with trazodone is described.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6725214_1_7530", "context": "A case of priapism associated with trazodone is described.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6725214_1_7531", "context": "A case of priapism associated with trazodone is described.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6725214_1_7532", "context": "A case of priapism associated with trazodone is described.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6725214_1_7533", "context": "A case of priapism associated with trazodone is described.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6725214_1_7534", "context": "A case of priapism associated with trazodone is described.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6725214_1_7535", "context": "A case of priapism associated with trazodone is described.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6725214_1_7536", "context": "A case of priapism associated with trazodone is described.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6725214_1_7537", "context": "A case of priapism associated with trazodone is described.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6725214_1_7538", "context": "A case of priapism associated with trazodone is described.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16678268_1_7539", "context": "Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16678268_1_7540", "context": "Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16678268_1_7541", "context": "Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16678268_1_7542", "context": "Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16678268_1_7543", "context": "Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16678268_1_7544", "context": "Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16678268_1_7545", "context": "Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16678268_1_7546", "context": "Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6693840_3_7547", "context": "No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6693840_3_7548", "context": "No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6693840_3_7549", "context": "No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6693840_3_7550", "context": "No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6693840_3_7551", "context": "No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6693840_3_7552", "context": "No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6693840_3_7553", "context": "No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6693840_3_7554", "context": "No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16018164_5_7555", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16018164_5_7556", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16018164_5_7557", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16018164_5_7558", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16018164_5_7559", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16018164_5_7560", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16018164_5_7561", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16018164_5_7562", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16018164_5_7563", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16018164_5_7564", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16018164_5_7565", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16018164_5_7566", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16018164_5_7567", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6651138_1_7568", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6651138_1_7569", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6651138_1_7570", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6651138_1_7571", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6651138_1_7572", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6651138_1_7573", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6651138_1_7574", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6651138_1_7575", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6651138_1_7576", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6651138_1_7577", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6651138_1_7578", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6651138_1_7579", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6651138_1_7580", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12218252_2_7581", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12218252_2_7582", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12218252_2_7583", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12218252_2_7584", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12218252_2_7585", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12218252_2_7586", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12218252_2_7587", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12218252_2_7588", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12218252_2_7589", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12218252_2_7590", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12218252_2_7591", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12218252_2_7592", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12218252_2_7593", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8726608_2_7594", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8726608_2_7595", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8726608_2_7596", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8726608_2_7597", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8726608_2_7598", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8726608_2_7599", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8726608_2_7600", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8726608_2_7601", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8726608_2_7602", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8726608_2_7603", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8726608_2_7604", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8726608_2_7605", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8726608_2_7606", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11197767_1_7607", "context": "Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11197767_1_7608", "context": "Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11197767_1_7609", "context": "Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11197767_1_7610", "context": "Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11197767_1_7611", "context": "Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11197767_1_7612", "context": "Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11197767_1_7613", "context": "Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11197767_1_7614", "context": "Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2717661_1_7615", "context": "The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2717661_1_7616", "context": "The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2717661_1_7617", "context": "The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2717661_1_7618", "context": "The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2717661_1_7619", "context": "The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2717661_1_7620", "context": "The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2717661_1_7621", "context": "The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2717661_1_7622", "context": "The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "589261_5_7623", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "589261_5_7624", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "589261_5_7625", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "589261_5_7626", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "589261_5_7627", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "589261_5_7628", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "589261_5_7629", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "589261_5_7630", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "589261_5_7631", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "589261_5_7632", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "589261_5_7633", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "589261_5_7634", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "589261_5_7635", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15863610_3_7636", "context": "Data suggest that tamoxifen is involved in the pathogenesis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15863610_3_7637", "context": "Data suggest that tamoxifen is involved in the pathogenesis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15863610_3_7638", "context": "Data suggest that tamoxifen is involved in the pathogenesis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15863610_3_7639", "context": "Data suggest that tamoxifen is involved in the pathogenesis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15863610_3_7640", "context": "Data suggest that tamoxifen is involved in the pathogenesis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15863610_3_7641", "context": "Data suggest that tamoxifen is involved in the pathogenesis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15863610_3_7642", "context": "Data suggest that tamoxifen is involved in the pathogenesis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15863610_3_7643", "context": "Data suggest that tamoxifen is involved in the pathogenesis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6794018_2_7644", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6794018_2_7645", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6794018_2_7646", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6794018_2_7647", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6794018_2_7648", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6794018_2_7649", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6794018_2_7650", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6794018_2_7651", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18262450_1_7652", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "18262450_1_7653", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "18262450_1_7654", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "18262450_1_7655", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "18262450_1_7656", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "18262450_1_7657", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "18262450_1_7658", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18262450_1_7659", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18262450_1_7660", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18262450_1_7661", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18262450_1_7662", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18262450_1_7663", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "18262450_1_7664", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "14742791_3_7665", "context": "OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis (AIN) due to pantoprazole.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14742791_3_7666", "context": "OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis (AIN) due to pantoprazole.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14742791_3_7667", "context": "OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis (AIN) due to pantoprazole.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14742791_3_7668", "context": "OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis (AIN) due to pantoprazole.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14742791_3_7669", "context": "OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis (AIN) due to pantoprazole.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14742791_3_7670", "context": "OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis (AIN) due to pantoprazole.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14742791_3_7671", "context": "OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis (AIN) due to pantoprazole.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14742791_3_7672", "context": "OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis (AIN) due to pantoprazole.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19555801_2_7673", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19555801_2_7674", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19555801_2_7675", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19555801_2_7676", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19555801_2_7677", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19555801_2_7678", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19555801_2_7679", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19555801_2_7680", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19555801_2_7681", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19555801_2_7682", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19555801_2_7683", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19555801_2_7684", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19555801_2_7685", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10682234_2_7686", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "10682234_2_7687", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "10682234_2_7688", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "10682234_2_7689", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "10682234_2_7690", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "10682234_2_7691", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "10682234_2_7692", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10682234_2_7693", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10682234_2_7694", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10682234_2_7695", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10682234_2_7696", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10682234_2_7697", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "10682234_2_7698", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "21330680_2_7699", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "21330680_2_7700", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "21330680_2_7701", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "21330680_2_7702", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "21330680_2_7703", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "21330680_2_7704", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21330680_2_7705", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21330680_2_7706", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21330680_2_7707", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21330680_2_7708", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21330680_2_7709", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21330680_2_7710", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21330680_2_7711", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4066620_1_7712", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "4066620_1_7713", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "4066620_1_7714", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "4066620_1_7715", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "4066620_1_7716", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "4066620_1_7717", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "4066620_1_7718", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4066620_1_7719", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4066620_1_7720", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4066620_1_7721", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4066620_1_7722", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4066620_1_7723", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4066620_1_7724", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19354059_1_7725", "context": "The most common complication of warfarin use is adverse bleeding.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19354059_1_7726", "context": "The most common complication of warfarin use is adverse bleeding.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19354059_1_7727", "context": "The most common complication of warfarin use is adverse bleeding.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19354059_1_7728", "context": "The most common complication of warfarin use is adverse bleeding.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19354059_1_7729", "context": "The most common complication of warfarin use is adverse bleeding.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19354059_1_7730", "context": "The most common complication of warfarin use is adverse bleeding.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19354059_1_7731", "context": "The most common complication of warfarin use is adverse bleeding.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19354059_1_7732", "context": "The most common complication of warfarin use is adverse bleeding.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18166746_2_7733", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18166746_2_7734", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18166746_2_7735", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18166746_2_7736", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18166746_2_7737", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18166746_2_7738", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18166746_2_7739", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18166746_2_7740", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18166746_2_7741", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18166746_2_7742", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18166746_2_7743", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18166746_2_7744", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18166746_2_7745", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15571949_2_7746", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15571949_2_7747", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15571949_2_7748", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15571949_2_7749", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15571949_2_7750", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15571949_2_7751", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15571949_2_7752", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15571949_2_7753", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15571949_2_7754", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15571949_2_7755", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15571949_2_7756", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15571949_2_7757", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15571949_2_7758", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11724089_3_7759", "context": "It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11724089_3_7760", "context": "It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11724089_3_7761", "context": "It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11724089_3_7762", "context": "It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11724089_3_7763", "context": "It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11724089_3_7764", "context": "It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11724089_3_7765", "context": "It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11724089_3_7766", "context": "It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21630612_1_7767", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21630612_1_7768", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21630612_1_7769", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21630612_1_7770", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21630612_1_7771", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21630612_1_7772", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21630612_1_7773", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21630612_1_7774", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9533061_10_7775", "context": "CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9533061_10_7776", "context": "CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9533061_10_7777", "context": "CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9533061_10_7778", "context": "CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9533061_10_7779", "context": "CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9533061_10_7780", "context": "CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9533061_10_7781", "context": "CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9533061_10_7782", "context": "CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8308951_2_7783", "context": "A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8308951_2_7784", "context": "A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8308951_2_7785", "context": "A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8308951_2_7786", "context": "A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8308951_2_7787", "context": "A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8308951_2_7788", "context": "A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8308951_2_7789", "context": "A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8308951_2_7790", "context": "A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3171334_3_7791", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3171334_3_7792", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3171334_3_7793", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3171334_3_7794", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3171334_3_7795", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3171334_3_7796", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3171334_3_7797", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3171334_3_7798", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3171334_3_7799", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3171334_3_7800", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3171334_3_7801", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3171334_3_7802", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3171334_3_7803", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10682234_5_7804", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "10682234_5_7805", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10682234_5_7806", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10682234_5_7807", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10682234_5_7808", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10682234_5_7809", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10682234_5_7810", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "10682234_5_7811", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7761316_1_7812", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7761316_1_7813", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7761316_1_7814", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7761316_1_7815", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7761316_1_7816", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7761316_1_7817", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7761316_1_7818", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7761316_1_7819", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7761316_1_7820", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7761316_1_7821", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7761316_1_7822", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7761316_1_7823", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7761316_1_7824", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8308951_1_7825", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8308951_1_7826", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8308951_1_7827", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8308951_1_7828", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8308951_1_7829", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8308951_1_7830", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8308951_1_7831", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8308951_1_7832", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16317298_2_7833", "context": "Gemcitabine should be added to the list of drugs known to cause radiation recall.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16317298_2_7834", "context": "Gemcitabine should be added to the list of drugs known to cause radiation recall.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16317298_2_7835", "context": "Gemcitabine should be added to the list of drugs known to cause radiation recall.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16317298_2_7836", "context": "Gemcitabine should be added to the list of drugs known to cause radiation recall.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16317298_2_7837", "context": "Gemcitabine should be added to the list of drugs known to cause radiation recall.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16317298_2_7838", "context": "Gemcitabine should be added to the list of drugs known to cause radiation recall.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16317298_2_7839", "context": "Gemcitabine should be added to the list of drugs known to cause radiation recall.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16317298_2_7840", "context": "Gemcitabine should be added to the list of drugs known to cause radiation recall.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12504711_1_7841", "context": "A paradoxical ocular effect of brimonidine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12504711_1_7842", "context": "A paradoxical ocular effect of brimonidine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12504711_1_7843", "context": "A paradoxical ocular effect of brimonidine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12504711_1_7844", "context": "A paradoxical ocular effect of brimonidine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12504711_1_7845", "context": "A paradoxical ocular effect of brimonidine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12504711_1_7846", "context": "A paradoxical ocular effect of brimonidine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12504711_1_7847", "context": "A paradoxical ocular effect of brimonidine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12504711_1_7848", "context": "A paradoxical ocular effect of brimonidine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12234159_1_7849", "context": "Fixed drug eruption to rofecoxib.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12234159_1_7850", "context": "Fixed drug eruption to rofecoxib.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12234159_1_7851", "context": "Fixed drug eruption to rofecoxib.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12234159_1_7852", "context": "Fixed drug eruption to rofecoxib.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12234159_1_7853", "context": "Fixed drug eruption to rofecoxib.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12234159_1_7854", "context": "Fixed drug eruption to rofecoxib.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12234159_1_7855", "context": "Fixed drug eruption to rofecoxib.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12234159_1_7856", "context": "Fixed drug eruption to rofecoxib.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9533061_8_7857", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9533061_8_7858", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9533061_8_7859", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9533061_8_7860", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9533061_8_7861", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9533061_8_7862", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9533061_8_7863", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9533061_8_7864", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9533061_8_7865", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9533061_8_7866", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9533061_8_7867", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9533061_8_7868", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9533061_8_7869", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14742791_1_7870", "context": "Acute interstitial nephritis due to pantoprazole.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14742791_1_7871", "context": "Acute interstitial nephritis due to pantoprazole.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14742791_1_7872", "context": "Acute interstitial nephritis due to pantoprazole.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14742791_1_7873", "context": "Acute interstitial nephritis due to pantoprazole.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14742791_1_7874", "context": "Acute interstitial nephritis due to pantoprazole.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14742791_1_7875", "context": "Acute interstitial nephritis due to pantoprazole.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14742791_1_7876", "context": "Acute interstitial nephritis due to pantoprazole.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14742791_1_7877", "context": "Acute interstitial nephritis due to pantoprazole.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16515630_3_7878", "context": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16515630_3_7879", "context": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16515630_3_7880", "context": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16515630_3_7881", "context": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16515630_3_7882", "context": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16515630_3_7883", "context": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16515630_3_7884", "context": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16515630_3_7885", "context": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1238016_1_7886", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1238016_1_7887", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1238016_1_7888", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1238016_1_7889", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1238016_1_7890", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1238016_1_7891", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1238016_1_7892", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1238016_1_7893", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1238016_1_7894", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1238016_1_7895", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1238016_1_7896", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1238016_1_7897", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1238016_1_7898", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3156465_2_7899", "context": "Isotretinoin teratogenicity.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3156465_2_7900", "context": "Isotretinoin teratogenicity.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3156465_2_7901", "context": "Isotretinoin teratogenicity.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3156465_2_7902", "context": "Isotretinoin teratogenicity.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3156465_2_7903", "context": "Isotretinoin teratogenicity.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3156465_2_7904", "context": "Isotretinoin teratogenicity.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3156465_2_7905", "context": "Isotretinoin teratogenicity.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3156465_2_7906", "context": "Isotretinoin teratogenicity.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7081289_1_7907", "context": "Hepatitis following cimetidine administration.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7081289_1_7908", "context": "Hepatitis following cimetidine administration.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7081289_1_7909", "context": "Hepatitis following cimetidine administration.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7081289_1_7910", "context": "Hepatitis following cimetidine administration.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7081289_1_7911", "context": "Hepatitis following cimetidine administration.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7081289_1_7912", "context": "Hepatitis following cimetidine administration.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7081289_1_7913", "context": "Hepatitis following cimetidine administration.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7081289_1_7914", "context": "Hepatitis following cimetidine administration.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10698143_4_7915", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10698143_4_7916", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10698143_4_7917", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10698143_4_7918", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10698143_4_7919", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10698143_4_7920", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10698143_4_7921", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10698143_4_7922", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10698143_4_7923", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10698143_4_7924", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10698143_4_7925", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10698143_4_7926", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10698143_4_7927", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17619811_5_7928", "context": "Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "17619811_5_7929", "context": "Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17619811_5_7930", "context": "Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "17619811_5_7931", "context": "Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17619811_5_7932", "context": "Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17619811_5_7933", "context": "Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17619811_5_7934", "context": "Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "17619811_5_7935", "context": "Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7526455_1_7936", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7526455_1_7937", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7526455_1_7938", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7526455_1_7939", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7526455_1_7940", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7526455_1_7941", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7526455_1_7942", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7526455_1_7943", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7526455_1_7944", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7526455_1_7945", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7526455_1_7946", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7526455_1_7947", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7526455_1_7948", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15522120_11_7949", "context": "Since the depressive symptoms returned sertraline medication was initiated.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "15522120_11_7950", "context": "Since the depressive symptoms returned sertraline medication was initiated.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15522120_11_7951", "context": "Since the depressive symptoms returned sertraline medication was initiated.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15522120_11_7952", "context": "Since the depressive symptoms returned sertraline medication was initiated.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15522120_11_7953", "context": "Since the depressive symptoms returned sertraline medication was initiated.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15522120_11_7954", "context": "Since the depressive symptoms returned sertraline medication was initiated.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15522120_11_7955", "context": "Since the depressive symptoms returned sertraline medication was initiated.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "15522120_11_7956", "context": "Since the depressive symptoms returned sertraline medication was initiated.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8589490_1_7957", "context": "Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8589490_1_7958", "context": "Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8589490_1_7959", "context": "Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8589490_1_7960", "context": "Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8589490_1_7961", "context": "Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8589490_1_7962", "context": "Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8589490_1_7963", "context": "Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8589490_1_7964", "context": "Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11105373_1_7965", "context": "A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11105373_1_7966", "context": "A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11105373_1_7967", "context": "A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11105373_1_7968", "context": "A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11105373_1_7969", "context": "A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2241449_3_7970", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2241449_3_7971", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2241449_3_7972", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2241449_3_7973", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2241449_3_7974", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2241449_3_7975", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2241449_3_7976", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2241449_3_7977", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2241449_3_7978", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2241449_3_7979", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2241449_3_7980", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2241449_3_7981", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2241449_3_7982", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17016002_2_7983", "context": "Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17016002_2_7984", "context": "Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17016002_2_7985", "context": "Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17016002_2_7986", "context": "Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17016002_2_7987", "context": "Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17016002_2_7988", "context": "Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17016002_2_7989", "context": "Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17016002_2_7990", "context": "Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11563738_1_7991", "context": "The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11563738_1_7992", "context": "The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11563738_1_7993", "context": "The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11563738_1_7994", "context": "The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11563738_1_7995", "context": "The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11563738_1_7996", "context": "The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11563738_1_7997", "context": "The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11563738_1_7998", "context": "The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2719905_1_7999", "context": "Long lasting respiratory depression induced by morphine-6-glucuronide?", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2719905_1_8000", "context": "Long lasting respiratory depression induced by morphine-6-glucuronide?", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2719905_1_8001", "context": "Long lasting respiratory depression induced by morphine-6-glucuronide?", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2719905_1_8002", "context": "Long lasting respiratory depression induced by morphine-6-glucuronide?", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2719905_1_8003", "context": "Long lasting respiratory depression induced by morphine-6-glucuronide?", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2719905_1_8004", "context": "Long lasting respiratory depression induced by morphine-6-glucuronide?", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2719905_1_8005", "context": "Long lasting respiratory depression induced by morphine-6-glucuronide?", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2719905_1_8006", "context": "Long lasting respiratory depression induced by morphine-6-glucuronide?", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "623061_1_8007", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "623061_1_8008", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "623061_1_8009", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "623061_1_8010", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "623061_1_8011", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "623061_1_8012", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "623061_1_8013", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "623061_1_8014", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "623061_1_8015", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "623061_1_8016", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "623061_1_8017", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "623061_1_8018", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "623061_1_8019", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "868978_1_8020", "context": "Oculomotor disturbances associated with 5-fluorouracil chemotherapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "868978_1_8021", "context": "Oculomotor disturbances associated with 5-fluorouracil chemotherapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "868978_1_8022", "context": "Oculomotor disturbances associated with 5-fluorouracil chemotherapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "868978_1_8023", "context": "Oculomotor disturbances associated with 5-fluorouracil chemotherapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "868978_1_8024", "context": "Oculomotor disturbances associated with 5-fluorouracil chemotherapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "868978_1_8025", "context": "Oculomotor disturbances associated with 5-fluorouracil chemotherapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "868978_1_8026", "context": "Oculomotor disturbances associated with 5-fluorouracil chemotherapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "868978_1_8027", "context": "Oculomotor disturbances associated with 5-fluorouracil chemotherapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18258513_1_8028", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18258513_1_8029", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18258513_1_8030", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18258513_1_8031", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18258513_1_8032", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18258513_1_8033", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18258513_1_8034", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18258513_1_8035", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18258513_1_8036", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18258513_1_8037", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18258513_1_8038", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18258513_1_8039", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18258513_1_8040", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21802143_5_8041", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "21802143_5_8042", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "21802143_5_8043", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "21802143_5_8044", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "21802143_5_8045", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "21802143_5_8046", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "21802143_5_8047", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "21802143_5_8048", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "21802143_5_8049", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "21802143_5_8050", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21802143_5_8051", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "21802143_5_8052", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "21802143_5_8053", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10682234_1_8054", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "10682234_1_8055", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10682234_1_8056", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10682234_1_8057", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10682234_1_8058", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10682234_1_8059", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10682234_1_8060", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "10682234_1_8061", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12567347_1_8062", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12567347_1_8063", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12567347_1_8064", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12567347_1_8065", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12567347_1_8066", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12567347_1_8067", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12567347_1_8068", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12567347_1_8069", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12567347_1_8070", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12567347_1_8071", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12567347_1_8072", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12567347_1_8073", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12567347_1_8074", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7783891_1_8075", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7783891_1_8076", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7783891_1_8077", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7783891_1_8078", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7783891_1_8079", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7783891_1_8080", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7783891_1_8081", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7783891_1_8082", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7783891_1_8083", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7783891_1_8084", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7783891_1_8085", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7783891_1_8086", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7783891_1_8087", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11563738_2_8088", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "11563738_2_8089", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "11563738_2_8090", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "11563738_2_8091", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "11563738_2_8092", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "11563738_2_8093", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "11563738_2_8094", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11563738_2_8095", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11563738_2_8096", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11563738_2_8097", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11563738_2_8098", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11563738_2_8099", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "11563738_2_8100", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7258204_1_8101", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7258204_1_8102", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7258204_1_8103", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7258204_1_8104", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7258204_1_8105", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7258204_1_8106", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7258204_1_8107", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7258204_1_8108", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7258204_1_8109", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7258204_1_8110", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7258204_1_8111", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7258204_1_8112", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7258204_1_8113", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16216617_1_8114", "context": "Prominent positive U waves appearing with high-dose intravenous phenylephrine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16216617_1_8115", "context": "Prominent positive U waves appearing with high-dose intravenous phenylephrine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16216617_1_8116", "context": "Prominent positive U waves appearing with high-dose intravenous phenylephrine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16216617_1_8117", "context": "Prominent positive U waves appearing with high-dose intravenous phenylephrine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16216617_1_8118", "context": "Prominent positive U waves appearing with high-dose intravenous phenylephrine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16216617_1_8119", "context": "Prominent positive U waves appearing with high-dose intravenous phenylephrine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16216617_1_8120", "context": "Prominent positive U waves appearing with high-dose intravenous phenylephrine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16216617_1_8121", "context": "Prominent positive U waves appearing with high-dose intravenous phenylephrine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16620273_2_8122", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16620273_2_8123", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16620273_2_8124", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16620273_2_8125", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16620273_2_8126", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16620273_2_8127", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16620273_2_8128", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16620273_2_8129", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16620273_2_8130", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16620273_2_8131", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16620273_2_8132", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16620273_2_8133", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16620273_2_8134", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1868481_1_8135", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1868481_1_8136", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1868481_1_8137", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1868481_1_8138", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1868481_1_8139", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1868481_1_8140", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1868481_1_8141", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1868481_1_8142", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1868481_1_8143", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1868481_1_8144", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1868481_1_8145", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1868481_1_8146", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1868481_1_8147", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16728538_4_8148", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16728538_4_8149", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16728538_4_8150", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16728538_4_8151", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16728538_4_8152", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16728538_4_8153", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16728538_4_8154", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16728538_4_8155", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16728538_4_8156", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16728538_4_8157", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16728538_4_8158", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16728538_4_8159", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16728538_4_8160", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20234160_3_8161", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20234160_3_8162", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20234160_3_8163", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20234160_3_8164", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20234160_3_8165", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20234160_3_8166", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20234160_3_8167", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20234160_3_8168", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20234160_3_8169", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20234160_3_8170", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20234160_3_8171", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20234160_3_8172", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20234160_3_8173", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19884751_2_8174", "context": "Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "19884751_2_8175", "context": "Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "19884751_2_8176", "context": "Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "19884751_2_8177", "context": "Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "19884751_2_8178", "context": "Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19884751_2_8179", "context": "Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "19884751_2_8180", "context": "Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "19884751_2_8181", "context": "Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7139589_3_8182", "context": "L-asparaginase-induced pancreatitis has been reported during or closely following administration of the drug.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7139589_3_8183", "context": "L-asparaginase-induced pancreatitis has been reported during or closely following administration of the drug.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7139589_3_8184", "context": "L-asparaginase-induced pancreatitis has been reported during or closely following administration of the drug.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7139589_3_8185", "context": "L-asparaginase-induced pancreatitis has been reported during or closely following administration of the drug.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7139589_3_8186", "context": "L-asparaginase-induced pancreatitis has been reported during or closely following administration of the drug.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7139589_3_8187", "context": "L-asparaginase-induced pancreatitis has been reported during or closely following administration of the drug.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7139589_3_8188", "context": "L-asparaginase-induced pancreatitis has been reported during or closely following administration of the drug.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7139589_3_8189", "context": "L-asparaginase-induced pancreatitis has been reported during or closely following administration of the drug.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15286697_3_8190", "context": "These novel findings may offer specific therapeutic targets in the treatment of BCNU-associated pulmonary fibrosis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15286697_3_8191", "context": "These novel findings may offer specific therapeutic targets in the treatment of BCNU-associated pulmonary fibrosis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15286697_3_8192", "context": "These novel findings may offer specific therapeutic targets in the treatment of BCNU-associated pulmonary fibrosis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15286697_3_8193", "context": "These novel findings may offer specific therapeutic targets in the treatment of BCNU-associated pulmonary fibrosis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15286697_3_8194", "context": "These novel findings may offer specific therapeutic targets in the treatment of BCNU-associated pulmonary fibrosis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15286697_3_8195", "context": "These novel findings may offer specific therapeutic targets in the treatment of BCNU-associated pulmonary fibrosis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15286697_3_8196", "context": "These novel findings may offer specific therapeutic targets in the treatment of BCNU-associated pulmonary fibrosis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15286697_3_8197", "context": "These novel findings may offer specific therapeutic targets in the treatment of BCNU-associated pulmonary fibrosis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19212144_1_8198", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19212144_1_8199", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19212144_1_8200", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19212144_1_8201", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19212144_1_8202", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19212144_1_8203", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19212144_1_8204", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19212144_1_8205", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19212144_1_8206", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19212144_1_8207", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19212144_1_8208", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19212144_1_8209", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19212144_1_8210", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9253492_1_8211", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9253492_1_8212", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9253492_1_8213", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9253492_1_8214", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9253492_1_8215", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9253492_1_8216", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9253492_1_8217", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9253492_1_8218", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9253492_1_8219", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9253492_1_8220", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9253492_1_8221", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9253492_1_8222", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9253492_1_8223", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18166746_1_8224", "context": "[Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review].", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18166746_1_8225", "context": "[Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review].", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18166746_1_8226", "context": "[Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review].", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18166746_1_8227", "context": "[Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review].", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18166746_1_8228", "context": "[Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review].", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18166746_1_8229", "context": "[Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review].", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18166746_1_8230", "context": "[Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review].", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18166746_1_8231", "context": "[Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review].", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "868978_3_8232", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "868978_3_8233", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "868978_3_8234", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "868978_3_8235", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "868978_3_8236", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "868978_3_8237", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "868978_3_8238", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "868978_3_8239", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "868978_3_8240", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "868978_3_8241", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "868978_3_8242", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "868978_3_8243", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "868978_3_8244", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11510798_4_8245", "context": "Once extensive microbiological studies proved negative, corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "11510798_4_8246", "context": "Once extensive microbiological studies proved negative, corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11510798_4_8247", "context": "Once extensive microbiological studies proved negative, corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11510798_4_8248", "context": "Once extensive microbiological studies proved negative, corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11510798_4_8249", "context": "Once extensive microbiological studies proved negative, corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11510798_4_8250", "context": "Once extensive microbiological studies proved negative, corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11510798_4_8251", "context": "Once extensive microbiological studies proved negative, corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "11510798_4_8252", "context": "Once extensive microbiological studies proved negative, corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9886213_1_8253", "context": "Disseminated muscular cysticercosis with myositis induced by praziquantel therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9886213_1_8254", "context": "Disseminated muscular cysticercosis with myositis induced by praziquantel therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9886213_1_8255", "context": "Disseminated muscular cysticercosis with myositis induced by praziquantel therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9886213_1_8256", "context": "Disseminated muscular cysticercosis with myositis induced by praziquantel therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9886213_1_8257", "context": "Disseminated muscular cysticercosis with myositis induced by praziquantel therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9886213_1_8258", "context": "Disseminated muscular cysticercosis with myositis induced by praziquantel therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9886213_1_8259", "context": "Disseminated muscular cysticercosis with myositis induced by praziquantel therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9886213_1_8260", "context": "Disseminated muscular cysticercosis with myositis induced by praziquantel therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "172214_1_8261", "context": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "172214_1_8262", "context": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "172214_1_8263", "context": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "172214_1_8264", "context": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "172214_1_8265", "context": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "172214_1_8266", "context": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "172214_1_8267", "context": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "172214_1_8268", "context": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11485141_3_8269", "context": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11485141_3_8270", "context": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11485141_3_8271", "context": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11485141_3_8272", "context": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11485141_3_8273", "context": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11485141_3_8274", "context": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11485141_3_8275", "context": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11485141_3_8276", "context": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10573314_12_8277", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10573314_12_8278", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10573314_12_8279", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10573314_12_8280", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10573314_12_8281", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10573314_12_8282", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10573314_12_8283", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10573314_12_8284", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10573314_12_8285", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10573314_12_8286", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10573314_12_8287", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10573314_12_8288", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10573314_12_8289", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15461766_2_8290", "context": "The harlequin color change and association with prostaglandin E1.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15461766_2_8291", "context": "The harlequin color change and association with prostaglandin E1.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15461766_2_8292", "context": "The harlequin color change and association with prostaglandin E1.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15461766_2_8293", "context": "The harlequin color change and association with prostaglandin E1.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15461766_2_8294", "context": "The harlequin color change and association with prostaglandin E1.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15461766_2_8295", "context": "The harlequin color change and association with prostaglandin E1.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15461766_2_8296", "context": "The harlequin color change and association with prostaglandin E1.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15461766_2_8297", "context": "The harlequin color change and association with prostaglandin E1.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19336028_1_8298", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19336028_1_8299", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19336028_1_8300", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19336028_1_8301", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19336028_1_8302", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19336028_1_8303", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19336028_1_8304", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19336028_1_8305", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19336028_1_8306", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19336028_1_8307", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19336028_1_8308", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19336028_1_8309", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19336028_1_8310", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10225085_1_8311", "context": "Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10225085_1_8312", "context": "Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10225085_1_8313", "context": "Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10225085_1_8314", "context": "Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10225085_1_8315", "context": "Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10225085_1_8316", "context": "Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10225085_1_8317", "context": "Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10225085_1_8318", "context": "Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6851259_1_8319", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6851259_1_8320", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6851259_1_8321", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6851259_1_8322", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6851259_1_8323", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6851259_1_8324", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6851259_1_8325", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6851259_1_8326", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6851259_1_8327", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6851259_1_8328", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6851259_1_8329", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6851259_1_8330", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6851259_1_8331", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19318596_4_8332", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19318596_4_8333", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19318596_4_8334", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19318596_4_8335", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19318596_4_8336", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19318596_4_8337", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19318596_4_8338", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19318596_4_8339", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19318596_4_8340", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19318596_4_8341", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19318596_4_8342", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19318596_4_8343", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19318596_4_8344", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15811174_3_8345", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15811174_3_8346", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15811174_3_8347", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15811174_3_8348", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15811174_3_8349", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15811174_3_8350", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15811174_3_8351", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15811174_3_8352", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15811174_3_8353", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15811174_3_8354", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15811174_3_8355", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15811174_3_8356", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15811174_3_8357", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8124920_2_8358", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8124920_2_8359", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8124920_2_8360", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8124920_2_8361", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8124920_2_8362", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8124920_2_8363", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8124920_2_8364", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8124920_2_8365", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8124920_2_8366", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8124920_2_8367", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8124920_2_8368", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8124920_2_8369", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8124920_2_8370", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11109149_3_8371", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11109149_3_8372", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11109149_3_8373", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11109149_3_8374", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11109149_3_8375", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11109149_3_8376", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11109149_3_8377", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11109149_3_8378", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11109149_3_8379", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11109149_3_8380", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11109149_3_8381", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11109149_3_8382", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11109149_3_8383", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2719905_2_8384", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2719905_2_8385", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2719905_2_8386", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2719905_2_8387", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2719905_2_8388", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2719905_2_8389", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2719905_2_8390", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2719905_2_8391", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2719905_2_8392", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2719905_2_8393", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2719905_2_8394", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2719905_2_8395", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2719905_2_8396", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18071101_1_8397", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18071101_1_8398", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18071101_1_8399", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18071101_1_8400", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18071101_1_8401", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18071101_1_8402", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18071101_1_8403", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18071101_1_8404", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18071101_1_8405", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18071101_1_8406", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18071101_1_8407", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18071101_1_8408", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18071101_1_8409", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3720318_1_8410", "context": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3720318_1_8411", "context": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3720318_1_8412", "context": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3720318_1_8413", "context": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3720318_1_8414", "context": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3720318_1_8415", "context": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3720318_1_8416", "context": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3720318_1_8417", "context": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "589261_1_8418", "context": "Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "589261_1_8419", "context": "Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "589261_1_8420", "context": "Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "589261_1_8421", "context": "Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "589261_1_8422", "context": "Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "589261_1_8423", "context": "Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "589261_1_8424", "context": "Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "589261_1_8425", "context": "Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18262450_7_8426", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "18262450_7_8427", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "18262450_7_8428", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "18262450_7_8429", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "18262450_7_8430", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "18262450_7_8431", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "18262450_7_8432", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18262450_7_8433", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18262450_7_8434", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18262450_7_8435", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18262450_7_8436", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18262450_7_8437", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "18262450_7_8438", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "22552763_4_8439", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "22552763_4_8440", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "22552763_4_8441", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "22552763_4_8442", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "22552763_4_8443", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "22552763_4_8444", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "22552763_4_8445", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22552763_4_8446", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22552763_4_8447", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22552763_4_8448", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22552763_4_8449", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22552763_4_8450", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22552763_4_8451", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2532694_2_8452", "context": "Dapsone-induced erythroderma with Beau's lines.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2532694_2_8453", "context": "Dapsone-induced erythroderma with Beau's lines.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2532694_2_8454", "context": "Dapsone-induced erythroderma with Beau's lines.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2532694_2_8455", "context": "Dapsone-induced erythroderma with Beau's lines.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2532694_2_8456", "context": "Dapsone-induced erythroderma with Beau's lines.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2532694_2_8457", "context": "Dapsone-induced erythroderma with Beau's lines.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2532694_2_8458", "context": "Dapsone-induced erythroderma with Beau's lines.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2532694_2_8459", "context": "Dapsone-induced erythroderma with Beau's lines.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9870779_2_8460", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9870779_2_8461", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9870779_2_8462", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9870779_2_8463", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9870779_2_8464", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9870779_2_8465", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9870779_2_8466", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9870779_2_8467", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9870779_2_8468", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9870779_2_8469", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9870779_2_8470", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9870779_2_8471", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9870779_2_8472", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15516308_3_8473", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15516308_3_8474", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15516308_3_8475", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15516308_3_8476", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15516308_3_8477", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15516308_3_8478", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15516308_3_8479", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15516308_3_8480", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15516308_3_8481", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15516308_3_8482", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15516308_3_8483", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15516308_3_8484", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15516308_3_8485", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2830062_3_8486", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2830062_3_8487", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2830062_3_8488", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2830062_3_8489", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2830062_3_8490", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2830062_3_8491", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2830062_3_8492", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2830062_3_8493", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2830062_3_8494", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2830062_3_8495", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2830062_3_8496", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2830062_3_8497", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2830062_3_8498", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16046172_1_8499", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16046172_1_8500", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16046172_1_8501", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16046172_1_8502", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16046172_1_8503", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16046172_1_8504", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16046172_1_8505", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16046172_1_8506", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16046172_1_8507", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16046172_1_8508", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16046172_1_8509", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16046172_1_8510", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16046172_1_8511", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21729965_1_8512", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "21729965_1_8513", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "21729965_1_8514", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "21729965_1_8515", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "21729965_1_8516", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "21729965_1_8517", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21729965_1_8518", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21729965_1_8519", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21729965_1_8520", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21729965_1_8521", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21729965_1_8522", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21729965_1_8523", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21729965_1_8524", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16341621_1_8525", "context": "Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16341621_1_8526", "context": "Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16341621_1_8527", "context": "Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16341621_1_8528", "context": "Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16341621_1_8529", "context": "Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16341621_1_8530", "context": "Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16341621_1_8531", "context": "Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16341621_1_8532", "context": "Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2532694_1_8533", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2532694_1_8534", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2532694_1_8535", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2532694_1_8536", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2532694_1_8537", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2532694_1_8538", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2532694_1_8539", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2532694_1_8540", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2532694_1_8541", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2532694_1_8542", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2532694_1_8543", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2532694_1_8544", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2532694_1_8545", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8912599_8_8546", "context": "Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8912599_8_8547", "context": "Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8912599_8_8548", "context": "Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8912599_8_8549", "context": "Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8912599_8_8550", "context": "Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8912599_8_8551", "context": "Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8912599_8_8552", "context": "Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8912599_8_8553", "context": "Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18755414_1_8554", "context": "Hemorrhage from a falx meningioma after internal use of low-dose aspirin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18755414_1_8555", "context": "Hemorrhage from a falx meningioma after internal use of low-dose aspirin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18755414_1_8556", "context": "Hemorrhage from a falx meningioma after internal use of low-dose aspirin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18755414_1_8557", "context": "Hemorrhage from a falx meningioma after internal use of low-dose aspirin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18755414_1_8558", "context": "Hemorrhage from a falx meningioma after internal use of low-dose aspirin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18755414_1_8559", "context": "Hemorrhage from a falx meningioma after internal use of low-dose aspirin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18755414_1_8560", "context": "Hemorrhage from a falx meningioma after internal use of low-dose aspirin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18755414_1_8561", "context": "Hemorrhage from a falx meningioma after internal use of low-dose aspirin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9671138_2_8562", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9671138_2_8563", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9671138_2_8564", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9671138_2_8565", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9671138_2_8566", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9671138_2_8567", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9671138_2_8568", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9671138_2_8569", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9671138_2_8570", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9671138_2_8571", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9671138_2_8572", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9671138_2_8573", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9671138_2_8574", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9149614_2_8575", "context": "Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9149614_2_8576", "context": "Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9149614_2_8577", "context": "Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9149614_2_8578", "context": "Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9149614_2_8579", "context": "Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9149614_2_8580", "context": "Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9149614_2_8581", "context": "Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9149614_2_8582", "context": "Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8316494_1_8583", "context": "Severe abdominal pain in low dosage clofazimine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8316494_1_8584", "context": "Severe abdominal pain in low dosage clofazimine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8316494_1_8585", "context": "Severe abdominal pain in low dosage clofazimine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8316494_1_8586", "context": "Severe abdominal pain in low dosage clofazimine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8316494_1_8587", "context": "Severe abdominal pain in low dosage clofazimine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8316494_1_8588", "context": "Severe abdominal pain in low dosage clofazimine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8316494_1_8589", "context": "Severe abdominal pain in low dosage clofazimine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8316494_1_8590", "context": "Severe abdominal pain in low dosage clofazimine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12908837_1_8591", "context": "Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12908837_1_8592", "context": "Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12908837_1_8593", "context": "Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12908837_1_8594", "context": "Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12908837_1_8595", "context": "Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12908837_1_8596", "context": "Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12908837_1_8597", "context": "Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12908837_1_8598", "context": "Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6671350_2_8599", "context": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6671350_2_8600", "context": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6671350_2_8601", "context": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6671350_2_8602", "context": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6671350_2_8603", "context": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6671350_2_8604", "context": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6671350_2_8605", "context": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6671350_2_8606", "context": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9865241_2_8607", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "9865241_2_8608", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "9865241_2_8609", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "9865241_2_8610", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "9865241_2_8611", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "17090724_3_8612", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17090724_3_8613", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17090724_3_8614", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17090724_3_8615", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17090724_3_8616", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17090724_3_8617", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17090724_3_8618", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17090724_3_8619", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17090724_3_8620", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17090724_3_8621", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17090724_3_8622", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17090724_3_8623", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17090724_3_8624", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16132305_1_8625", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16132305_1_8626", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16132305_1_8627", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16132305_1_8628", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16132305_1_8629", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16132305_1_8630", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16132305_1_8631", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16132305_1_8632", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16132305_1_8633", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16132305_1_8634", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16132305_1_8635", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16132305_1_8636", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16132305_1_8637", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15836666_1_8638", "context": "Chronic fentanyl application induces adrenocortical insufficiency.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15836666_1_8639", "context": "Chronic fentanyl application induces adrenocortical insufficiency.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15836666_1_8640", "context": "Chronic fentanyl application induces adrenocortical insufficiency.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15836666_1_8641", "context": "Chronic fentanyl application induces adrenocortical insufficiency.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15836666_1_8642", "context": "Chronic fentanyl application induces adrenocortical insufficiency.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15836666_1_8643", "context": "Chronic fentanyl application induces adrenocortical insufficiency.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15836666_1_8644", "context": "Chronic fentanyl application induces adrenocortical insufficiency.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15836666_1_8645", "context": "Chronic fentanyl application induces adrenocortical insufficiency.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16132305_5_8646", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "16132305_5_8647", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "16132305_5_8648", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "16132305_5_8649", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "16132305_5_8650", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "16132305_5_8651", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "16132305_5_8652", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16132305_5_8653", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16132305_5_8654", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "16132305_5_8655", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16132305_5_8656", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16132305_5_8657", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "16132305_5_8658", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12927328_1_8659", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12927328_1_8660", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12927328_1_8661", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12927328_1_8662", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12927328_1_8663", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12927328_1_8664", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12927328_1_8665", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12927328_1_8666", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12927328_1_8667", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12927328_1_8668", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12927328_1_8669", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12927328_1_8670", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12927328_1_8671", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17016002_3_8672", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17016002_3_8673", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17016002_3_8674", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17016002_3_8675", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17016002_3_8676", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17016002_3_8677", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17016002_3_8678", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17016002_3_8679", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17016002_3_8680", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17016002_3_8681", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17016002_3_8682", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17016002_3_8683", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17016002_3_8684", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3343188_2_8685", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3343188_2_8686", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3343188_2_8687", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3343188_2_8688", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3343188_2_8689", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3343188_2_8690", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3343188_2_8691", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3343188_2_8692", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3343188_2_8693", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3343188_2_8694", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3343188_2_8695", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3343188_2_8696", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3343188_2_8697", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8151270_3_8698", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8151270_3_8699", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8151270_3_8700", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8151270_3_8701", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8151270_3_8702", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8151270_3_8703", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8151270_3_8704", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8151270_3_8705", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8151270_3_8706", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8151270_3_8707", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8151270_3_8708", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8151270_3_8709", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8151270_3_8710", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11352235_2_8711", "context": "Leflunomide-associated weight loss in rheumatoid arthritis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11352235_2_8712", "context": "Leflunomide-associated weight loss in rheumatoid arthritis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11352235_2_8713", "context": "Leflunomide-associated weight loss in rheumatoid arthritis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11352235_2_8714", "context": "Leflunomide-associated weight loss in rheumatoid arthritis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11352235_2_8715", "context": "Leflunomide-associated weight loss in rheumatoid arthritis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11352235_2_8716", "context": "Leflunomide-associated weight loss in rheumatoid arthritis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11352235_2_8717", "context": "Leflunomide-associated weight loss in rheumatoid arthritis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11352235_2_8718", "context": "Leflunomide-associated weight loss in rheumatoid arthritis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11450788_1_8719", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11450788_1_8720", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11450788_1_8721", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11450788_1_8722", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11450788_1_8723", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11450788_1_8724", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11450788_1_8725", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11450788_1_8726", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1756352_1_8727", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1756352_1_8728", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1756352_1_8729", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1756352_1_8730", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1756352_1_8731", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1756352_1_8732", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1756352_1_8733", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1756352_1_8734", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1756352_1_8735", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1756352_1_8736", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1756352_1_8737", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1756352_1_8738", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1756352_1_8739", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8308951_4_8740", "context": "Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8308951_4_8741", "context": "Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8308951_4_8742", "context": "Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8308951_4_8743", "context": "Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8308951_4_8744", "context": "Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8308951_4_8745", "context": "Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8308951_4_8746", "context": "Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8308951_4_8747", "context": "Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10752888_2_8748", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10752888_2_8749", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10752888_2_8750", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10752888_2_8751", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10752888_2_8752", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10752888_2_8753", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10752888_2_8754", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10752888_2_8755", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10752888_2_8756", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10752888_2_8757", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10752888_2_8758", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10752888_2_8759", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10752888_2_8760", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17619811_4_8761", "context": "Colchicine-induced rhabdomyolysis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17619811_4_8762", "context": "Colchicine-induced rhabdomyolysis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17619811_4_8763", "context": "Colchicine-induced rhabdomyolysis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17619811_4_8764", "context": "Colchicine-induced rhabdomyolysis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17619811_4_8765", "context": "Colchicine-induced rhabdomyolysis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17619811_4_8766", "context": "Colchicine-induced rhabdomyolysis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17619811_4_8767", "context": "Colchicine-induced rhabdomyolysis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17619811_4_8768", "context": "Colchicine-induced rhabdomyolysis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16678268_2_8769", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16678268_2_8770", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16678268_2_8771", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16678268_2_8772", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16678268_2_8773", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16678268_2_8774", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16678268_2_8775", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16678268_2_8776", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16678268_2_8777", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16678268_2_8778", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16678268_2_8779", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16678268_2_8780", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16678268_2_8781", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10573314_7_8782", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10573314_7_8783", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10573314_7_8784", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10573314_7_8785", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10573314_7_8786", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10573314_7_8787", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10573314_7_8788", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10573314_7_8789", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10573314_7_8790", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10573314_7_8791", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10573314_7_8792", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10573314_7_8793", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10573314_7_8794", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9007910_4_8795", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9007910_4_8796", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9007910_4_8797", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9007910_4_8798", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9007910_4_8799", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9007910_4_8800", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9007910_4_8801", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9007910_4_8802", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9007910_4_8803", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9007910_4_8804", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9007910_4_8805", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9007910_4_8806", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9007910_4_8807", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21515865_11_8808", "context": "According to the Drug Interaction Probability Scale, the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21515865_11_8809", "context": "According to the Drug Interaction Probability Scale, the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21515865_11_8810", "context": "According to the Drug Interaction Probability Scale, the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21515865_11_8811", "context": "According to the Drug Interaction Probability Scale, the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21515865_11_8812", "context": "According to the Drug Interaction Probability Scale, the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21515865_11_8813", "context": "According to the Drug Interaction Probability Scale, the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21515865_11_8814", "context": "According to the Drug Interaction Probability Scale, the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21515865_11_8815", "context": "According to the Drug Interaction Probability Scale, the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17921794_1_8816", "context": "Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17921794_1_8817", "context": "Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17921794_1_8818", "context": "Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17921794_1_8819", "context": "Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17921794_1_8820", "context": "Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17921794_1_8821", "context": "Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17921794_1_8822", "context": "Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17921794_1_8823", "context": "Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6671350_1_8824", "context": "Cephalosporins are most likely associated with Vitamin K deficiency.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6671350_1_8825", "context": "Cephalosporins are most likely associated with Vitamin K deficiency.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6671350_1_8826", "context": "Cephalosporins are most likely associated with Vitamin K deficiency.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6671350_1_8827", "context": "Cephalosporins are most likely associated with Vitamin K deficiency.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6671350_1_8828", "context": "Cephalosporins are most likely associated with Vitamin K deficiency.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6671350_1_8829", "context": "Cephalosporins are most likely associated with Vitamin K deficiency.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6671350_1_8830", "context": "Cephalosporins are most likely associated with Vitamin K deficiency.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6671350_1_8831", "context": "Cephalosporins are most likely associated with Vitamin K deficiency.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18042092_2_8832", "context": "Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18042092_2_8833", "context": "Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18042092_2_8834", "context": "Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18042092_2_8835", "context": "Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18042092_2_8836", "context": "Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18042092_2_8837", "context": "Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18042092_2_8838", "context": "Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18042092_2_8839", "context": "Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3084231_3_8840", "context": "Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3084231_3_8841", "context": "Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3084231_3_8842", "context": "Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3084231_3_8843", "context": "Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3084231_3_8844", "context": "Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17316891_1_8845", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17316891_1_8846", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17316891_1_8847", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17316891_1_8848", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17316891_1_8849", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17316891_1_8850", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17316891_1_8851", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17316891_1_8852", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17316891_1_8853", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17316891_1_8854", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17316891_1_8855", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17316891_1_8856", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17316891_1_8857", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18628507_3_8858", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18628507_3_8859", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18628507_3_8860", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18628507_3_8861", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18628507_3_8862", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18628507_3_8863", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18628507_3_8864", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18628507_3_8865", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18628507_3_8866", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18628507_3_8867", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18628507_3_8868", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18628507_3_8869", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18628507_3_8870", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18037876_2_8871", "context": "Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18037876_2_8872", "context": "Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18037876_2_8873", "context": "Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18037876_2_8874", "context": "Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18037876_2_8875", "context": "Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18037876_2_8876", "context": "Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18037876_2_8877", "context": "Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18037876_2_8878", "context": "Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9413296_1_8879", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9413296_1_8880", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9413296_1_8881", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9413296_1_8882", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9413296_1_8883", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9413296_1_8884", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9413296_1_8885", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9413296_1_8886", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9413296_1_8887", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9413296_1_8888", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9413296_1_8889", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9413296_1_8890", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9413296_1_8891", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18569796_2_8892", "context": "Nodular scleritis following alendronate therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18569796_2_8893", "context": "Nodular scleritis following alendronate therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18569796_2_8894", "context": "Nodular scleritis following alendronate therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18569796_2_8895", "context": "Nodular scleritis following alendronate therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18569796_2_8896", "context": "Nodular scleritis following alendronate therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18569796_2_8897", "context": "Nodular scleritis following alendronate therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18569796_2_8898", "context": "Nodular scleritis following alendronate therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18569796_2_8899", "context": "Nodular scleritis following alendronate therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10573314_8_8900", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "10573314_8_8901", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "10573314_8_8902", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "10573314_8_8903", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "10573314_8_8904", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "10573314_8_8905", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "10573314_8_8906", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10573314_8_8907", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10573314_8_8908", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10573314_8_8909", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10573314_8_8910", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10573314_8_8911", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "10573314_8_8912", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "2022118_1_8913", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2022118_1_8914", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2022118_1_8915", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2022118_1_8916", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2022118_1_8917", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2022118_1_8918", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2022118_1_8919", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2022118_1_8920", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2022118_1_8921", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2022118_1_8922", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2022118_1_8923", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2022118_1_8924", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2022118_1_8925", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "681921_2_8926", "context": "Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "681921_2_8927", "context": "Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "681921_2_8928", "context": "Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "681921_2_8929", "context": "Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "681921_2_8930", "context": "Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "681921_2_8931", "context": "Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "681921_2_8932", "context": "Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "681921_2_8933", "context": "Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10717401_1_8934", "context": "Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10717401_1_8935", "context": "Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10717401_1_8936", "context": "Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10717401_1_8937", "context": "Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10717401_1_8938", "context": "Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10717401_1_8939", "context": "Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10717401_1_8940", "context": "Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10717401_1_8941", "context": "Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4063627_3_8942", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "4063627_3_8943", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4063627_3_8944", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4063627_3_8945", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4063627_3_8946", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4063627_3_8947", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4063627_3_8948", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4063627_3_8949", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18262450_14_8950", "context": "This study provides the first evidence that co-administration of prolonged-release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "18262450_14_8951", "context": "This study provides the first evidence that co-administration of prolonged-release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18262450_14_8952", "context": "This study provides the first evidence that co-administration of prolonged-release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18262450_14_8953", "context": "This study provides the first evidence that co-administration of prolonged-release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18262450_14_8954", "context": "This study provides the first evidence that co-administration of prolonged-release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18262450_14_8955", "context": "This study provides the first evidence that co-administration of prolonged-release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18262450_14_8956", "context": "This study provides the first evidence that co-administration of prolonged-release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "18262450_14_8957", "context": "This study provides the first evidence that co-administration of prolonged-release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17504225_4_8958", "context": "In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17504225_4_8959", "context": "In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17504225_4_8960", "context": "In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17504225_4_8961", "context": "In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17504225_4_8962", "context": "In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17504225_4_8963", "context": "In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17504225_4_8964", "context": "In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17504225_4_8965", "context": "In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10190739_1_8966", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10190739_1_8967", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10190739_1_8968", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10190739_1_8969", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10190739_1_8970", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10190739_1_8971", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10190739_1_8972", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10190739_1_8973", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10190739_1_8974", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10190739_1_8975", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10190739_1_8976", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10190739_1_8977", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10190739_1_8978", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16018164_3_8979", "context": "Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16018164_3_8980", "context": "Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16018164_3_8981", "context": "Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16018164_3_8982", "context": "Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16018164_3_8983", "context": "Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16018164_3_8984", "context": "Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16018164_3_8985", "context": "Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16018164_3_8986", "context": "Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16490518_1_8987", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16490518_1_8988", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16490518_1_8989", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16490518_1_8990", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16490518_1_8991", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16490518_1_8992", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16490518_1_8993", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16490518_1_8994", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16490518_1_8995", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16490518_1_8996", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16490518_1_8997", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16490518_1_8998", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16490518_1_8999", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7369302_2_9000", "context": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7369302_2_9001", "context": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7369302_2_9002", "context": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7369302_2_9003", "context": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7369302_2_9004", "context": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7369302_2_9005", "context": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7369302_2_9006", "context": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7369302_2_9007", "context": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10682234_6_9008", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10682234_6_9009", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10682234_6_9010", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10682234_6_9011", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10682234_6_9012", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10682234_6_9013", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10682234_6_9014", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10682234_6_9015", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10682234_6_9016", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10682234_6_9017", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10682234_6_9018", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10682234_6_9019", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10682234_6_9020", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9777751_1_9021", "context": "Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9777751_1_9022", "context": "Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9777751_1_9023", "context": "Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9777751_1_9024", "context": "Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9777751_1_9025", "context": "Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9777751_1_9026", "context": "Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9777751_1_9027", "context": "Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9777751_1_9028", "context": "Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18751717_2_9029", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18751717_2_9030", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18751717_2_9031", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18751717_2_9032", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18751717_2_9033", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18751717_2_9034", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18751717_2_9035", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18751717_2_9036", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18751717_2_9037", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18751717_2_9038", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18751717_2_9039", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18751717_2_9040", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18751717_2_9041", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14522628_2_9042", "context": "Skin rash and splinter hemorrhages from ganciclovir.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14522628_2_9043", "context": "Skin rash and splinter hemorrhages from ganciclovir.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14522628_2_9044", "context": "Skin rash and splinter hemorrhages from ganciclovir.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14522628_2_9045", "context": "Skin rash and splinter hemorrhages from ganciclovir.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14522628_2_9046", "context": "Skin rash and splinter hemorrhages from ganciclovir.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14522628_2_9047", "context": "Skin rash and splinter hemorrhages from ganciclovir.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14522628_2_9048", "context": "Skin rash and splinter hemorrhages from ganciclovir.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14522628_2_9049", "context": "Skin rash and splinter hemorrhages from ganciclovir.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15368548_5_9050", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15368548_5_9051", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15368548_5_9052", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15368548_5_9053", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15368548_5_9054", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15368548_5_9055", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15368548_5_9056", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15368548_5_9057", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15368548_5_9058", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15368548_5_9059", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15368548_5_9060", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15368548_5_9061", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15368548_5_9062", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11804071_3_9063", "context": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11804071_3_9064", "context": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11804071_3_9065", "context": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11804071_3_9066", "context": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11804071_3_9067", "context": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11804071_3_9068", "context": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11804071_3_9069", "context": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11804071_3_9070", "context": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10646879_3_9071", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "10646879_3_9072", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10646879_3_9073", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10646879_3_9074", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10646879_3_9075", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10646879_3_9076", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10646879_3_9077", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "10646879_3_9078", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18354950_2_9079", "context": "Hyponatraemia during low-dose carbamazepine therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18354950_2_9080", "context": "Hyponatraemia during low-dose carbamazepine therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18354950_2_9081", "context": "Hyponatraemia during low-dose carbamazepine therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18354950_2_9082", "context": "Hyponatraemia during low-dose carbamazepine therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18354950_2_9083", "context": "Hyponatraemia during low-dose carbamazepine therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18354950_2_9084", "context": "Hyponatraemia during low-dose carbamazepine therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18354950_2_9085", "context": "Hyponatraemia during low-dose carbamazepine therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18354950_2_9086", "context": "Hyponatraemia during low-dose carbamazepine therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16697705_1_9087", "context": "Acute coronary syndrome induced by capecitabine therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16697705_1_9088", "context": "Acute coronary syndrome induced by capecitabine therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16697705_1_9089", "context": "Acute coronary syndrome induced by capecitabine therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16697705_1_9090", "context": "Acute coronary syndrome induced by capecitabine therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16697705_1_9091", "context": "Acute coronary syndrome induced by capecitabine therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16697705_1_9092", "context": "Acute coronary syndrome induced by capecitabine therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16697705_1_9093", "context": "Acute coronary syndrome induced by capecitabine therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16697705_1_9094", "context": "Acute coronary syndrome induced by capecitabine therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3171334_1_9095", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3171334_1_9096", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3171334_1_9097", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3171334_1_9098", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3171334_1_9099", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3171334_1_9100", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3171334_1_9101", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3171334_1_9102", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3171334_1_9103", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3171334_1_9104", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3171334_1_9105", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3171334_1_9106", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3171334_1_9107", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16357738_3_9108", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16357738_3_9109", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16357738_3_9110", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16357738_3_9111", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16357738_3_9112", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16357738_3_9113", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16357738_3_9114", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16357738_3_9115", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16357738_3_9116", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16357738_3_9117", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16357738_3_9118", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16357738_3_9119", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16357738_3_9120", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12507063_1_9121", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12507063_1_9122", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12507063_1_9123", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12507063_1_9124", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12507063_1_9125", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12507063_1_9126", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12507063_1_9127", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12507063_1_9128", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12507063_1_9129", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12507063_1_9130", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12507063_1_9131", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12507063_1_9132", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12507063_1_9133", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4014301_2_9134", "context": "Self-limited edema is a well-recognized complication of insulin therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "4014301_2_9135", "context": "Self-limited edema is a well-recognized complication of insulin therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4014301_2_9136", "context": "Self-limited edema is a well-recognized complication of insulin therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4014301_2_9137", "context": "Self-limited edema is a well-recognized complication of insulin therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4014301_2_9138", "context": "Self-limited edema is a well-recognized complication of insulin therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4014301_2_9139", "context": "Self-limited edema is a well-recognized complication of insulin therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4014301_2_9140", "context": "Self-limited edema is a well-recognized complication of insulin therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4014301_2_9141", "context": "Self-limited edema is a well-recognized complication of insulin therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15061230_1_9142", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15061230_1_9143", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15061230_1_9144", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15061230_1_9145", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15061230_1_9146", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15061230_1_9147", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15061230_1_9148", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15061230_1_9149", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15061230_1_9150", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15061230_1_9151", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15061230_1_9152", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15061230_1_9153", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15061230_1_9154", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12397859_1_9155", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12397859_1_9156", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12397859_1_9157", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12397859_1_9158", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12397859_1_9159", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12397859_1_9160", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12397859_1_9161", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12397859_1_9162", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12397859_1_9163", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12397859_1_9164", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12397859_1_9165", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12397859_1_9166", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12397859_1_9167", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3156465_1_9168", "context": "Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3156465_1_9169", "context": "Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3156465_1_9170", "context": "Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3156465_1_9171", "context": "Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3156465_1_9172", "context": "Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3156465_1_9173", "context": "Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3156465_1_9174", "context": "Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3156465_1_9175", "context": "Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12022905_6_9176", "context": "The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12022905_6_9177", "context": "The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12022905_6_9178", "context": "The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12022905_6_9179", "context": "The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12022905_6_9180", "context": "The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12022905_6_9181", "context": "The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12022905_6_9182", "context": "The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12022905_6_9183", "context": "The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6572542_4_9184", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6572542_4_9185", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6572542_4_9186", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6572542_4_9187", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6572542_4_9188", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6572542_4_9189", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6572542_4_9190", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6572542_4_9191", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6572542_4_9192", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6572542_4_9193", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6572542_4_9194", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6572542_4_9195", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6572542_4_9196", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11724089_1_9197", "context": "CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11724089_1_9198", "context": "CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11724089_1_9199", "context": "CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11724089_1_9200", "context": "CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11724089_1_9201", "context": "CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11724089_1_9202", "context": "CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11724089_1_9203", "context": "CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11724089_1_9204", "context": "CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18755414_3_9205", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18755414_3_9206", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18755414_3_9207", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18755414_3_9208", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18755414_3_9209", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18755414_3_9210", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18755414_3_9211", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18755414_3_9212", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10225085_2_9213", "context": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10225085_2_9214", "context": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10225085_2_9215", "context": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10225085_2_9216", "context": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10225085_2_9217", "context": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10225085_2_9218", "context": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10225085_2_9219", "context": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10225085_2_9220", "context": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10812579_3_9221", "context": "Nonconvulsive status epilepticus: the role of morphine and its antagonist.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10812579_3_9222", "context": "Nonconvulsive status epilepticus: the role of morphine and its antagonist.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10812579_3_9223", "context": "Nonconvulsive status epilepticus: the role of morphine and its antagonist.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10812579_3_9224", "context": "Nonconvulsive status epilepticus: the role of morphine and its antagonist.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10812579_3_9225", "context": "Nonconvulsive status epilepticus: the role of morphine and its antagonist.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10812579_3_9226", "context": "Nonconvulsive status epilepticus: the role of morphine and its antagonist.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10812579_3_9227", "context": "Nonconvulsive status epilepticus: the role of morphine and its antagonist.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10812579_3_9228", "context": "Nonconvulsive status epilepticus: the role of morphine and its antagonist.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8579054_1_9229", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8579054_1_9230", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8579054_1_9231", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8579054_1_9232", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8579054_1_9233", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8579054_1_9234", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8579054_1_9235", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8579054_1_9236", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8579054_1_9237", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8579054_1_9238", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8579054_1_9239", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8579054_1_9240", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8579054_1_9241", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10698143_1_9242", "context": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10698143_1_9243", "context": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10698143_1_9244", "context": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10698143_1_9245", "context": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10698143_1_9246", "context": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10698143_1_9247", "context": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10698143_1_9248", "context": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10698143_1_9249", "context": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20465622_2_9250", "context": "BACKGROUND: Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20465622_2_9251", "context": "BACKGROUND: Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20465622_2_9252", "context": "BACKGROUND: Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20465622_2_9253", "context": "BACKGROUND: Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20465622_2_9254", "context": "BACKGROUND: Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20465622_2_9255", "context": "BACKGROUND: Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20465622_2_9256", "context": "BACKGROUND: Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20465622_2_9257", "context": "BACKGROUND: Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18675768_4_9258", "context": "The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18675768_4_9259", "context": "The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18675768_4_9260", "context": "The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18675768_4_9261", "context": "The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18675768_4_9262", "context": "The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18675768_4_9263", "context": "The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18675768_4_9264", "context": "The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18675768_4_9265", "context": "The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7949255_1_9266", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7949255_1_9267", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7949255_1_9268", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7949255_1_9269", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7949255_1_9270", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7949255_1_9271", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7949255_1_9272", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7949255_1_9273", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7949255_1_9274", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7949255_1_9275", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7949255_1_9276", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7949255_1_9277", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7949255_1_9278", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18675768_13_9279", "context": "This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18675768_13_9280", "context": "This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18675768_13_9281", "context": "This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18675768_13_9282", "context": "This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18675768_13_9283", "context": "This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18675768_13_9284", "context": "This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18675768_13_9285", "context": "This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18675768_13_9286", "context": "This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1082426_1_9287", "context": "Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1082426_1_9288", "context": "Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1082426_1_9289", "context": "Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1082426_1_9290", "context": "Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1082426_1_9291", "context": "Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1082426_1_9292", "context": "Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1082426_1_9293", "context": "Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1082426_1_9294", "context": "Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16685007_1_9295", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "16685007_1_9296", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "16685007_1_9297", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "16685007_1_9298", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "16685007_1_9299", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "16685007_1_9300", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "16685007_1_9301", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16685007_1_9302", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16685007_1_9303", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "16685007_1_9304", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16685007_1_9305", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16685007_1_9306", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "16685007_1_9307", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8250714_1_9308", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8250714_1_9309", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8250714_1_9310", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8250714_1_9311", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8250714_1_9312", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8250714_1_9313", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8250714_1_9314", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8250714_1_9315", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8250714_1_9316", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8250714_1_9317", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8250714_1_9318", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8250714_1_9319", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8250714_1_9320", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12022905_1_9321", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12022905_1_9322", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12022905_1_9323", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12022905_1_9324", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12022905_1_9325", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12022905_1_9326", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12022905_1_9327", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12022905_1_9328", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12022905_1_9329", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12022905_1_9330", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12022905_1_9331", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12022905_1_9332", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12022905_1_9333", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6401771_2_9334", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6401771_2_9335", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6401771_2_9336", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6401771_2_9337", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6401771_2_9338", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6401771_2_9339", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6401771_2_9340", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6401771_2_9341", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6401771_2_9342", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6401771_2_9343", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6401771_2_9344", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6401771_2_9345", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6401771_2_9346", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9870779_1_9347", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9870779_1_9348", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9870779_1_9349", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9870779_1_9350", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9870779_1_9351", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9870779_1_9352", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9870779_1_9353", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9870779_1_9354", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9870779_1_9355", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9870779_1_9356", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9870779_1_9357", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9870779_1_9358", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9870779_1_9359", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9627209_1_9360", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9627209_1_9361", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9627209_1_9362", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9627209_1_9363", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9627209_1_9364", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9627209_1_9365", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9627209_1_9366", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9627209_1_9367", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7355327_3_9368", "context": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7355327_3_9369", "context": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7355327_3_9370", "context": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7355327_3_9371", "context": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7355327_3_9372", "context": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7355327_3_9373", "context": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7355327_3_9374", "context": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7355327_3_9375", "context": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6362443_2_9376", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6362443_2_9377", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6362443_2_9378", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6362443_2_9379", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6362443_2_9380", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6362443_2_9381", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6362443_2_9382", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6362443_2_9383", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6362443_2_9384", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6362443_2_9385", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6362443_2_9386", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6362443_2_9387", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6362443_2_9388", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6725214_2_9389", "context": "Priapism associated with trazodone therapy: case report.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6725214_2_9390", "context": "Priapism associated with trazodone therapy: case report.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6725214_2_9391", "context": "Priapism associated with trazodone therapy: case report.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6725214_2_9392", "context": "Priapism associated with trazodone therapy: case report.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6725214_2_9393", "context": "Priapism associated with trazodone therapy: case report.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6725214_2_9394", "context": "Priapism associated with trazodone therapy: case report.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6725214_2_9395", "context": "Priapism associated with trazodone therapy: case report.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6725214_2_9396", "context": "Priapism associated with trazodone therapy: case report.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7639655_3_9397", "context": "OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7639655_3_9398", "context": "OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7639655_3_9399", "context": "OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7639655_3_9400", "context": "OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7639655_3_9401", "context": "OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7639655_3_9402", "context": "OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7639655_3_9403", "context": "OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7639655_3_9404", "context": "OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8850251_4_9405", "context": "Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8850251_4_9406", "context": "Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8850251_4_9407", "context": "Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8850251_4_9408", "context": "Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8850251_4_9409", "context": "Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8850251_4_9410", "context": "Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8850251_4_9411", "context": "Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8850251_4_9412", "context": "Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15927910_2_9413", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15927910_2_9414", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15927910_2_9415", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15927910_2_9416", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15927910_2_9417", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15927910_2_9418", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15927910_2_9419", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15927910_2_9420", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23115227_6_9421", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "23115227_6_9422", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "23115227_6_9423", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "23115227_6_9424", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "23115227_6_9425", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "23115227_6_9426", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "23115227_6_9427", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "23115227_6_9428", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "23115227_6_9429", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "23115227_6_9430", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23115227_6_9431", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "23115227_6_9432", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "23115227_6_9433", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "3806824_2_9434", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3806824_2_9435", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3806824_2_9436", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3806824_2_9437", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3806824_2_9438", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3806824_2_9439", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3806824_2_9440", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3806824_2_9441", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3806824_2_9442", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3806824_2_9443", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3806824_2_9444", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3806824_2_9445", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3806824_2_9446", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6865827_3_9447", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6865827_3_9448", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6865827_3_9449", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6865827_3_9450", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6865827_3_9451", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6865827_3_9452", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6865827_3_9453", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6865827_3_9454", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6865827_3_9455", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6865827_3_9456", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6865827_3_9457", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6865827_3_9458", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6865827_3_9459", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15522120_1_9460", "context": "Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15522120_1_9461", "context": "Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15522120_1_9462", "context": "Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15522120_1_9463", "context": "Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15522120_1_9464", "context": "Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15522120_1_9465", "context": "Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15522120_1_9466", "context": "Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15522120_1_9467", "context": "Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18262450_11_9468", "context": "Oxycodone-gabapentin co-administration was associated with less escape medication use (P = 0.03) and fewer nights of disturbed sleep (P < 0.05).", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18262450_11_9469", "context": "Oxycodone-gabapentin co-administration was associated with less escape medication use (P = 0.03) and fewer nights of disturbed sleep (P < 0.05).", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18262450_11_9470", "context": "Oxycodone-gabapentin co-administration was associated with less escape medication use (P = 0.03) and fewer nights of disturbed sleep (P < 0.05).", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18262450_11_9471", "context": "Oxycodone-gabapentin co-administration was associated with less escape medication use (P = 0.03) and fewer nights of disturbed sleep (P < 0.05).", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18262450_11_9472", "context": "Oxycodone-gabapentin co-administration was associated with less escape medication use (P = 0.03) and fewer nights of disturbed sleep (P < 0.05).", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18262450_11_9473", "context": "Oxycodone-gabapentin co-administration was associated with less escape medication use (P = 0.03) and fewer nights of disturbed sleep (P < 0.05).", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18262450_11_9474", "context": "Oxycodone-gabapentin co-administration was associated with less escape medication use (P = 0.03) and fewer nights of disturbed sleep (P < 0.05).", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18262450_11_9475", "context": "Oxycodone-gabapentin co-administration was associated with less escape medication use (P = 0.03) and fewer nights of disturbed sleep (P < 0.05).", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6618859_2_9476", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6618859_2_9477", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6618859_2_9478", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6618859_2_9479", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6618859_2_9480", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6618859_2_9481", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6618859_2_9482", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6618859_2_9483", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6618859_2_9484", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6618859_2_9485", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6618859_2_9486", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6618859_2_9487", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6618859_2_9488", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3542612_1_9489", "context": "Captopril-induced lichen planus pemphigoides with pemphigus-like features.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3542612_1_9490", "context": "Captopril-induced lichen planus pemphigoides with pemphigus-like features.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3542612_1_9491", "context": "Captopril-induced lichen planus pemphigoides with pemphigus-like features.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3542612_1_9492", "context": "Captopril-induced lichen planus pemphigoides with pemphigus-like features.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3542612_1_9493", "context": "Captopril-induced lichen planus pemphigoides with pemphigus-like features.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3542612_1_9494", "context": "Captopril-induced lichen planus pemphigoides with pemphigus-like features.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3542612_1_9495", "context": "Captopril-induced lichen planus pemphigoides with pemphigus-like features.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3542612_1_9496", "context": "Captopril-induced lichen planus pemphigoides with pemphigus-like features.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6873616_3_9497", "context": "The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6873616_3_9498", "context": "The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6873616_3_9499", "context": "The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6873616_3_9500", "context": "The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6873616_3_9501", "context": "The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6873616_3_9502", "context": "The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6873616_3_9503", "context": "The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6873616_3_9504", "context": "The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8523340_2_9505", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "8523340_2_9506", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "8523340_2_9507", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "8523340_2_9508", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "8523340_2_9509", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "8523340_2_9510", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "8523340_2_9511", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8523340_2_9512", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8523340_2_9513", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8523340_2_9514", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8523340_2_9515", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8523340_2_9516", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "8523340_2_9517", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "23970584_3_9518", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "23970584_3_9519", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "23970584_3_9520", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "23970584_3_9521", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "23970584_3_9522", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "23970584_3_9523", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "23970584_3_9524", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "23970584_3_9525", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "23970584_3_9526", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "23970584_3_9527", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23970584_3_9528", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "23970584_3_9529", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "23970584_3_9530", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "6731466_2_9531", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6731466_2_9532", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6731466_2_9533", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6731466_2_9534", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6731466_2_9535", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6731466_2_9536", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6731466_2_9537", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6731466_2_9538", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6731466_2_9539", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6731466_2_9540", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6731466_2_9541", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6731466_2_9542", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6731466_2_9543", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11341670_1_9544", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11341670_1_9545", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11341670_1_9546", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11341670_1_9547", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11341670_1_9548", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11341670_1_9549", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11341670_1_9550", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11341670_1_9551", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11341670_1_9552", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11341670_1_9553", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11341670_1_9554", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11341670_1_9555", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11341670_1_9556", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10682234_7_9557", "context": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "10682234_7_9558", "context": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10682234_7_9559", "context": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10682234_7_9560", "context": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10682234_7_9561", "context": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10682234_7_9562", "context": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10682234_7_9563", "context": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "10682234_7_9564", "context": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "19318596_1_9565", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19318596_1_9566", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19318596_1_9567", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19318596_1_9568", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19318596_1_9569", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19318596_1_9570", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19318596_1_9571", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19318596_1_9572", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19318596_1_9573", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19318596_1_9574", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19318596_1_9575", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19318596_1_9576", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19318596_1_9577", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3171334_5_9578", "context": "Visual loss after a single small dose of vincristine has never been reported.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3171334_5_9579", "context": "Visual loss after a single small dose of vincristine has never been reported.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3171334_5_9580", "context": "Visual loss after a single small dose of vincristine has never been reported.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3171334_5_9581", "context": "Visual loss after a single small dose of vincristine has never been reported.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3171334_5_9582", "context": "Visual loss after a single small dose of vincristine has never been reported.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3171334_5_9583", "context": "Visual loss after a single small dose of vincristine has never been reported.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3171334_5_9584", "context": "Visual loss after a single small dose of vincristine has never been reported.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3171334_5_9585", "context": "Visual loss after a single small dose of vincristine has never been reported.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12786839_2_9586", "context": "Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12786839_2_9587", "context": "Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12786839_2_9588", "context": "Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12786839_2_9589", "context": "Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12786839_2_9590", "context": "Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12786839_2_9591", "context": "Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12786839_2_9592", "context": "Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12786839_2_9593", "context": "Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23970584_8_9594", "context": "Clinicians should be aware of raltegravir-induced DRESS syndrome as well as the potential for drug-drug interactions due to protease inhibitor-based therapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "23970584_8_9595", "context": "Clinicians should be aware of raltegravir-induced DRESS syndrome as well as the potential for drug-drug interactions due to protease inhibitor-based therapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "23970584_8_9596", "context": "Clinicians should be aware of raltegravir-induced DRESS syndrome as well as the potential for drug-drug interactions due to protease inhibitor-based therapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "23970584_8_9597", "context": "Clinicians should be aware of raltegravir-induced DRESS syndrome as well as the potential for drug-drug interactions due to protease inhibitor-based therapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "23970584_8_9598", "context": "Clinicians should be aware of raltegravir-induced DRESS syndrome as well as the potential for drug-drug interactions due to protease inhibitor-based therapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23970584_8_9599", "context": "Clinicians should be aware of raltegravir-induced DRESS syndrome as well as the potential for drug-drug interactions due to protease inhibitor-based therapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "23970584_8_9600", "context": "Clinicians should be aware of raltegravir-induced DRESS syndrome as well as the potential for drug-drug interactions due to protease inhibitor-based therapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "23970584_8_9601", "context": "Clinicians should be aware of raltegravir-induced DRESS syndrome as well as the potential for drug-drug interactions due to protease inhibitor-based therapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12504711_2_9602", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12504711_2_9603", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12504711_2_9604", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12504711_2_9605", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12504711_2_9606", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12504711_2_9607", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12504711_2_9608", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12504711_2_9609", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12504711_2_9610", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12504711_2_9611", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12504711_2_9612", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12504711_2_9613", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12504711_2_9614", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12659609_9_9615", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12659609_9_9616", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12659609_9_9617", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12659609_9_9618", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12659609_9_9619", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12659609_9_9620", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12659609_9_9621", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12659609_9_9622", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12659609_9_9623", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12659609_9_9624", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12659609_9_9625", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12659609_9_9626", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12659609_9_9627", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20925534_15_9628", "context": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20925534_15_9629", "context": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20925534_15_9630", "context": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20925534_15_9631", "context": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20925534_15_9632", "context": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20925534_15_9633", "context": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20925534_15_9634", "context": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20925534_15_9635", "context": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18855892_2_9636", "context": "Anaphylactic/anaphylactoid reactions to methotrexate are rare.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18855892_2_9637", "context": "Anaphylactic/anaphylactoid reactions to methotrexate are rare.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18855892_2_9638", "context": "Anaphylactic/anaphylactoid reactions to methotrexate are rare.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18855892_2_9639", "context": "Anaphylactic/anaphylactoid reactions to methotrexate are rare.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18855892_2_9640", "context": "Anaphylactic/anaphylactoid reactions to methotrexate are rare.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18855892_2_9641", "context": "Anaphylactic/anaphylactoid reactions to methotrexate are rare.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18855892_2_9642", "context": "Anaphylactic/anaphylactoid reactions to methotrexate are rare.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18855892_2_9643", "context": "Anaphylactic/anaphylactoid reactions to methotrexate are rare.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1422497_3_9644", "context": "Continuous bladder irrigation of a 1% alum solution is a simple and generally safe method of chemical cautery to treat the bleeding urothelium.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "1422497_3_9645", "context": "Continuous bladder irrigation of a 1% alum solution is a simple and generally safe method of chemical cautery to treat the bleeding urothelium.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "1422497_3_9646", "context": "Continuous bladder irrigation of a 1% alum solution is a simple and generally safe method of chemical cautery to treat the bleeding urothelium.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "1422497_3_9647", "context": "Continuous bladder irrigation of a 1% alum solution is a simple and generally safe method of chemical cautery to treat the bleeding urothelium.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "1422497_3_9648", "context": "Continuous bladder irrigation of a 1% alum solution is a simple and generally safe method of chemical cautery to treat the bleeding urothelium.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1422497_3_9649", "context": "Continuous bladder irrigation of a 1% alum solution is a simple and generally safe method of chemical cautery to treat the bleeding urothelium.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "1422497_3_9650", "context": "Continuous bladder irrigation of a 1% alum solution is a simple and generally safe method of chemical cautery to treat the bleeding urothelium.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "1422497_3_9651", "context": "Continuous bladder irrigation of a 1% alum solution is a simple and generally safe method of chemical cautery to treat the bleeding urothelium.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10759907_3_9652", "context": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10759907_3_9653", "context": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10759907_3_9654", "context": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10759907_3_9655", "context": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10759907_3_9656", "context": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10759907_3_9657", "context": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10759907_3_9658", "context": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10759907_3_9659", "context": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1756352_2_9660", "context": "Delusional parasitosis associated with phenelzine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1756352_2_9661", "context": "Delusional parasitosis associated with phenelzine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1756352_2_9662", "context": "Delusional parasitosis associated with phenelzine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1756352_2_9663", "context": "Delusional parasitosis associated with phenelzine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1756352_2_9664", "context": "Delusional parasitosis associated with phenelzine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1756352_2_9665", "context": "Delusional parasitosis associated with phenelzine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1756352_2_9666", "context": "Delusional parasitosis associated with phenelzine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1756352_2_9667", "context": "Delusional parasitosis associated with phenelzine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8610807_2_9668", "context": "CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8610807_2_9669", "context": "CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8610807_2_9670", "context": "CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8610807_2_9671", "context": "CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8610807_2_9672", "context": "CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8610807_2_9673", "context": "CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8610807_2_9674", "context": "CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8610807_2_9675", "context": "CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9007910_1_9676", "context": "Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9007910_1_9677", "context": "Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9007910_1_9678", "context": "Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9007910_1_9679", "context": "Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9007910_1_9680", "context": "Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9007910_1_9681", "context": "Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9007910_1_9682", "context": "Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9007910_1_9683", "context": "Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16393774_2_9684", "context": "Interferon-beta (IFN-beta) is a type I interferon used in the management of multiple sclerosis.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "16393774_2_9685", "context": "Interferon-beta (IFN-beta) is a type I interferon used in the management of multiple sclerosis.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16393774_2_9686", "context": "Interferon-beta (IFN-beta) is a type I interferon used in the management of multiple sclerosis.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16393774_2_9687", "context": "Interferon-beta (IFN-beta) is a type I interferon used in the management of multiple sclerosis.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "16393774_2_9688", "context": "Interferon-beta (IFN-beta) is a type I interferon used in the management of multiple sclerosis.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16393774_2_9689", "context": "Interferon-beta (IFN-beta) is a type I interferon used in the management of multiple sclerosis.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16393774_2_9690", "context": "Interferon-beta (IFN-beta) is a type I interferon used in the management of multiple sclerosis.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "16393774_2_9691", "context": "Interferon-beta (IFN-beta) is a type I interferon used in the management of multiple sclerosis.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18071101_2_9692", "context": "Quetiapine-induced leucopenia and thrombocytopenia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18071101_2_9693", "context": "Quetiapine-induced leucopenia and thrombocytopenia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18071101_2_9694", "context": "Quetiapine-induced leucopenia and thrombocytopenia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18071101_2_9695", "context": "Quetiapine-induced leucopenia and thrombocytopenia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18071101_2_9696", "context": "Quetiapine-induced leucopenia and thrombocytopenia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18071101_2_9697", "context": "Quetiapine-induced leucopenia and thrombocytopenia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18071101_2_9698", "context": "Quetiapine-induced leucopenia and thrombocytopenia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18071101_2_9699", "context": "Quetiapine-induced leucopenia and thrombocytopenia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18425523_2_9700", "context": "CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18425523_2_9701", "context": "CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18425523_2_9702", "context": "CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18425523_2_9703", "context": "CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18425523_2_9704", "context": "CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18425523_2_9705", "context": "CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18425523_2_9706", "context": "CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18425523_2_9707", "context": "CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18425523_1_9708", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18425523_1_9709", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18425523_1_9710", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18425523_1_9711", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18425523_1_9712", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18425523_1_9713", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18425523_1_9714", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18425523_1_9715", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18425523_1_9716", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18425523_1_9717", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18425523_1_9718", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18425523_1_9719", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18425523_1_9720", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20234160_2_9721", "context": "Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as \"red man syndrome\" and anaphylaxis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20234160_2_9722", "context": "Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as \"red man syndrome\" and anaphylaxis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20234160_2_9723", "context": "Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as \"red man syndrome\" and anaphylaxis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20234160_2_9724", "context": "Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as \"red man syndrome\" and anaphylaxis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20234160_2_9725", "context": "Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as \"red man syndrome\" and anaphylaxis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20234160_2_9726", "context": "Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as \"red man syndrome\" and anaphylaxis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20234160_2_9727", "context": "Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as \"red man syndrome\" and anaphylaxis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20234160_2_9728", "context": "Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as \"red man syndrome\" and anaphylaxis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15093850_2_9729", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15093850_2_9730", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15093850_2_9731", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15093850_2_9732", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15093850_2_9733", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15093850_2_9734", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15093850_2_9735", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15093850_2_9736", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15093850_2_9737", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15093850_2_9738", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15093850_2_9739", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15093850_2_9740", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15093850_2_9741", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16357738_1_9742", "context": "Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16357738_1_9743", "context": "Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16357738_1_9744", "context": "Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16357738_1_9745", "context": "Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16357738_1_9746", "context": "Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16357738_1_9747", "context": "Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16357738_1_9748", "context": "Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16357738_1_9749", "context": "Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12854039_2_9750", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12854039_2_9751", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12854039_2_9752", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12854039_2_9753", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12854039_2_9754", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12854039_2_9755", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12854039_2_9756", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12854039_2_9757", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12854039_2_9758", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12854039_2_9759", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12854039_2_9760", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12854039_2_9761", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12854039_2_9762", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9550246_1_9763", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9550246_1_9764", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9550246_1_9765", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9550246_1_9766", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9550246_1_9767", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9550246_1_9768", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9550246_1_9769", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9550246_1_9770", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9550246_1_9771", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9550246_1_9772", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9550246_1_9773", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9550246_1_9774", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9550246_1_9775", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16393774_3_9776", "context": "Therapy with IFN-beta has rarely been associated with the development of autoimmune disorders.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16393774_3_9777", "context": "Therapy with IFN-beta has rarely been associated with the development of autoimmune disorders.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16393774_3_9778", "context": "Therapy with IFN-beta has rarely been associated with the development of autoimmune disorders.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16393774_3_9779", "context": "Therapy with IFN-beta has rarely been associated with the development of autoimmune disorders.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16393774_3_9780", "context": "Therapy with IFN-beta has rarely been associated with the development of autoimmune disorders.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16393774_3_9781", "context": "Therapy with IFN-beta has rarely been associated with the development of autoimmune disorders.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16393774_3_9782", "context": "Therapy with IFN-beta has rarely been associated with the development of autoimmune disorders.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16393774_3_9783", "context": "Therapy with IFN-beta has rarely been associated with the development of autoimmune disorders.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18977778_1_9784", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18977778_1_9785", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18977778_1_9786", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18977778_1_9787", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18977778_1_9788", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18977778_1_9789", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18977778_1_9790", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18977778_1_9791", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18977778_1_9792", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18977778_1_9793", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18977778_1_9794", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18977778_1_9795", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18977778_1_9796", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18354950_1_9797", "context": "Hyponatraemia developed after rechallenge with controlled release carbamazepine.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18354950_1_9798", "context": "Hyponatraemia developed after rechallenge with controlled release carbamazepine.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18354950_1_9799", "context": "Hyponatraemia developed after rechallenge with controlled release carbamazepine.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18354950_1_9800", "context": "Hyponatraemia developed after rechallenge with controlled release carbamazepine.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18354950_1_9801", "context": "Hyponatraemia developed after rechallenge with controlled release carbamazepine.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18354950_1_9802", "context": "Hyponatraemia developed after rechallenge with controlled release carbamazepine.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18354950_1_9803", "context": "Hyponatraemia developed after rechallenge with controlled release carbamazepine.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18354950_1_9804", "context": "Hyponatraemia developed after rechallenge with controlled release carbamazepine.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18505911_1_9805", "context": "Azathioprine-induced warfarin resistance.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18505911_1_9806", "context": "Azathioprine-induced warfarin resistance.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18505911_1_9807", "context": "Azathioprine-induced warfarin resistance.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18505911_1_9808", "context": "Azathioprine-induced warfarin resistance.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18505911_1_9809", "context": "Azathioprine-induced warfarin resistance.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18505911_1_9810", "context": "Azathioprine-induced warfarin resistance.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18505911_1_9811", "context": "Azathioprine-induced warfarin resistance.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18505911_1_9812", "context": "Azathioprine-induced warfarin resistance.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3084231_2_9813", "context": "Reversible valproic acid-induced dementia: a case report.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3084231_2_9814", "context": "Reversible valproic acid-induced dementia: a case report.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3084231_2_9815", "context": "Reversible valproic acid-induced dementia: a case report.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3084231_2_9816", "context": "Reversible valproic acid-induced dementia: a case report.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3084231_2_9817", "context": "Reversible valproic acid-induced dementia: a case report.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3084231_2_9818", "context": "Reversible valproic acid-induced dementia: a case report.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3084231_2_9819", "context": "Reversible valproic acid-induced dementia: a case report.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3084231_2_9820", "context": "Reversible valproic acid-induced dementia: a case report.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6697887_1_9821", "context": "Parenteral-verapamil-induced sustained hypotension.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6697887_1_9822", "context": "Parenteral-verapamil-induced sustained hypotension.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6697887_1_9823", "context": "Parenteral-verapamil-induced sustained hypotension.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6697887_1_9824", "context": "Parenteral-verapamil-induced sustained hypotension.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6697887_1_9825", "context": "Parenteral-verapamil-induced sustained hypotension.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6697887_1_9826", "context": "Parenteral-verapamil-induced sustained hypotension.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6697887_1_9827", "context": "Parenteral-verapamil-induced sustained hypotension.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6697887_1_9828", "context": "Parenteral-verapamil-induced sustained hypotension.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1711090_6_9829", "context": "The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1711090_6_9830", "context": "The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1711090_6_9831", "context": "The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1711090_6_9832", "context": "The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1711090_6_9833", "context": "The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1711090_6_9834", "context": "The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1711090_6_9835", "context": "The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1711090_6_9836", "context": "The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6738830_2_9837", "context": "Unique behavioral change with cinepazide in parkinsonism.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6738830_2_9838", "context": "Unique behavioral change with cinepazide in parkinsonism.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6738830_2_9839", "context": "Unique behavioral change with cinepazide in parkinsonism.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6738830_2_9840", "context": "Unique behavioral change with cinepazide in parkinsonism.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6738830_2_9841", "context": "Unique behavioral change with cinepazide in parkinsonism.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6738830_2_9842", "context": "Unique behavioral change with cinepazide in parkinsonism.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6738830_2_9843", "context": "Unique behavioral change with cinepazide in parkinsonism.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6738830_2_9844", "context": "Unique behavioral change with cinepazide in parkinsonism.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3171334_4_9845", "context": "The literature of vincristine optic nerve toxicity is reviewed.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3171334_4_9846", "context": "The literature of vincristine optic nerve toxicity is reviewed.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3171334_4_9847", "context": "The literature of vincristine optic nerve toxicity is reviewed.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3171334_4_9848", "context": "The literature of vincristine optic nerve toxicity is reviewed.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3171334_4_9849", "context": "The literature of vincristine optic nerve toxicity is reviewed.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3171334_4_9850", "context": "The literature of vincristine optic nerve toxicity is reviewed.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3171334_4_9851", "context": "The literature of vincristine optic nerve toxicity is reviewed.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3171334_4_9852", "context": "The literature of vincristine optic nerve toxicity is reviewed.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7639655_4_9853", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7639655_4_9854", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7639655_4_9855", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7639655_4_9856", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7639655_4_9857", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7639655_4_9858", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7639655_4_9859", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7639655_4_9860", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7639655_4_9861", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7639655_4_9862", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7639655_4_9863", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7639655_4_9864", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7639655_4_9865", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14968106_2_9866", "context": "Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14968106_2_9867", "context": "Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14968106_2_9868", "context": "Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14968106_2_9869", "context": "Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14968106_2_9870", "context": "Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14968106_2_9871", "context": "Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14968106_2_9872", "context": "Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14968106_2_9873", "context": "Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14522628_1_9874", "context": "Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14522628_1_9875", "context": "Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14522628_1_9876", "context": "Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14522628_1_9877", "context": "Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14522628_1_9878", "context": "Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14522628_1_9879", "context": "Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14522628_1_9880", "context": "Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14522628_1_9881", "context": "Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "129501_1_9882", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "129501_1_9883", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "129501_1_9884", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "129501_1_9885", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "129501_1_9886", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "129501_1_9887", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "129501_1_9888", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "129501_1_9889", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "129501_1_9890", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "129501_1_9891", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "129501_1_9892", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "129501_1_9893", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "129501_1_9894", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9253492_3_9895", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9253492_3_9896", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9253492_3_9897", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9253492_3_9898", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9253492_3_9899", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9253492_3_9900", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9253492_3_9901", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9253492_3_9902", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9253492_3_9903", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9253492_3_9904", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9253492_3_9905", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9253492_3_9906", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9253492_3_9907", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18166746_7_9908", "context": "An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18166746_7_9909", "context": "An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18166746_7_9910", "context": "An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18166746_7_9911", "context": "An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18166746_7_9912", "context": "An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18166746_7_9913", "context": "An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18166746_7_9914", "context": "An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18166746_7_9915", "context": "An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11236070_2_9916", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11236070_2_9917", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11236070_2_9918", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11236070_2_9919", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11236070_2_9920", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11236070_2_9921", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11236070_2_9922", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11236070_2_9923", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11236070_2_9924", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11236070_2_9925", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11236070_2_9926", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11236070_2_9927", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11236070_2_9928", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18371508_1_9929", "context": "Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18371508_1_9930", "context": "Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18371508_1_9931", "context": "Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18371508_1_9932", "context": "Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18371508_1_9933", "context": "Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18371508_1_9934", "context": "Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18371508_1_9935", "context": "Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18371508_1_9936", "context": "Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16620273_1_9937", "context": "CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16620273_1_9938", "context": "CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16620273_1_9939", "context": "CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16620273_1_9940", "context": "CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16620273_1_9941", "context": "CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16620273_1_9942", "context": "CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16620273_1_9943", "context": "CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16620273_1_9944", "context": "CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18037876_3_9945", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18037876_3_9946", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18037876_3_9947", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18037876_3_9948", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18037876_3_9949", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18037876_3_9950", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18037876_3_9951", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18037876_3_9952", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18037876_3_9953", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18037876_3_9954", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18037876_3_9955", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18037876_3_9956", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18037876_3_9957", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10579985_3_9958", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10579985_3_9959", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10579985_3_9960", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10579985_3_9961", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10579985_3_9962", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10579985_3_9963", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10579985_3_9964", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10579985_3_9965", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10579985_3_9966", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10579985_3_9967", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10579985_3_9968", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10579985_3_9969", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10579985_3_9970", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16317298_6_9971", "context": "We suggest discontinuing gemcitabine if radiation recall is observed.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16317298_6_9972", "context": "We suggest discontinuing gemcitabine if radiation recall is observed.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16317298_6_9973", "context": "We suggest discontinuing gemcitabine if radiation recall is observed.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16317298_6_9974", "context": "We suggest discontinuing gemcitabine if radiation recall is observed.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16317298_6_9975", "context": "We suggest discontinuing gemcitabine if radiation recall is observed.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16317298_6_9976", "context": "We suggest discontinuing gemcitabine if radiation recall is observed.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16317298_6_9977", "context": "We suggest discontinuing gemcitabine if radiation recall is observed.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16317298_6_9978", "context": "We suggest discontinuing gemcitabine if radiation recall is observed.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18523232_4_9979", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18523232_4_9980", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18523232_4_9981", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18523232_4_9982", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18523232_4_9983", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18523232_4_9984", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18523232_4_9985", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18523232_4_9986", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18523232_4_9987", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18523232_4_9988", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18523232_4_9989", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18523232_4_9990", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18523232_4_9991", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7712052_6_9992", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "7712052_6_9993", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "7712052_6_9994", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "7712052_6_9995", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "7712052_6_9996", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "7712052_6_9997", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "7712052_6_9998", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "7712052_6_9999", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "7712052_6_10000", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "7712052_6_10001", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7712052_6_10002", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "7712052_6_10003", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "7712052_6_10004", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "6928097_1_10005", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6928097_1_10006", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6928097_1_10007", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6928097_1_10008", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6928097_1_10009", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6928097_1_10010", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6928097_1_10011", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6928097_1_10012", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6928097_1_10013", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6928097_1_10014", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6928097_1_10015", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6928097_1_10016", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6928097_1_10017", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12477460_2_10018", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12477460_2_10019", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12477460_2_10020", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12477460_2_10021", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12477460_2_10022", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12477460_2_10023", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12477460_2_10024", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12477460_2_10025", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12477460_2_10026", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12477460_2_10027", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12477460_2_10028", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12477460_2_10029", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12477460_2_10030", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15368548_1_10031", "context": "L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15368548_1_10032", "context": "L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15368548_1_10033", "context": "L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15368548_1_10034", "context": "L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15368548_1_10035", "context": "L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15368548_1_10036", "context": "L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15368548_1_10037", "context": "L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15368548_1_10038", "context": "L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21515865_3_10039", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "21515865_3_10040", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "21515865_3_10041", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "21515865_3_10042", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "21515865_3_10043", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "21515865_3_10044", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "21515865_3_10045", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "21515865_3_10046", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "21515865_3_10047", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "21515865_3_10048", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21515865_3_10049", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "21515865_3_10050", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "21515865_3_10051", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12851279_14_10052", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "Subject.Age", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "12851279_14_10053", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "Subject.Gender", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "12851279_14_10054", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "Subject.Population", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "12851279_14_10055", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "Subject.Race", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "12851279_14_10056", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "Subject.Disorder", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "12851279_14_10057", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "Treatment.Drug", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "12851279_14_10058", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "Treatment.Dosage", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12851279_14_10059", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "Treatment.Freq", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12851279_14_10060", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "Treatment.Route", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12851279_14_10061", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "Treatment.Time_elapsed", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12851279_14_10062", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "Treatment.Duration", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12851279_14_10063", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "Treatment.Disorder", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "12851279_14_10064", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "Combination.Drug", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "6572542_1_10065", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "Subject.Age", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6572542_1_10066", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "Subject.Gender", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6572542_1_10067", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "Subject.Population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6572542_1_10068", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "Subject.Race", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6572542_1_10069", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "Subject.Disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6572542_1_10070", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6572542_1_10071", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6572542_1_10072", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6572542_1_10073", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6572542_1_10074", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6572542_1_10075", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6572542_1_10076", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6572542_1_10077", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11452245_11_10078", "context": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11452245_11_10079", "context": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11452245_11_10080", "context": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11452245_11_10081", "context": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11452245_11_10082", "context": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11452245_11_10083", "context": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11452245_11_10084", "context": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11452245_11_10085", "context": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1888256_1_10086", "context": "Drug-induced fever due to diltiazem.", "question": "Treatment.Drug", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1888256_1_10087", "context": "Drug-induced fever due to diltiazem.", "question": "Treatment.Dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1888256_1_10088", "context": "Drug-induced fever due to diltiazem.", "question": "Treatment.Freq", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1888256_1_10089", "context": "Drug-induced fever due to diltiazem.", "question": "Treatment.Route", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1888256_1_10090", "context": "Drug-induced fever due to diltiazem.", "question": "Treatment.Time_elapsed", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1888256_1_10091", "context": "Drug-induced fever due to diltiazem.", "question": "Treatment.Duration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1888256_1_10092", "context": "Drug-induced fever due to diltiazem.", "question": "Treatment.Disorder", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1888256_1_10093", "context": "Drug-induced fever due to diltiazem.", "question": "Combination.Drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}]}